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Pseudomonas aeruginosa (P. aeruginosa) a nosocomial pathogen, has become a 
serious public health threat due to its high mortality rates and serious antibiotic 
resistance issue.1,2,3,4 The Pseudomonas quinolone signal (pqs) system of  P. 
aeruginosa is essential in regulating the biosynthesis of virulence factors.5–9 The 
transcriptional regulator of pqs system PqsR has been regarded as an interesting 
research topic for the treatment of P. aeruginosa infections.10,11,12 This thesis is 
focused on using multiple hit-to-lead optimization methods to find novel PqsR 
antagonists to overcome P. aeruginosa infections.  
Chapter 1 provides background information about P. aeruginosa pathogenicity, the 
pqs system and current progress towards finding PqsR antagonists. An overview of 
fragment-based lead discovery (FBLD) including hit identification, fragment library 
construction, biophysical methods and hit-to-lead evolution methods is also provided.  
Chapter 2 describes a classic hit-to-lead optimisation process starting from the virtual 
screening of an in-house compound library against PqsR protein to obtain 19. 
Compound 19 displayed good hit likeness and was subjected to hit-to-lead 
optimization to achieve a potent drug sized PqsR antagonist 69 with IC50 values of 
0.25 μM and 0.34 μM in PAO1-LmCTX::PpqsA-lux and PA14mCTX::PpqsA-lux 
reporter assays respectively (Figure 1). The X-ray crystal structure of the 69-PqsR 






Figure 1. The structures of compounds 19 and 69.  
Chapter 3 focuses on fragment-based methods in the discovery of PqsR antagonists. 
Assisted by in silico methods, five fragment libraries were screened against PqsR 
protein and the high scoring fragments were subjected to a thermal shift assay (TSA) 
to give fragment hits 106, 107. Through hit exploration study, fragments 106, 107 were 
optimised and led to the identification of fragments 145a, 145c and 146b displaying 
improved biophysical profiles and these fragments can act as good starting points for 
the identification drug-sized PqsR antagonists (350 < MWt < 500).   
 
Figure 2. Structures of 106, 107, 145a, 145c, 146b. 
Chapter 4 demonstrates the evolution of fragment hits 106, 149, 145a, 145c and 146b 
to drug-sized molecules through fragment linking, merging, and growing methods. 
Applying a fragment growing method on 106 led to the discovery of 148b and 148c 




at 50 μM screening concentration in PAO1-LmCTX::PpqsA-lux reporter assays, 
respectively. Linking fragment 146b and 152a led to the discovery of compound 154b 
showing a RA% value of 34% at 10 μM screening concentration (Figure 3). It was 
hypothesized that two fragments bound to the PqsR LBD in different sub-pockets can 
functionalize as synergistic combinations observed as the fragment cocktails 
displaying a greater effect in bioreporter assay and biophysical experiments than the 
single fragments. A synergistic exploration experiment was designed assisted by TSA 
and mCTX::PpqsA-lux based bioreporter assay and led to the identification of  two 
pairs of synergistic combinations (81 and 108, 81 and 105) showing improved in vitro 
or biophysical profiles in combination than in single fragments. 
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Chapter 1: Introduction  
Developing novel antivirulence strategies targeting the pqs 
system for the treatment of Pseudomonas aeruginosa 
infections 
1. 1 Pseudomonas aeruginosa pathogenicity and its antibiotic 
resistance situation 
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative bacterium, which was 
initially discovered in the late 19th century.14 This opportunistic pathogen is able to 
infect almost any site in the human body and causes serious tissue damage, blood 
stream invasion, and systemic dissemination.15, 16, 17 P. aeruginosa is particularly 
devastating for immunocompromised patients and most often targets epithelial tissues. 
It is now becoming the leading cause of death in cystic fibrosis patients.18, 19 
The pathogenicity of P. aeruginosa stems from biofilm formation and biosynthesis and 
secretion of a wide range of virulence factors, which are bacteria-associated 
extracellular products released by bacteria20,21 to invade the host and cause diseases, 
including siderophores, pyocyanin.22 Siderophores are organic compounds secreted 
by bacteria for iron chelation where iron is an essential nutrient acting as catalyst in 
bacteria metabolism and biofilm formation. 23–25 Pyocyanin is a redox-active molecule 
secreted by P. aeruginosa to inhibit the growth of other competing microbes and 
damage mammalian cells.26–28 
When bacteria attach to a surface, they grow in a community defined as a biofilm 
(Figure 4), which is characterized by the formation of highly hydrated extracellular 
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polymeric substance (EPS) and provides protection from antimicrobial treatments.29 
Additionally, biofilms commonly attach to extracellular DNA (eDNA) that provides a 
breeding platform for mutations. It has been reported that bacteria within biofilms are 
commonly 10-1000 times more tolerant to antibiotics than planktonic cells.30 P. 
aeruginosa is more susceptible to antimicrobial treatments when the bacteria are 
dispersed or removed from the biofilm and antibiotic therapy alone barely cures the 
infections when the bacteria grow within the biofilm.31 It has been reported that chronic 
infections are almost impossible to eradicate when P. aeruginosa grows in biofilms 
especially for cystic fibrosis patients.29 For multidrug-resistant P. aeruginosa strains, 
removing the biofilm helps restore antibiotic sensitivity.16, 32, 33 
 
Figure 4. (a and b) Scanning electron micrographs of a P. aeruginosa PAO1 strain 
biofilm. a) A biofilm on the surface of a pebble. b) high magnification of P. aeruginosa 
embedded in an extracellular polymeric (EPS) matrix.33 (c) Gram-negative cell wall 
diagram. The outer membrane consists of a lipid bilayer anchored with 
lipopolysaccharide (LPS) which is consisted of three components: O-polysaccharide, 
core polysaccharide and lipid A. LPS has multiple functions for the bacteria including 
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stabilizing the outer membrane, providing a physical protection for the bacteria, and 
acting as toxin causing  pathogenicity such as fever. Peptidoglycan is the polymer of 
sugar and amino acids and formed the overall structure of the bacteria cell wall. The 
periplasmic space stores macromolecules including amino acids, iron, and enzymes, 
which is vital for bacteria nutrition.  
The primary treatment for P. aeruginosa infection is antibiotic therapy, which is 
becoming less effective due to the increasing level of resistance to many clinically 
employed antibiotics.31 There are multiple mechanisms underlying P. aeruginosa 
antibiotic resistance.  P. aeruginosa possesses a markedly large and complex genome 
(6.3 million base pairs), which gives huge potential for high adaptability to diverse 
environments and developing antimicrobial resistance.34 These resistance genes can 
be further transferred through horizontal transfer to non-resistant strains.31 The 
intrinsic resistance mechanisms also include low cell permeability of its outer 
memrane35–37, various efflux systems and biofilm natural protection.15 Overexpressed 
efflux systems and the additional outer membrane barrier limit the penetration rate of 
drugs38, whilst biofilm serves as a diffusion barrier to also decrease antibiotic entry into 
bacterial cells.31 
In 2013, the Centre of Disease Control and Prevention (CDC) announced that P. 
aeruginosa was a severe threat to public health because of emerging antibiotic 
resistance.39 There are approximately 50,000 P. aeruginosa infection cases in the 
USA every year and around 13% are multidrug-resistant P. aeruginosa infections that 
have proved to be resistant to nearly all antibiotics, including aminoglycosides, 
cephalosporins, fluoroquinolones and even carbapenem.40, 39, 41, 42 
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1. 2 The P. aeruginosa quorum sensing system, a promising 
antivirulence target for the treatment of P. aeruginosa infections  
P. aeruginosa recruits quorum-sensing (QS) systems to regulate virulence 
mechanisms which makes QS an attractive antivirulence target.19, 15, 43, 44, 45, 46 
Antivirulence therapy has been regarded as a promising alternative to antibiotics. The 
overall strategy is to disarm the pathogen, and in doing so not disturb bacteria growth 
or cause bacteria cell death which could lead to antibiotic resistance.40, 45 Antivirulence 
agents have several advantages over traditional antibiotics. Firstly, they specifically 
target the pathogens without disturbing the healthy microbiome, which is essential for 
the overall health of the human body. Secondly, inhibition of virulence factors is not 
vital for bacteria survival and therefore decreases the chances of selective pressure 
for development and therefore resistance. Therefore, antivirulence agents have been 
regarded as a promising strategy to be used alone or in combination with antibiotic 
therapy. 47, 39, 43  
1. 2. 1 Quorum sensing in P. aeruginosa 
Quorum sensing is a cell-to-cell communication system that allows bacteria to 
coordinate gene expression in response to local population density. This process 
relies on the production, detection and response to extracellular signalling molecules 
called autoinducers (AIs). AIs are chemically diverse, and include a range of small 
peptides and organic molecules.11 At low cell density, AIs diffuse freely out of the cell 
and accumulate in the extracellular environment, but the overall concentration of AIs 
is below the threshold required for detection. When bacteria population density 
increases, AIs accumulate and lead to a locally high concentration that enables 
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bacteria to detect and respond. In this case, accumulated AIs are able to interact with 
cognate receptors and lead collectively to gene expression alteration.48, 49, 50 
Many Gram-negative bacteria employ QS to regulate the expression of certain genes 
and the QS system in P. aeruginosa is an intricate regulatory network. There are some 
detailed mechanisms of the QS systems that still remain unknown. In general, QS 
signals acting as multifunctional signals regulate the organism’s behaviour and 
virulence mechanisms. The genes controlled by QS can be classified into four 
categories based on their functions: cell maintenance and proliferation (siderophore 
production), cell behaviours (biofilm formation), horizontal gene transfer and 
interactions between host and other microbes (virulence factors secretion).51 
Disturbing the QS cascade enables inhibition of almost all the virulence mechanisms 
including biofilm formation, iron scavenging, cytotoxicity, and even antibiotic 
resistance without triggering resistance.52 A significant number of QS signalling 
molecules have been found at the sites of infection in vivo, which also suggests QS is 
an attractive therapeutic area to target for P. aeruginosa infections.19, 15, 44, 46,45 
1. 2. 1. 1 Two N-acylhomoserine lactone (AHL)-dependent QS Systems  
There are three QS systems in P. aeruginosa: two N-acylhomoserine lactone (AHL)-
dependent QS Systems (the las and rhl systems) and one Pseudomonas Quinolone 
Signal (pqs) system. The three QS systems in P. aeruginosa are highly interconnected 
and complex (Figure 5). 




Figure 5. The three QS systems in P. aeruginosa are highly interconnected. (-) 
represents down regulation. (+) represents up regulation. The las system is the 
dominant system and it positively controls pqs and rhl system through regulating the 
transcription of pqsH and pqsR.  rhl system negatively regulate the pqs system through 
inhibition the transcription of pqsR and pqsA promoter region. The pqs system involves 
with rhl system regulation.  The three QS systems in P. aeruginosa are highly 
interconnected. The PqsR-PQS complex is able to activate rhlR the same as the LasR-
3OC12HSL complex. The las and rhl quorum sensing systems control the production 
of PQS through determining the expression of pqsABCDE. The LasR–3-OC12-HSL 
complex positively controls the transcription of pqsR, while RhlR-C4HSL suppresses 
this transcription.19, 53 Additionally, RhIR are able to bind to the promoter region of 
pqsR and pqsA and LasR is able to bind to the promoter region of pqsR and pqsH.54, 
55 PQS inhibits the expression of rhlI 53 however is required for the expression of rhl-
dependent phenotypes.19 
The AHL system in P. aeruginosa contains two LuxR-type transcriptional regulators 
(LasR and RhlR) and two LuxI homologs (LasI and RhlI). Together they regulate over 
200 genes56. LasI and RhlI synthesize 3-oxo-C12-homoseine lactone (3OC12-HSL) 
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and butanoyl homoserine lactone (C4HSL) respectively (Figure 6). 3OC12HSL and 
C4HSL acting as AIs bind to and stabilize LuxR-type transcriptional regulators LasR 
and RhlR respectively. LasR-3OC12-HSL and RhlR-C4HSL complexes are then able 
to bind to the promoter region of target genes and initiate gene transcription.46, 52 For 
example, 3OC12HSL binds to the transcriptional regulator LasR and results in the 
LasR hydrophobic core folding and dimerizing, which then activates the transcription 
of the target genes. Through this process, the las system controls the production of a 
wide range of virulence factors, including exotoxin, and biofilm.19, 55 The LasR-
3OC12HSL complex is also involved in regulating the rhl and pqs systems48, 55. The 
las system is the dominant QS system in P. aeruginosa, however shutting down the 
las system in P. aeruginosa does not stop the transcription of virulence factor related 
genes, an observation which led to the discovery of the pqs system.57 
 
Figure 6. Examples of autoinducer structures of P. aeruginosa quorum sensing 
systems 
When C4HSL binds to RhlR, the rhl signally cascade is initiated and the RhlR-C4HSL 
complex activates the transcription of target genes. The rhl system is upregulated by 
the las system directly through interaction between the LasR-3OC12HSL complex and 
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rhlI and rhlR.19, 55, 56 The rhl system also plays an important role in regulating virulence 
factors biosynthesis, such as pyocyanin and siderophores.58,59   
1. 2. 1. 2 The pqs system 
The pqs system is unique to P. aeruginosa, which employs a LysR-type transcriptional 
regulator MvfR (Multiple virulence factor regulator, also known as PqsR), synthases 
PqsABCDH and AIs especially 2-heptyl-3,4-dihydroxyquinoline (PQS, Pseudomonas 
quinolone signal) and 4-hydroxy-2-heptylquinoline (HHQ) (Figure 6). The synthases 
PqsABCDH are in charge of biosynthesis of PQS and its precursor HHQ. PQS and 
HHQ bind to their cognate receptor PqsR and enhance DNA-binding of PqsR to the 
pqsA-E promoter, which leads to the transcription of pqsA-E and phnAB genes.60, 61 
The transcription regulator PqsR belongs to LysR-type transcription regulators (LTTR) 
family encoded by pqsR, and controls pqsABCDE gene transcription to PqsABCDH 
synthases.62, 63 PqsR contains a highly conserved N-terminal DNA binding domain, a 
large C-terminal ligand binding domain (LBD) and a hinge region that connects the 
two sub-domains. The small cognate autoinducers, such as PQS and HHQ are able 
to bind to the C-termini LBD and leads to a conformation change on PqsR. The helix-
turn-Helix DNA binding domain in PqsR is then activated and able to bind to the pqsA 
promoter region54 and therefore initiates transcription of pqsABCDE, phnAB and 
regulates a wide range of virulence factors, such as pyocyanin, hydrogen cyanide and 
4-hydroxy-2-alkylquinolines (HAQs).60, 18 
The biosynthesis of HHQ and PQS is controlled by the PqsR-regulated operons 
pqsABCDH and phnAB (Figure 7).60 PhnAB enzymes encoded by phnAB genes are 
responsible for conversion of shikimic acid to anthranilic acid, while PqsABCDH 
enzymes encoded by pqsABCDH catalyze the biosynthesis of PQS and HHQ from 
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anthranilic acid.65, 56 PqsH controls the last synthesis step oxidizing HHQ to PQS, 
which is limited by oxygen,66 whilst the specific function of PqsE is unknown. It has 
been proven that PqsE is not involved in HHQ and PQS biosynthesis but is able to 
positively regulate virulence genes in the absence of PQS and HHQ.64, 11 Mutations in 
pqsA or pqsE led to a significant decrease of virulence factor production in vivo, 
indicating the importance of PqsA and PqsE in this process.42 HHQ alone is able to 
activate PqsR-dependent gene transcription55 but PQS is more potent than HHQ in 
terms of PqsR binding and activation.60 HHQ and PQS are released into the 
extracellular medium that allows them to be taken up by neighbouring cells.55 
 
Figure 7. Biosynthesis of HHQ and PQS involves PqsABCDH enzymes and is an 
auto-induced feedback loop. Anthranilic acid can be synthesized from shikimic acid 
pathway. PqsABCDH enzymes then catalyse the biosynthesis of PQS from anthranilic 
acid. PqsR in complex with PQS or HHQ is then activate the transcription of 
pqsABCDE and then initiate the transcription of phnAB and pqsR, which in turn 
activates the biosynthesis of anthranilic acid through shikimic acid pathway. 
PQS is an essential AI for P. aeruginosa pathogenicity. PQS, and not HHQ, is able to 
activate the phzA1-phzG1, which is responsible for pyocyanin biosynthesis.55 PQS is 
found in infection sites in cystic fibrosis patients65 and in wild type P. aeruginosa, 
provision of exogenous PQS leads to significant increase in virulence secretion 
including pyocyanin and biofilm.54 Loss of PQS signalling can result in reduction of 
pyocyanin production.19  With the 3-OH group, PQS can also act as iron chelator and 
inhibit other species take up irons in the same environment.67,68,69 
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1. 2. 2 Targeting the pqs system 
There have been several attempts to target the pqs system in P. aeruginosa as shown 
in Table 1. Shutting down the las system does not stop virulence factors biosynthesis57 
and clinically isolated P. aeruginosa strains frequently contain las system mutations, 
which limits the therapeutic use of LasR inhibitors.70 Disturbing the rhl system alone 
does not have a significant impact on virulence factor biosynthesis.58,59 Lack of RhlR 
and RhlI protein structures also hinders the development of rhl inhibitors. 
Table 1. Examples of pqs inhibitors. 11,71,72,52,61 
No. Structure Biological target IC50 
5 
 
PqsR 5.0 ± 1.6 µM 
6 
 




PqsR 0.32 ± 0.14 µM 
8 
 
PqsA 88 ± 12 nM 
The pqs system is crucial for P. aeruginosa pathogenicity and finding novel PQS 
inhibitors has been regarded as a promising research area for overcoming P. 
aeruginosa infection and antibiotic resistance. The crystal structures for PqsR, PqsA, 
PqsD, PqsBC have been published and there have been some recent advances 
towards finding new inhibitors of pqs, especially for PqsR (Table 1). 
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Some PqsR antagonists were discovered based on the structural modification of 
native agonists 4-hydroxy-2-alkylquinolines (HAQs) such as compounds 5 and 6 in 
Table 1. Some other PqsR antagonists have unique structures such as compound 7 
in Table 1. The crystal structure of PqsR in complex with 7 revealed that 7 and PQS 
bind in the same binding pocket. The sulfur atom in 7 helps the compound bend in a 
particular conformation that allows the compound to fit into the ligand-binding domain. 
The amide bond, acting as a hydrogen bond acceptor (HBA), interacts with Gln194 
while the Tyr258 is involved in a p-p interaction with the aromatic moiety on 7 (Figure. 
8).61, 73  
 
Figure 8. Schematic presentation of 7 (named as M64 on literature) binding to the 
hydrophobic ligand binding pockets of PqsR.61 (A) Crystal structure of MvfR in complex 
with M64. (B) Two-dimensional diagram of 7 in complex with PqsR LBD. Green dash 
line indicates p interactions. Black dash line indicates hydrogen bonding and green 
solid line indicates hydrophobic effect. 
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Current perspectives in fragment-based lead discovery 
1.3 Concepts and an overview of fragment-based lead discovery 
(FBLD) 
Traditional high-throughput screening (HTS) methods start from screening of 
compound libraries against interested biological targets where HTS libraries normally 
contain several hundreds of thousands or even millions of compounds with molecular 
weight (MWt.) in a range from 300 Da to 550 Da (Figure 9). Screening such a large 
compound library is time-consuming and requires a high financial investment.74,75,76 
For allosteric sites or protein-protein interaction targets, HTS of compound libraries 
with molecular weight (MWt.) in a range from 300 Da to 550 Da can provide a low hit 
rate.77, 78, 79 
 
Figure 9.  Comparison between fragment-based and HTS hit-based lead discovery 
process. Fragment hits are smaller (molecular weight 150 <MWt < 300 Da) and weakly 
bind to their targets with affinity in a µM-mM range, whilst HTS hits (molecular weight 
300 <MWt< 550 Da) are larger with stronger affinity to the biological targets. In FBLD, 
the approach used is to screen much smaller compound libraries, normally containing 
a few hundred to a thousand fragments (molecular weight 150 <MWt < 300 Da) against 
biological targets of interest using either biophysical or biochemical methods to identify 
Rui Ling Liu                                                                             University of Nottingham  
13 
 
chemical starting points,80 and tend to achieve higher hit rates compared with HTS.81 
The resulting fragment hits are smaller and less lipophilic compared with HTS hits and 
therefore provide greater opportunity for structure modification in order to optimize 
physicochemical properties and biological activity.82 FBLD approaches have been 
regarded as powerful methods in structural characterization of orthosteric and 
allosteric binding sites providing new starting points even for well characterized 
targets.80 
In FBLD approaches, fragments are defined as small, low molecular weight 
compounds (normally below 300 Da). By reducing structure complexity, fragments are 
more likely to occupy a single pocket or multiple pockets in the biomacromolecule of 
interest. Some fragments can bind to and produce weak but measurable binding or 
inhibitory events observed using biophysical or pharmacological methods. If these 
active fragments have the desired physicochemical properties and pharmacological 
activities, they can be defined as fragment hits and act as chemical starting points for 
the hit-to-lead process (Figure 10).80 Additionally, combined with biophysical methods 
such as X-ray crystallography or protein-observed NMR, it is possible to identify 
functional portions of the molecules that are key in ligand binding and resolve detailed 
binding mechanisms. In addition,  fragments tend to be weak but efficient binders (as 
measured by ligand efficiency metrics).80, 82, 83  
FBLD methods aim to provide fewer lipophilic hits84 and address a common issue of 
low hit rates in traditional HTS methods, especially for difficult targets or new classes 
of biological targets classes.81, 82, 85 FBLD methods have been regarded as an 
alternative to traditional HTS based lead discovery and an important lead discovery 
technique for both well-characterized or new drug targets in the last 20 years.86,81, 87, 
88, 89  
 




Figure 10. Schematic representation of drug-sized HTS hits and fragment hits as 
starting points followed by structure modification. (a) Representation of the active site 
of interest in a biomacromolecule, in which there are three main sub-pockets available 
within the active site. (b) Representation of a drug-sized hit compound from high-
throughput screening (HTS). The hit compound can be active in pharmacological 
assays, but the compound is functionally complex. Some parts of the molecule can 
have unfavoured clashes within the binding site and the ligand efficiency can be quite 
low. (c) Representation of a lead compound obtained from the hit from (b) after SAR 
study. Lead compounds can have better shape complementarity with the active site 
by either removing unfavoured clashes with residues within the binding site or by 
occupying unexplored regions in the binding site. However, synthetic complexity and 
poor physicochemical properties, including high lipophilicity, low solubility and poor 
metabolic stability can arise with a significant increase in structure complexity and 
molecule size. (d) Representation of fragments binding to different sub-pockets in the 
active site of biological targets. Fragments are small and more likely to fit into regions 
of the binding pocket that are often hard to target with larger molecules. (e) 
Representation of SAR study around fragments. SAR studies around original fragment 
hits are essential to probe or optimise interactions between fragments and the binding 
sites. (f) Representation of a lead compound driven from the hit from (e). The new lead 
compound can have less structure complexity compared with (c), which provides more 
opportunity to further modify the compound’s structure and improve drug-likeness. 
Besides, fragments can occupy unexplored regions and the resulting compound (f) 
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1.4 General approaches to fragment-based lead discovery   
The general procedures for FBLD method have been well established and 
summarized as shown in Figure.11. Fragment library design and selection requires a 
manual inspection step where the diversity and quality of fragments needs to be 
considered.79,90,91 X-ray crystal structure of protein-fragment complexes are also 
essential for the guidance of fragment evolution.92,93 
Fragments are small molecules with affinity generally in the range from micromolar 
(µM) to millimolar (mM). Therefore, the selection of the appropriate fragment screening 
method is an important consideration in the FBLD project. An inappropriate screening 
method can lead to either false positives or a low hit rate. Pharmacological assays, in 
silico screening methods and more importantly biophysical methods are all widely 
used and, in order to obtain more accurate and reliable results, it is common to cross 
validate results through different methods.85 
After fragment screening, a manual inspection step is required where medicinal 
chemists evaluate and select fragment hits for further hit-to-lead optimization. In this 
step, physicochemical properties, synthetic complexity as well as the chemical 
evolution potential of fragments need be carefully considered. Once initial fragment 
hits have been chosen, a structure activity relationship (SAR) study should be 
conducted around hits to probe and/or optimize binding interactions. This activity has 
been recently named “SAR by catalog”.94 In order to exclude non-specific binding, the 
fragment binding mode or site should be confirmed and the most informative method 
to achieve this is X-ray crystallography.95, 96 
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There are three main fragment evolution methods, which are fragment growing, 
fragment linking and fragment merging. Each of these will be discussed in detail later. 
Fragments are grown to form new interactions or occupy new pockets guided by 
rational structure-based design using either computer-assisted methods or high-
quality X-ray crystallography data. The fragment evolution step is an iterative cycle 
and the resulting lead compounds should expect at least a 10 times increase in 
potency and/or affinity.90  





Figure 11. General workflow of the fragment-based lead discovery approach.  Structure active relationship (SAR) study indicates the 
relationship between chemical groups and its biological effects.  
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1.5 General considerations for fragment library construction and 
evaluation  
The selection of good quality fragments as chemical starting points for the hit-to-lead 
optimization process is fundamental to the FBLD approach. There are several 
considerations in the construction of the fragment library and hit selection.  
1. 5. 1 The physicochemical properties of fragments  
Physicochemical properties are key in fragment selection and evaluation. Starting with 
fragments possessing good physicochemical properties can reduce attrition rates in 
later hit-to-lead optimisation.84  
1. 5. 1. 1 Fragment rule of three 
Similar to drug-like compounds with a “rule of five” to indicate the desired 
physicochemical properties,97, 98 , 99 there is the “rule of three” (Ro3) to describe 
fragment-like properties, which include: molecular weight less than 300, the number 
of HBA or the number of hydrogen bond donors (HBD) less than 3 and the calculated 
partition coefficient (cLogP) no more than 3. It also suggests that the number of 
rotatable bonds (below 3) and polar surface area (below 60 Å2) should be considered 
to minimise the entropic energy penalty and facilitate better oral bioavailability. In 
general, fragments should be simple enough to minimize steric hinderance or 
electrostatic repulsion in target binding sites yet have sufficient complexity to hold 
enough chemical elaboration points.100 Ro3 rules describe desirable physicochemical 
properties for fragments and also limit molecular complexity, which is key in fragment 
library construction and fragment evaluation.2, 83, 101, 102, 103, 104 
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1.5.2 Fragment library construction and preselection and general 
considerations 
Fragment libraries need to cover a wide and diverse chemical space and there are 
two main considerations in assembling fragment libraries: the quality of fragments and 
the balance between fragment diversity and size.80  
1. 5. 2. 1 Fragment library assembly and preselection  
Fragments originate from different sources including natural products, privileged 
scaffolds and approved drugs.105 Privileged scaffolds from drugs are commonly 
introduced to fragment libraries and these libraries tend to have higher hit rates. Some 
fragment libraries are carefully built based on biological target structural features. 
Structure deconstruction and extraction from potent compounds for a specific target 
followed by synthesis or purchasing of interested fragments and their analogues are 
also common approaches in fragment library construction.106 
It has been widely accepted that introducing sp3 carbon atoms into fragments enable 
more “natural product-like” features and provide improved three-dimensional shape.107, 
108 These fragments are often designed to target protein-protein interactions (PPIs) or 
new biological target classes. This may result from the assumption that PPI targets 
require more three-dimensionality in compounds compared with other protein 
targets.109 Common fragment libraries tend to have more flat topographies and lead to 
lower hit rates against PPIs and new biological target classes. However, synthetic 
difficulties and the increase in fragment size should be considered when design sp3 
carbon rich fragments.110 
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Another feature for FBLD is that a high-quality fragment library can be used to screen 
against different biological targets and the outcome fragment screening results can be 
similar. Therefore, the final selection of fragment hits normally requires a manual 
inspection step where medicinal chemists need to assess fragment hits and decide 
how to optimize them. This step is one of the most important steps in fragment-to-lead 
optimization process.  
1. 5. 2. 2 Stability and solubility of fragments  
Fragments are normally stored and screened at a relatively high concentration for a 
significant length of time, depending on the size of fragment library and screening 
methods. Therefore, fragment properties in terms of purity, stability and solubility 
should be regularly checked.  
In primary screening, fragment screening concentrations can be above 500 µM and 
up to 1 mM allowing the detection of weak binders.78 Therefore, fragments should be 
soluble at these high concentrations in dimethylsulfoxide (DMSO) and phosphate 
buffered saline. Additionally, the purity of fragment samples should be checked as 
even minor impurities at high concentrations could lead to false positive results, e.g. a 
1% impurity in 1 mM fragment solution can lead to 10 µM contaminant.111, 102 The 
analysis of molecular purity and solubility is commonly carried out using analytical 
methods such as liquid chromatography–mass spectrometry (LC-MS) and nuclear 
magnetic resonance (NMR). 
The most commonly used solvent for stock solution preparation is DMSO, which is a 
mild oxidant and is also hygroscopic. Fragment library screening can take a significant 
length of time and fragments need to have long term stability in DMSO or aqueous 
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solution. 112,111 Therefore, fragments are stored either as solids and dissolved into 
media buffer immediately before use or are solubilized in DMSO and stored under an 
inert, dry atmosphere to maintain their integrity. 
Another important concern in fragment library construction and hit selection stages is 
the exclusion of highly reactive chemical functionalities such as acyl chlorides and 
Michael acceptors to avoid instability and reactivity issues. These functional groups 
can non-specifically bind to proteins and cause proteins or fragment precipitation and 
aggregation, which influences the accuracy of screening results.78, 85, 111 
In general, screening of a relatively small but diverse fragment library enables 
coverage of a large chemical space. According to Reymond’s group, addition of one 
heavy atom to fragments increases the chemical space approximately 8.3-fold. A 
fragment library containing 1000 fragments with molecular weight around 190 Da 
covers a similar chemical space as 1018 compounds with molecular weight around 450 
Da.112 Therefore, FBLD approaches tend to require lower investment and achieve 
higher hit rates compared with the traditional methods.81, 102 
1.6 Biophysical methods in FBLD  
Fragments generally have weak but highly efficient binding to the biological targets 
Therefore, the selection of an appropriate method to detect and measure fragment 
binding is essential. Bioactivity assays are widely used in HTS, however much higher 
concentrations are required in fragment screening and sometimes these methods, 
such as radio-ligand binding or outputs from reporter gene assays will give false 
positive results because of potential precipitation and aggregation of the fragments.103, 
113 Sensitive biophysical methods are commonly used for primary fragment screening 
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including isothermal titration calorimetry (ITC), thermal shift assay (TSA), surface 
plasmon resonance (SPR), ligand-observed and protein-observed NMR and X-ray 
crystallography.114 These biophysical methods have different sensitivity range shown 
in Figure 12 and the selection of an appropriate method for fragment screening is key 
in hit identification and optimization. 
 
Figure 12. A representation of affinity range of different biophysical methods. 
1. 6. 1 Isothermal titration calorimetry (ITC) 
Isothermal titration calorimetry (ITC) is a sensitive biophysical method that accurately 
determines thermodynamic parameters of ligand-protein interactions. A calorimeter 
consists of a reference cell containing buffer or water as a control and a sample cell 
where binding partners are mixed.115 The common experimental set up is ligand 
samples in higher concentrations are titrated into protein solutions in lower 
concentration in the sample cell. However, if a ligand suffers poor solubility, the 
components can be reversed.116  
When binding components are mixed in the sample cell, heat can be released or 
absorbed. Through measuring the differential power required to maintain a zero-
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temperature difference between reference and sample cell, the calorimeter is able to 
monitor ligand-protein interactions and determine thermodynamic parameters 
including the enthalpy change (DHobs), binding stoichiometry (N), and binding affinity 
(Kd) 115. The entropy change (DS) and Gibbs free energy change (DG) can be further 
calculated using the equations (1) and (2). It should be noticed that the ITC experiment 
is very sensitive and the buffers for dissolving ligands and protein should be matched 
in order to avoid the heat of dilution from titrating two different buffers.112, 79, 117, 118 
ΔG	=	-	RT	lnKd                                                                                                       (1) 
ΔG	=	∆H	-	T∆S                                                                                                      (2) 
Where DG indicates Gibbs free energy; DH indicates enthalpy; DS indicates entropy; 
R is the gas constant (1.985 cal K-1mol-1); T is the temperature in Kelvin; Kd indicates 
affinity.  
Through ITC experiments, thermodynamic parameters for ligand-protein interactions 
are determined. However, ITC experiments cannot provide detailed ligand binding 
modes. In order to confirm ligand binding site interactions, a competitive displacement 
ITC experiment can be conducted in which protein samples are mixed with a known 
competitive ligand and you then titrate in the fragment of interest. The main limitations 
for ITC methods are the large consumption of protein sample and high solubility 
requirement for ligands. ITC experiments are also time-consuming as a single 
experiment can take approximately 90 minutes and therefore this approach is not 
suitable for fragment library screening.119, 120 
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1. 6. 2 Thermal shift assay (TSA) 
Thermal shift assay, also known as differential scanning fluorimetry (DSF) is an 
effective biophysical method to monitor protein denaturation and can be used in a 
parallel format. It has been widely used in fragment library screening and protein buffer 
optimization for storage or crystallization.121 
In a TSA experiment, protein samples are dissolved in aqueous-based buffer with 
addition of an environmental sensitive fluorescent dye, such as SYPRO™ Orange. 
Proteins are in a denatured equilibrium between folded and unfolded states 
( Native ⇌ Denatured ) and the energy changes of the environment, such as 
temperature or pressure or the addition of ligands/denaturants would change the 
equilibrium towards one side.122 When the protein unfolds, the dye is able to bind to 
the protein hydrophobic core and this leads to a large increase in fluorescence.123 
Through monitoring the fluorescent change during the protein-unfolding transition 
process, a sigmoidal curve can be obtained (Figure 13) and this allows determination 
of the melting temperature (Tm), defined as the temperature where 50% of protein 
sample is unfolded. 




Figure 13. A protein thermal denaturation curve. In stage I, protein samples are all in 
teh folded form and the dye (sypro-orange) is quenched by aqueous buffer. With 
temperature increase, proteins start to unfold, which allows sypro-orange to bind to 
the hydrophobic core and gives a fluorescence signal. When 50% of the proteins are 
melted in stage II, the temperature is defined as Tm. With the temperature continues 
increasing, the percentage of protein samples in unfolded form is also increasing till 
the fluorescence signal reach to the peak where the proteins are all in complex with 
the dye (stage III). After that, protein started to aggregate with dye dissociation 
reflecting as fluorescence signal decrease (Stage IV).  
With the addition of ligand samples, the protein thermodynamic equilibrium 
(Native ⇌ Denatured) is moved towards one side with the ligand binding equilibrium 
( protein + ligand ⇌ Protein-ligand complex ). If ligands stabilize the protein, it 
manifests as an increasing of Tmligand with a positive ∆Tm value. The calculation of 
∆Tm is calculated using the equation (5) shown below: 
                               ∆Tm = Tmligand - TmDMSO control                                                        (3) 
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Where, Tmligand is the protein melting point with the addition of ligand sample. TmDMSO 
control is the protein melting point with the addition of DMSO as control.  
It has been accepted that ∆Tm values correlated with hit-likeness shown below124: 
• For more druggable ligand binding site: 
∆Tm > 2.5 ℃: strong hit  
1 ℃ < ∆Tm < 2.5 ℃: medium hit 
0.5 ℃ < ∆Tm < 1 ℃: weak hit  
• For less druggable ligand binding site:  
∆Tm > 1.5 ℃: strong hit  
0.5 ℃ < ∆Tm < 1 ℃: medium hit 
0.2 ℃ < ∆Tm < 0.5 ℃: weak hit  
The TSA experiment requires less protein compared with ITC experiment and is able 
to work on a 96-well plate format with approximately 90 minutes per run on a q-PCR 
instrument.125 Therefore, TSA is suitable for fragment libraries screening. However, 
TSA is not as accurate as an ITC experiment and cannot provide thermodynamic 
parameters such as KD or DH values. Proteins or the dye aggregation can lead to false 
positive or negative results and therefore TSA is more accurate in detecting strong 
hits with affinity in the range of 1 nM- 100 µm. Fragment hits selected from TSA tend 
to require a cross validation using another biophysical method to exclude false 
positives.124, 126,127 
Rui Ling Liu                                                                             University of Nottingham  
27 
 
1. 6. 3 Surface plasmon resonance (SPR), NMR and X-ray crystallography  
There are some other biophysical methods commonly used in detecting fragment 
binding interactions, such as SPR and ligand- or protein- observed NMR. Surface 
plasmon resonance (SPR) is a very sensitive biophysical method measuring changes 
in molecular weight in real time. The SPR biosensor contains a glass prism with a 
biocompatible coated gold film with one of the components (either protein or ligand) 
immobilised to it through different kits such as histidine tagging whilst another binding 
component in solution is passed over. When an optical beam is directed at the gold 
surface, the change in the angle or intensity of reflection index can be used to 
determine the compound binding interactions shown in Figure 14.128, 119 
SPR is a very powerful screening method, which is able to determine both drug-sized 
and fragment-sized ligand binding and provides affinity (Kd) and kinetic measurements 
(the association rate constant Kon, and the dissociation rate constant Koff). SPR 
experiments are suitable for fragment library screening as up to 8 samples can be 
screened at the same time with each run taking 3-10 mins.128, 129 However, SPR 
method does not provide detailed molecular binding mode or thermodynamic 
parameters, such as ΔG or ΔH. The detection of fragments binding to the protein 
targets can also be difficult due to the large molecular size differences.  
 
Figure 14. SPR interaction sensor scheme.128  
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NMR methods are highly recommended in fragment screening as they are sensitive 
enough to detect weak binding with an affinity range from 100 nM to 1 mM129 and both 
ligand-observed and protein-observed NMR are widely used. Ligand-observed NMR 
detects the changes of ligand signal in terms of intensity, sign and relaxation. It 
requires tens of milligrams of unlabelled protein and is able to maintain protein and 
ligand sample integrity. The main limitation for ligand-observed NMR is the limited 
structure information obtained, i.e. it cannot provide detailed information on ligand-
protein binding mode.130, 131 
Protein-observed NMR detects the changes of isotopically labelled protein signals and 
generally requires 2D 1H-15N HSQC (heteronuclear signal-quantum 
correlation/coherence) experiments. In 1H-15N HSQC spectrum, each amide on the 
backbone of the protein sample yields a peak and is sensitive to local chemical 
environment, especially to ligand binding.128,130 Detailed structure binding information 
can be obtained from the sequence-specific assignments of the protein132, which is 
useful in detecting fragments binding in allosteric sites. However, the size of the 
protein should be less than 40 kDa otherwise the amide signals can be very broad due 
to slower tumbling time.119  
X-ray crystallography is a very informative method and provides detailed binding 
modes of fragment hits despite low binding affinity. It allows rapid assessment to 
decide which fragment is able to progress into hit-to-lead chemistry. There are two 
main methods to obtain crystals of protein-ligand complexes, which are soaking and 
co-crystallization.133 The co-crystallization method requires the exposure of ligands to 
protein solutions allowing the ligand-protein complex crystallized. The soaking method 
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is more commonly used which requires the exposure of pre-manufactured protein 
crystals to ligand solutions. 133–136 
1. 6. 4 Computational methods  
Well-developed biophysical and biochemical experimental techniques are able to 
confirm ligand-protein binding interactions but are very expensive and time-consuming, 
particularly in fragment library screening where hundreds of fragments need to be 
tested. In contrast, in silico methods significantly decrease financial and time 
investment and are now widely applied in the FBLD process.111,137,138 
Taking the advantages of the protein three-dimensional structural information in the 
Protein Data Bank (PDB), computational methods are applied in fragment library 
virtual screening and fragment evolution simulation.139 In these experiments, 
fragments can be docked into selected regions on the macromolecule and ranked 
according to docking scores. It should be noticed that grid-based algorithms tend to 
lack the description about protein flexibility and thermodynamic parameter calculations, 
which lower accuracy of the docking results.140, 95,141–146 It is common to use 
biophysical and/or biochemical experiment after in-silico experiments to cross validate 
those fragments with a high docking score.142,144,147    
1.7 Fragment evolution methods 
Once the fragment hits have been selected, there are three main fragment evolution 
methods, which are fragment growing, linking, and merging. As the name suggests, 
fragment growing methods involve using structure-based approaches to guide 
fragment size increase to obtain new binding interactions and/or occupy new pockets. 
The fragment growing method is the most used strategy. To date, there are in total 46 
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clinical candidates or drugs which have their origins from fragment-based approaches 
and used fragment growing methods.148 The fragment linking method describes joining 
two non-competitive fragments through a linker. Fragment linking methods are the 
most attractive method as the resulting compound normally shows a significant 
enhancement in potency and affinity. However, the design of an appropriate linker can 
be quite challenging and generally requires structure characterization of the target 
protein.  
Fragment merging methods describes combining two fragment hits together, which 
are partially overlapping in terms of their ligand binding sites. This method strongly 
relies on high quality crystal structures and careful structure based design80 and there 
is only one clinical candidate (14, AZD5991) acting as a myeloid cell leukemin-1 (Mcl-
1) inhibitor using a fragment merging method to guide the hit-to-lead optimization 
process (Figure 15).149, 150  




Figure 15. Development of a microcyclic Myeloid cell leukemin-1 inhibitor, AZD5991 
from fragment 16-Mcl-1 and 17 Mcl-1. 9 was initially found as an active lead 
compound for the project of finding Mcl-1 inhibitor from AstraZeneca. The 
crystallography experiment revealed that myeloid cell leukemin-1 (Mcl-1) bound with 
two molecules of 9 in the same binding pocket but different sites. One of the 9 molecule 
enlarged the binding pocket that allowed the second 9 to fit into the pocket. This finding 
suggested that the hybrid compound from merging the two molecules of 9 can show 
improved potency because of better occupancy of the binding pockets. Compound 10 
showed better physicochemical properties than 9, was selected as the monomer and 
built into a hybrid compound 11. The hybrid compound 11 didn’t show improved 
potency compared with 10, however, the by-product 12 showed improved Mcl-1 
inhibition. The crystallography data revealed that the tethered ring enlarged the 
binding pocket, which was similar to the previous 9. 13 showed improved affinity and 
finally lead to the identification of clinical candidate 14, AZD5991.150, 149, 151 
1.8 Using a fragment-based approach to find pqs inhibitors 
Finding novel pqs inhibitors for the treatment of P. aeruginosa infections has been a 
focus of current research. There is only one publication to date that describes using 
fragment growing methods to find pqs inhibitors shown in Figure 16. 152 




Figure 16. Schematic description of hit-to-lead optimisation starting from fragment 15 
to final active inhibitor 18 and crystal structure of 18 in complex with PqsR LBD.152 
In this work, different biophysical screening methods (SPR and ITC) were used to 
detect and confirm fragment binding. Based on LE and EE values (based on ITC 
experiments), the low affinity compound 15 was selected as the hit. SAR studies were 
then conducted around fragment 15 and fragment growing methods were used to 
guide hit-to-lead optimization giving compound 18 as a potent PqsR inhibitor (IC50= 
5.9 μM).152 This work provide confidence for the focus of this thesis, which is to use 
fragment-based approaches to discover novel pqs inhibitors. 
1.9 Aims and hypothesis  
P. aeruginosa infections and the associated multidrug resistance issue has become a 
serious public health threat and pqs inhibitors acting as anti-virulence agents are able 
to cure P. aeruginosa infections and relieve antibiotic resistance situation. 31,153  In this 
work, different hit-to-lead discovery and optimisation methods were attempted for the 
identification of novel PqsR antagonists to overcome P. aeruginosa infections.  
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In previous work from our group, compound 19 was identified through a virtual 
screening of an in-house compound library against PqsR ligand binding domain (LBD) 
followed by an in vitro PAO1-PpqsA-lux reporter gene assay (IC50 = 0.98 μM). 
Compound 19 displaying good hit-likeness was selected as hit compound and can act 
as the starting point for the hit-to-lead optimisation process (Figure 17).  
The protocols for the purification and crystallization of PqsR LBD were published, 
which provides opportunities to investigate compound binding modes through ligand-
protein complex crystals.  
 
Figure 17. The proposed workflow of the hit-to-lead optimisation workflow starting 
from compound 19.  
Fragment-based methods was then applied for identification of novel PqsR 
antagonists inspired by literature compound 18. In silico method was introduced for 
fragment libraries screening against PqsR LBD and the resulting fragment hits can be 
validated using bioreporter assay and biophysical methods, such as TSA and ITC. 
Through hit exploration studies around the initial hits, chemistry starting points can be 
confirmed for later fragment evolution. The ultimate aim in this fragment-based method 
guided project was to advance fragment hits using fragment growing, linking and 
merging methods into drug-sized PqsR antagonists (300 < Mwt. < 500) (Figure 18).  




Figure 18. Proposed workflow of the fragment-based lead discovery approach starting 
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Chapter II: Hit to lead optimization of new potent PqsR 
antagonists as inhibitors of quorum sensing in 
Pseudomonas aeruginosa 
2.1 Introduction and project aims  
In previous work, a virtual screen on the PqsR ligand binding domain against the 
University of Nottingham Medicinal Chemistry Compound Collection (MCCC) - an in-
house compound library containing approximately 80,000 compounds was conducted 
by Dr. Fadi Soukarieh using Glide HTVS (high throughput virtual screening). The cut-
off filter docking score was set as -9.0 where the GlideScore is a scoring function to 
predict compounds affinity and the virtual hits satisfying these criteria were subjected 
to a PAO1-L mCTX::PpqsA-lux luminescence-based bioreporter assay, which led to the 
discovery of 19 a moderate PqsR  antagonist (IC50 = 0.98 µM) (Figure 19). 
 
Figure 19. The structure of hit compound 19. 
The mCTX::PpqsA-lux-based bioreporter was used in both the parent strain of P. 
aeruginosa (PAO1-L) and the more clinically relevant PA14 strain for the evaluation of 
the compound pqs inhibition in this thesis. PAO1-L strain is a derivative of the original 
Australian PAO isolate, whilst PA14 is a hypervirulent strain isolated from a patient 
with burn infection.154 It has been shown that P. aeruginosa strain PA14 is more 
virulent than PAO1-L in diverse infection models, which could result from horizontal 
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gene transfer of the two pathogenicity islands, PAPI-1 and PAPI-2.155 The whole-cell 
based bioreporter assay was designed through the insertion of 
miniCTX::PpqsA::luxCDABE bioreporter into the chromosome of the pqsA mutant 
PAO1-L and PA14 strains. The activation of pqs system initiates the transcription of 
pqsA::luxCDABE and leads to the expression of the LuxCDABE protein, which 
produces the bioluminescent luciferase. The growth and bioluminescence of the 
strains can be monitored using microplate readers and compound pqs inhibitory 
activity was evaluated through the remaining activity (RA%), which is the ratio of 
Δluminescence (the detected luminescence of compound minus the DMSO control) 
over OD600 (the strains optical density at 600 nm).156–159  
Through the miniCTX::PpqsA::luxCDABE based bioreporter assay, the activation or 
inhibition of the pqs system can be monitored. In this work, PAO1-L and PA14 strains 
were treated with a 10 µM compound solution and compounds showing a pqs activity 
reduction greater than 50% (i.e. RA% < 50%) were regarded as being active. 
Compound 19 was active against PAO1-L with a IC50 value of 0.98 µM, whilst it was 
inactive against PA14 strain (RA% = 73%). Due to solubility limitation, binding affinity 
of compound 19 against PqsR LBD cannot be obtained through ITC method. However, 
the initial virtual screening was conducted against PqsR LBD and the later TSA and 
X-ray crystallography experiments proved the binding of the 5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thiol analogues to PqsR LBD. These results suggested 
that the 5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thiol analogues can function as 
PqsR antagonists.  
Compound 19, contains a (5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thiol head 
group, a 4-chlorophenyl substituted tail group, and an acetamide linker. It displays 
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good physicochemical properties including moderate lipophilicity reflected as 
calculated partition coefficient, (ClogP), topological polar surface area (tPSA) and 
hydrogen bond donor/acceptor (HBD/HBA) values (Figure 19). According to the 
‘Lipinski rule of five’ (Ro5), which is commonly used for the evaluation of molecules 
optimal physicochemical properties99, 19 shows good hit-likeness and was 
subsequently selected as a hit. 
Docking studies were conducted to predict the binding mode of 19 against the PqsR 
LBD using Glide SP (standard precision) (force field: OPLS3e; PDB: 4JVD). According 
to the docking study, 19 can occupy the PqsR LBD with two potential binding modes 
with flipped orientations (Figure 20B and C). The X-ray crystal of the 5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thiol analogue compound 69 in complex with PqsR LBD 
was obtained (Figure 20A), which will discuss in details in later in this chapter. 
Comparing the predicted binding mode of 19 with the 69-PqsR LBD crystal complex, 
it was noticed that the 5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thiol head groups of 
compound 19 and 69 were pointing towards different direction (Figure 20A and B). 
This finding suggested that the docking study of compound 19 may not be accurate 
for the prediction of ligand binding modes, whilst docking study can still be a powerful 
method to guide analogues SAR study design. 
In this work, a hit-to-lead optimisation workflow was presented including design, 
synthesis, and biological evaluation of a series of novel PqsR inhibitors and was 
published in Frontiers Chemistry 04 May 2020 
(doi.org/10.3389/fchem.2020.00204).13 
 




Figure 20. (A)The X-ray crystallography data of 69 in complex with PqsR LBD. (B and 
C) Three-dimensional diagram of predicted binding mode for 19 against PqsR LBD 
(PDB 4JVD). The docking shows that 5d can fit into the PqsR LBD in two possible 
modes. (B) The head group inserts deeply in the binding site, whilst the terminal aryl 
group points outside of the pocket π-stacking with Tyr258. (C) The aryl tail group inserts 
deeply in the binding pocket and the head group points outside the pocket π-stacking 
with Tyr258. The scaffold structure of 19 is represented in orange. The scaffold 
structure of 69 is represented in green. The blue dashed line indicates a π-stacking 
interaction. 
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2.2 Hit-to-lead optimisation process 
2.2.1 The first SAR study around 19 
2.2.1.1 The design of the first SAR study around 19 
Compound 19 showing moderate pqs inhibition against PAO1-L and good hit-likeness 
was selected as a hit and advanced to the hit-to-lead optimisation process. According 
to docking studies, 19 binds to the PqsR ligand-binding site and leaves significant 
empty space allowing further modification around 19 (Figure 21). Increasing the ligand 
binding pocket occupancy by introducing substituents on 19 may lead to a more 
favourable shape complementarity or allow it to probe new binding interactions. Based 
on this hypothesis, the first SAR study was designed in which the tail group (R2) was 
modified as well as the 8-position of the tricyclic head group (R1). Based on the 
structural differences of R1, the designed analogues were classified into three series: 
R1 = H (series 1), R1 = Br (series 2) and R1= OMe (series 3).  




Figure 21. The design of the first SAR study. The docking study shows the possible 
binding orientations of 19 in the PqsL LBD. The SAR study initially focused on 
modifying the aryl tail group and the 8-position of the tricyclic head group. In the first 
series analogues, the head group was initially kept unsubstituted (R1=H) and a set of 
diverse tail groups (R2) were explored. Once finished the design and synthesis of 
series 1 analogues, different substituents including electron donating (OMe) and 
withdrawing (Br) groups were introduced to R1, which allowed to investigate the 
influence of substituents on the head group.  
 
2.2.1.2 The synthesis of series 1, 2 and 3 compounds in the first SAR study 
1,2,4-Triazino[5,6-b]indole-3-thiol derivatives have been well documented for their 
pharmaceutical potential, and have been used in anticonvulsant160,  antiviral161, 
antimalarial162  and antileishmanial163 inhibitors. In recent publications,164 1,2,4-
triazino[5,6-b]indole-3-thiol analogues have been reported to display antibacteria and 
antifungal activity against P. aeruginosa 163–165 (Figure 22). The functionalization of 
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1,2,4-triazino[5,6-b]indole-3-thiol derivatives has been well studied and in this work 
the synthetic routes for the preparation of the 1,2,4-triazino[5,6-b]indole-3-thiol 
analogues are shown in Scheme 1 and 2163,166–168. 
 
Figure 22. Literature 1,2,4-triazino[5,6-b]indole-3-thiol derivatives showed therapeutic 
potential. 163–165 
The forward synthetic scheme for the majority of the 1,2,4-triazino[5,6-b]indole-3-thiol 
analogues is depicted in Scheme 1. 5-Substituted N-methylisatins 26-28 were 
obtained by methylation of isatin and its analogues 23-25 using CH3I and NaH in N,N-
dimethylformamide (DMF) under an inert atmosphere of N2. Compounds 26-28 were 
then cyclised by thiosemicarbazide in the presence of K2CO3 base in 1,4-dioxane and 
H2O at reflux to afford intermediates 29-31. The intermediates 35-37 were synthesised 
through classic nucleophilic aromatic substitution reactions starting from 29-31 using 
tert-butyl-2-bromoacetate and Et3N as base, followed by deprotection of the  tert-butyl 
group using 4M HCl in 1,4-dioxane to achieve free acids 35-37. The key intermediates 
35-37 were then subjected to amide coupling reactions with a wide range of anilines 
using N-Boc-piperazine,1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium-3-oxide hexafluorophosphate (HATU) as coupling reagent to give 
compounds 19, 38, and 40-62.  
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Scheme 1. Preparation of targeted compound 19, 38, 40-51, 53-62
 
aReagents and conditions: (i) CH3I, NaH, DMF, 0°C to rt, N2, 73%-92%; (ii) 
thiosemicarbazide, K2CO3, Dioxane, H2O, Reflux, 45%-96%; (iii) t-butyl-2-
bromoacetate, Triethylamine (Et3N), toluene, 0 °C to rt, 52%-88%; (iv) 4M HCl in 
dioxane, rt, >100%; (v) various anilines, HATU, 4-(dimethylamino)pyridine (DMAP), 
N,N-Diisopropylethylamine (DIPEA), N-methylpyrrolidone (NMP), rt, 13%-30%; 
Ortho-chloro substituted aniline (63) failed in the amide coupling reaction with 35 due 
to a possible steric hinderance effect with the chlorine atom. Therefore, the preparation 
of 39 and 52 were using Scheme 2 starting from alkylation of 63 using bromoacetyl 
chloride followed by nucleophilic substitution with 29 or 30 to give compound 39 and 
52, respectively.  
Scheme 2 Preparation of target compound 39 and 52 




aReagents and conditions: (i) Bromoacetyl chloride, Et3N, dichloromethane (DCM), 
0 °C to rt; (ii) Et3N, DCM, 0 °C to rt.  
2.2.1.3 The initial structure-activity relationship (SAR) study around the head 
and tail groups for pqs inhibition   
The synthesized analogues were then subjected to bioreporter assays for the 
determination of pqs inhibition. The SAR study showed that removal of the chlorine 
atom at R2 (38), abolished biological activity demonstrating the importance of 
substitutions on the aryl tail group. Changing the chlorine atom from the para- position 
(hit, 19) to the ortho- or meta- positions, 39 and 40 gave no inhibition against PAO1-L 
and PA14 strains when screened at 10 µM concentration. The 3,4-dichloro substituted 
analogue (41) showed reduced activity against both strains. These results 
demonstrated that the para-substituted chlorine analogue (19) was optimal for activity. 
The influence of introducing substituents at the para- position was then investigated.   
Replacing the para- chlorine (19) with fluorine (45) caused a loss in activity against 
both strains. Introducing other electron withdrawing groups (EWGs), such as 
trifluoromethoxy (48) and bromine (46), retained activity against PAO1-L. Especially, 
the bromine substituted analogue (46) led to improved PA14 inhibition (IC50 = 1.35 
μM). Replacing the chlorine atom with a similarly sized but weakly electron-donating 
methyl substituent, 47 retained activity against PAO1-L.  
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Functional groups that can act as either HBD or HBA (amide group) and pure HBA 
(methoxy group) were also introduced to the aryl group. However, compounds 42-44, 
50 lost activity against both strains.  
Table 2. The SAR around the head and tail group  
 
 R1 R2 
Remaining Activity (%)a, b IC50 (μM)c 
PAO1-L PA14 PAO1-L PA14 
DMSO / / 100.00 ± 8.37 100.00 ± 3.87 - - 
Sen19f / / 26.20 ± 10.33 24.57 ± 3.87 - - 
7 (M64 f)     0.32± 0.14 1.22± 0.34 
19 H 4-Cl 32.98 ±10.30 73.41 ± 24.52 0.98 ± 0.15 NA 
38 H H 80.26 ± 23.75 110.15 ± 16.28 - - 
39 H 2-Cl 76.13 ± 8.68 94.78 ± 13.54 - - 
40 H 3-Cl 93.27 ± 11.85 102.86 ± 8.57 - - 
41 H 3,4-di-Cl 71.10 ± 33.97 98.54 ± 9.83 - - 
42 H 2-OMe 62.57 ± 20.40 99.02 ± 6.90 - - 
43 H 4-OMe 79.46 ± 10.56 110.55 ± 19.23 - - 
44 H 3,4-di-OMe 73.90 ± 12.64 - - - 
45 H 4-F 64.43 ± 9.14 86.31 ± 18.28 - - 
46 H 4-Br 16.83 ± 3.34 22.38 ± 7.58 1.71 ± 0.26 1.35 ± 0.19 
47 H 4-Me - NA 1.86 ± 0.01 - 
48 H 4-OCF3 28.71 ± 5.98 95.37 ± 9.13 - - 
50 H 3-CONH2 93.86 ± 15.39 - - - 
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 R1 R2 
Remaining Activity (%)a, b IC50 (μM)c 
PAO1-L PA14 PAO1-L PA14 
51 Br H 66.21 ± 13.13 98.92 ± 4.46 - - 
52 Br 2-Cl 82.29 ± 15.52 101.68 ± 10.82 - - 
53 Br 3-Cl 42.76 ± 20.18 103.20 ± 9.94 - - 
54 Br 4-Cl 19.71 ± 10.34 17.21 ± 3.90 1.99 ± 0.23 1.60 ± 0.16 
55 Br 3,4-di-Cl 17.22 ± 8.07 57.19 ± 18.51 3.1 ± 0.52 7.58 ± 0.82 
56 Br 2-OMe 14.23 ± 2.10 24.46 ± 5.72 1.19 ± 0.24 7.36 ± 0.24 
57 Br 4-OMe 64.46 ± 10.11 98.09 ± 15.64 - - 
58 Br 4-F 25.95 ± 11.51 73.81 ± 15.12 1.36 ± 0.21 - 
59 Br 4-Br 22.65 ± 8.96 78.74 ± 29.54 - - 
60 Br 4-Me 31.82 ± 6.19 NA - - 
61 Br 4-OCF3 22.85 ± 8.98 67.14 ± 21.16 - - 
62 OMe 4-Cl 55.84 ± 6.79 - - - 
aData shown are mean values obtained from three independent experiments 
performed in triplicates. b% Remaining Activity (RA%) screening at single 
concentration (10 μM) in triplicates. c The inhibitory effect evaluated using PAO1-
LmCTX::PpqsA-lux and PA14mCTX::PpqsA-lux reporter assays. Remaining activity 
(RA%) values below 50%, compounds were regarded as active. RA% values do not 
have a linear relationship with IC50. dNA : not active. e-: not available. f positive control. 
Sen19 is a PqsR antagonist with confirmed IC50 and Kd values. The determination of 
RA% and IC50 for compounds 7, 19, 38-62 was conducted by Dr. Fadi Soukarieh. 
The effect of substitutions on the 8-position of the tricyclic head group was then 
investigated and interestingly, when R1 is either bromine (51-61) or methoxy (62) 
compounds displayed a divergent SAR compared with analogues containing an 
unsubstituted head group (19, 38-50).  
Comparing 62 with the original hit 19, demonstrated that introducing an electron 
donating methoxy group to R1, whilst keeping R2 as para-Cl, led to a decrease in pqs 
inhibition activity. Introducing a bromine atom to R1, 54 retained a moderate pqs 
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inhibitory effect with IC50 values of 1.99 μM and 1.60 μM against PAO1-L and PA14 
strains respectively.  
Further SAR study on the 8-bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indole analogues 
showed that removal of the chlorine atom (51) reduced activity against both strains 
emphasizing the importance of substituents on R2. Changing the chlorine atom from 
para- (54) to ortho- (52) or meta- (53) positions resulted in a significant decrease in 
pqs inhibition. The 3,4-di-Cl substituted analogue (55) was active against both PAO1-
L and PA14 strains, which was inactive in the matched-pair analogue 41. These results 
showed that the para- position on the aryl tail group can be optimal for introducing 
substituents compared with other positions. The tolerance of substituents at the para- 
position in relation to pqs inhibitory activity was then investigated.  
Furthermore, replacing the chlorine atom with other EWGs, such as fluorine (58), 
bromine (59) or trifluoromethoxy (61) retained moderate pqs inhibitory effect against 
PAO1-L but were inactive against PA14. The para-methyl (60) and para-methoxy (57) 
analogues were weakly active against PAO1-L and inactive against PA14. It was also 
noticed that the ortho-methoxy substituted analogue (56) restored pqs inhibition with 
IC50 values of 1.19 μM and 7.36 μM against PAO1-L and PA14 strains respectively, 
whilst it was inactive in the matched-pair analogue 42.  
In the first SAR study, it was noticed that the 8-bromo-5-methyl-5H-[1,2,4]triazino[5,6-
b]indole and 5-methyl-5H-[1,2,4]triazino[5,6-b]indole analogues demonstrated 
divergent SAR results. However, We did not find any compound showing improved 
activity against PAO1-L compared with 19 but analogues 46, 54-56 displayed 
improved pqs inhibition against the more clinically relevant PA14 strain.  
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2.2.2 The second SAR study around the tail group to improve analogues’ pqs 
inhibition 
2.2.2.1 The design of the second SAR study  
Given that analogues bearing an R2 para- substituent displayed the best pqs inhibitory 
activity in the previous SAR studies, it was decided to further investigate SAR through 
introducing a set of substituents at the para position of the aryl tail group.  
Assisted by docking studies, it was found that when R2 was cyanomethyl and R1 kept 
as hydrogen, the resulting compound 65 displayed the highest docking score (Glide 
SP, -8.850) among all compounds (Figure 23). 
 
Figure 23. The predicted compound binding mode for 65 in the PqsR LBD. It 
suggested that the head group of 65 can have a π stacking with Tyr258, whilst the 
amide linker can act as HBD and hydrogen bond with Leu207. The yellow line indicates 
hydrogen binding. The blue line indicates a π- π stacking. The scaffold of 65 was 
represented in yellow.  
Inspired by literature compound 7 in which the para-phenoxy group of 7 has a π 
stacking interaction with Tyr258, compound 66, 67, and 68 containing a para-phenoxy 
group were designed (Figure 24).  




Figure 24. The structure of compound 7 and 66-70.  
Based on the high level of scaffold similarity between 7 and 66 and combined with 
docking studies, it was hypothesised that 66 may have a similar ligand binding mode 
to 7 in which the para-phenoxy group may also be able to partake in a π-stacking 
interaction with Tyr258 (Figure 25). Based on this hypothesis, compound 69 and 70 
were designed to enhance this potential π-stacking by adding inductive electron-
withdrawing nitrogen atoms for the design of electron deficient rings. 




Figure 25. Structural comparison between 7 and 66 and predicted binding mode of 
66 and X-ray crystal of 69-PqsR LBD. (A) 3D- alignment of 7 and 66. It suggested that 
compounds 66 and 7 can have a similar ligand binding mode considering the structure 
similarity; (B) The predicted compound binding mode for 66 in PqsR LBD (PDB: 4JVD). 
(C) X-ray crystal of 69-PqsR LBD. Comparing (B) and (C), it was noticed that 
compound 66 and 69 adapted to PqsR LBD in a similar conformation, which suggested 
that the docking study can be accurate for the prediction of 66 ligand binding 
mode.The yellow dash lines indicate hydrogen bond interactions. The blue line 
indicates a π-stacking. The scaffold of 66 was represented in orange. The scaffold of 
69 was represented in green. 
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2.2.2.2 The synthesis of compound 66-70 for the second SAR study  
The synthetic route for 66-70 is summarised in Scheme 3. Key intermediates 35-37 
were subjected to amide coupling reactions with the aniline 71 using HATU as coupling 
reagent to give compounds 66-68. 
The N-Boc-4-hydroxyaniline 72 was subjected to an Ullmann-type cross coupling 
reaction with 2-bromopyridine or 2-bromopyrimidine using CuI as catalyst and picolinic 
acid as the ligand to give N-Boc-protected intermediates 73 and 75. After acidic 
treatment of 73 and 75, the resulting anilines 74 and 76 were then subjected to 
alkylation followed by nucleophilic aromatic substitution reactions with key 
intermediate 29 to yield analogues 69 and 70.  
Scheme 3 Preparation of target compound 66-70 
 
aReagents and conditions: (i) 71, HATU, DMAP, NMP, rt (ii) 2-bromopyridine or 2-
bromopyrimidine, CuI, picolinic acid, K3PO4, DMF, 100oC, 20%; (ii) 4M HCl in 1,4-
dioxane, rt, >100%; (iii) 2-bromoacetyl chloride, Et3N, DCM, 0°C to rt; (iv) 29, Et3N, 
DCM, 0°C to rt, overall 30%. 
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2.2.2.3 Results for the second SAR study  
The synthesized analogues were then evaluated in bioreporter assays for the 
determination of pqs inhibition. These showed that 65 was more active than hit 19 
against both PAO1-L and PA14 with IC50 values of 0.62 μM and 2 μM, respectively 
Table 3. Compounds 66-68 containing a para-phenoxy tail group were active against 
PAO1-L in which 66 was equal potent with 7 and displayed improved pqs inhibition 
than 19 against PAO1-L.  
Introducing heteroatoms on the R2 aromatic substituent, the resulting pyridine-2-yloxy 
analogue (69) was equal potent with 7 against PAO1 strain displaying an IC50 value 
of 0.25 μM and slightly more potent than 7 against PA14 showing an IC50 value of 0.34 
μM. 
Table 3. The SAR around the tail group for compound 65-70 
 
 R1 R2 
Remaining Activity (%)a,b,c,e IC50 (μM) c,d,e 
PAO1 PA14 PAO1-L PA14 
DMSO   100.00 ± 8.37 100.00 ± 3.87 - - 
7f   - - 0.32 ± 0.14 1.22 ± 0.34 
19 H 4-Cl 32.98 ±10.30 73.41 ± 24.52 0.98 ± 0.15 NA 
65 H cyanomethyl 16 ± 6.5 19 ± 5.4 0.62 ± 0.1 2 ± 0.17 
66 H phenoxy 11.54 ± 2.22 15.37± 12.24 0.38 ± 0.06 0.35 ± 0.06 
67 Br phenoxy 11.85 ± 2.32 56.63 ± 46.23 4.36 ± 0.42 - 
68 OMe phenoxy 14.49 ± 2.28 - 4.81±0.49 3.15 ± 0.45 
69 H pyridin-2-yloxy 12 ± 2.7 21 ± 9.7 0.25 ± 0.12 0.34 ± 0.03 
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 R1 R2 
Remaining Activity (%)a,b,c,e IC50 (μM) c,d,e 
PAO1 PA14 PAO1-L PA14 
70 H pyrimidin-2-yloxy 21 ± 5.5 49 ± 1.0 - - 
aData shown are mean values obtained from three independent experiments 
performed in triplicates. b% Remaining Activity (RA%) screening at single 
concentration (10 μM) in triplicates. c The inhibitory effect evaluated using PAO1-
LmCTX::PpqsA-lux and PA14mCTX::PpqsA-lux reporter assays. Remaining activity 
(RA%) values below 50%, compounds were regarded as active. RA% values do not 
have a linear relationship with IC50. dNA : not active. e-: not available. f positive control. 
The determination of RA% and IC50 for compounds 65-70 was conducted by Dr. Fadi 
Soukarieh. 
The X-ray co-crystal structure of 69 in complex with PqsR LBD was determined using 
soaking method (Figure 26A). It revealed that 69 binds to the pqsR LBD hydrophobic 
pocket where native ligands PQS and HHQ also bind. The tricyclic head group inserts 
deeply into the hydrophobic pocket, whilst the thioamide linker penetrates through the 
narrow U-shaped channel. Similar to 7, the sulfur atom on the linker locked the overall 
conformation that allowed 66 to bend and accommodate into the hydrophobic pocket. 
The aromatic tail group points outside the pocket and has a π-stacking interaction with 
Tyr258 with a distance of 4.55 Å. Interestingly, compound 69 lost the hydrogen bonding 
with Gln194 compared with 7 but obtained a new hydrogen bonding interaction with 
Leu207 with a distance of 3.43 Å. The X-ray structure also showed that the pyridinyl 
side chain of compound 69 had better overlap with Tyr258 compared to the phenyl side 
chain of 7 (Figure 26 B), which suggested that 69 may have a stronger π stacking 
interaction with Tyr258.  
Compound 69 was found to be more active than 7 PA14 and it may suggest that the 
π-stacking with Tyr258 could be more important for analogues to retain pqs inhibition 
than hydrogen bonding interactions. Unfortunately, the co-crystal structures of 66 and 
67 in complex with PqsR LBD did not obtain mainly due to poor ligand solubility. 




Figure 26. (A) X-ray co-crystal structure of 69 bound to PqsR ligand binding domain 
with a resolution of 3.2 Å. The scaffold structure of 69 is represented in green. (B) 
Comparison of ligand binding modes between 69 and 7 in PqsR LBD. The scaffold 
structure of 69 is represented in blue and 7 is represented in green.  The X-ray 
crystallography experiment was conducted by William Richardson.  
2.2.3 The design of compound 79 to improve solubility   
The 5-methyl-5H-[1,2,4]triazino[5,6-b]indole analogues suffer poor solubility mainly 
due to the planar hydrophobic tricyclic head group. Whilst there are some general 
formulation approaches to enhance compound solubility such as decrease of particle 
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size, salt formation and solid suspension formation169, the improvement of intrinsic 
compound solubility is more desirable as it can reduce the need to rely up later 
formulation approaches. In this work, a 4-methylpiperazine group was introduced as 
an ionizable centre to improve solubility. According to docking study (Figure 27), 
introducing a 4-methylpiperazinyl group at the 3-position of the terminal aryl group, 79 
can still bind in the PqsR LBD without unfavourable steric clash.  
 
Figure 27. Predicted binding modes of compound 79 with PqsR LBD and 69-PqsR 
LBD crystal.  (A) Compound 79 is predicted to hydrogen bond with Leu207 and form a 
π-stacking interaction with Tyr258.  Comparing (A) and (B), it was noticed that 
compounds 69 and 79 adapted in the PqsR LBD in a similar conformation. This 
suggested that the docking study can be accurate for the prediction of compound 79 
ligand binding mode. Hydrogen bonds are shown as yellow dash lines. π stacking is 
shown as green dash lines. The ligand scaffolds were represented in green.  
2.2.3.1 The synthesis of 79   
Compound 79 bearing the N-methylpiperazine solubilising moiety was synthesized as 
outlined in Scheme 4. Compound 80 was subjected to reductive amination with 1-
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methylpiperazine using NaBH(OAc)3 as the reducing reagent to give intermediate 81. 
Compound 82 was obtained by Ullmann-type cross coupling reaction starting from 81 
using CuI as catalyst and picolinic acid as the ligand. Key intermediate 83 was 
synthesised through nitro reduction from 82 using NH4Cl and Fe in EtOH and H2O at 
55-90 oC, followed by amide coupling to give final compound 79. 
Scheme 4. Preparation of 79 from 2-hydroxy- 5-nitrobenzaldehyde (80) 
 
aReagents and conditions: (i) 1-methylpiperazine, HOAc, sodium 
triacetoxyborohydride  (NaBH(OAc)3), THF, rt; (ii) phenol, CuI, picolinic acid,  K3PO4, 
DMF, 100oC; (iii) NH4Cl, Fe, EtOH, H2O, 55-90 oC; (iv) 35, HATU, DMAP, DIPEA, NMP, 
rt. 
2.2.3.2 Biophysical and bioreporter assay screening of 79 
Compound 79 was subjected to mCTX::PpqsA-lux-based bioreporter assay based 
bioreporter assays for the determination of pqs inhibition and shown to be inactive in 
vitro assays. This may indicate the poor cell permeability of compound 79 at 
physiological pH where the majority of compound 79 in solution will be protonated 
considering the pKa values of the 4-methylpiperazinyl group (approximate 10.5 and 
7.0).  
In this thesis, a thermal shift assay (TSA) was introduced as a powerful biophysical 
method to detect ligand and protein interactions, which detects ligand binding with an 
affinity range from mM to µM. TSA detects ligand-protein interactions directly and 
therefore eliminates ligand penetration problems, which is commonly noticed in whole-
cell based bioreporter assays.  
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Table 4. The in vitro and physiochemical data for compounds 69 and 79 






DMSO / 100.00 ± 8.37 0 0 
69 
 
12 ± 2.7 + 4.4 + 3.6 
79 
 
NA + 6.4 + 6.2 
aData shown are mean values obtained from three independent experiments 
performed in triplicates. b% Remaining Activity (RA%) screening at single 
concentration (10 μM) in triplicates. c The inhibitory effect evaluated using PAO1-
LmCTX::PpqsA-lux. Remaining activity (RA%) values below 50%, compounds were 
regarded as active. RA% values do not have a linear relationship with IC50. dNA : not 
active. e Thermal shift assay (TSA, °C) at two ligand concentrations (250 and 500 µM) 
in triplicates.f: positive control. The determination of RA% for 69 was conducted by Dr. 
Fadi Soukarieh.  
In TSA, PqsR LBD was treated with 79 at 250 µM and 500 µM ligand concentrations 
in the presence of SYPRO™ Orange. As mentioned previously, when the protein 
unfolds, the environmentally sensitive fluorescent dye, SYPRO™ Orange, is able to 
bind to the protein hydrophobic core, leading to a large increase in fluorescence. 
Through monitoring the fluorescence change during the protein-unfolding transition 
process, the melting temperature (Tm), defined as the temperature where 50% of 
protein sample is unfolded, can be determined. When ligands bind to the protein, this 
could either stabilize or destabilize the protein reflected as an increase or decrease of 
Tm. If the ΔTm is higher than 0.5 °C, it is generally considered that ligand binding has 
taken place.  
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Compound 79 stabilized the protein with an increase of ∆Tm value for 6.4 °C and 
6.2 °C at 250 µM and 500 µM ligand concentration, respectively Table 4, which is 
higher than the most potent compound 79. These results suggested that 79 stabilised 
the PqsR protein and the loss of pqs inhibition on the whole cell-based assay may be 
due to either cell-penetrating or efflux mechanisms. 
2.2.4 Investigation of the pharmacophore model based on an SAR exploration 
around the 5-methyl-5H-[1,2,4]triazino[5,6-b]indole analogues 
2.2.4.1 The design of three series of analogues to investigate the 
pharmacophore for the 5-methyl-5H-[1,2,4]triazino[5,6-b]indole derivatives 
The 5-methyl-5H-[1,2,4]triazino[5,6-b]indole analogues are structurally distinct from 
PqsR native ligands but display common structural features: a tricyclic head group, an 
aryl tail group and a linear linker. Further SAR was conducted to investigate the 
influence of these structural features on pqs inhibition and the proposed 
pharmacophore (Figure 28).  
 
Figure 28. The schematic representation of the design of the SAR study to investigate 
pharmacophores for the 5-methyl-5H-[1,2,4]triazino[5,6-b]indole derivatives. Methyl 
groups were introduced to the linker region to investigate the influence of ligand 
conformation, ligand flexibility and HBD/HBA on pqs inhibition (scaffold A). The aryl 
tail group were replaced to a non-aromatic ring system to investigate the influence of 
aryl tail group to pqs inhibition (scaffold B). In order to investigate the head group ring-
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size effects on pqs inhibition, the linker and tail group were kept constant as for 19, 
whilst the head group were changed to single ring systems (scaffold C).  
2.2.4.2 The synthesis of designed analogues 
The forward synthetic scheme for the preparation of 92-95, 98 and 100 was depicted 
in Scheme 5. For analogues with substituted linkers, the para-chloro aniline or 4-
chloro-N-methylaniline was firstly acylated with acyl chlorides 84-86 using Et3N base 
to give amide intermediates 87-91, which were then subjected to nucleophilic 
substitution to give analogues 92-95. Intermediate 96 was prepared through acylation 
of cyclohexanamine with 86, which was then subjected to nucleophilic substitution with 
29 to give 98. Compound 97 were subjected to amide coupling reactions with 35 using 
HATU as coupling reagent to give compounds 99 followed by acidic treatment to yield 
the targeted compound 100. 
Scheme 5. Preparation of 92-95, 98 and 100 
 
aReagents and conditions: (i) 4-chloro-N-methylaniline or 4-chloro-aniline or 29, Et3N, 
DCM, 0 °C to rt. (ii) 35, HATU, DMAP, NMP, rt, overall 30%; (iii) 4M HCl in dioxane, 
rt, >100%; 
The preparation for analogues with a single ring system as the head group (103 and 
104) is represented in Scheme 6. 2-Mercaptopyrimidine 101 and its 4,6-dimethyl 
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analogue 102 were alkylated with intermediate 91 using Et3N in DCM to give thioethers 
101 and 102. 
Scheme 6. Preparation of compounds 101 and 102 
 
aReagents and conditions: (i) 101, 91, Et3N, DCM, 0°C to rt, 24%; (ii) 102, 91, NaH, 
DMF, 0°C to rt, 36%. 
2.2.4.3 The pharmacophore analysis based on bioreporter assay screening 
results 
The results showed that when introducing methyl groups in R2 and/or R3, whilst the 
head and tail groups were maintained as in 19, the resulting compounds 92-95 proved 
inactive against PA01-L and PA14 (Table 5, scaffold A).  
Table 5. The in vitro data for compounds 92-95, 98, 100, 103, and 104 
 
Entry  Scaffold R1d R2 R3d Xd 
Remaining Activity (%)a, b, e 
PAO1-L PA14 
DMSO /  100.00 ± 8.37 100.00 ± 3.87 
Sen19f / 26.20 ± 10.33 24.57 ± 3.87 
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Entry  Scaffold R1d R2 R3d Xd 
Remaining Activity (%)a, b, e 
PAO1-L PA14 
92 A / CH3 H / 83.60 ± 5.43 / 
93 A / (CH3)2 H / 110.14 ± 8.36 / 
94 A / H CH3 / 80.24 ± 20.14 97.02± 6.36 
95 A / CH3 CH3 / 64.64 ± 17.52 96.17± 10.74 
98 B / CH2 92.86 ± 12.05 / 
100 B / NH 100.92 ± 13.33 / 
103 C H / NA / 
104 C CH3 / NA / 
aData shown are mean values obtained from three independent experiments 
performed in triplicates. b% Remaining Activity (RA%) screening at single 
concentration (10 μM) in triplicates. c The inhibitory effect evaluated using PAO1-
LmCTX::PpqsA-lux and PA14mCTX::PpqsA-lux reporter assays. Remaining activity 
(RA%) values below 50%, compounds were regarded as active. RA% values do not 
have a linear relationship with IC50. dNA : not active. e/: not available. f positive control. 
The determination of RA% for compounds 92-95, 98, 100 was conducted by Dr. Fadi 
Soukarieh. 
The terminal aryl tail group were replaced with a non-aromatic ring system (Table 5, 
scaffold B) and the resulting compounds 98 and 100 lost activity. This may result from 
the loss of π stacking between the aryl tail and Tyr258, which was commonly noticed 
in previous active analogues. This finding indicates that it is important to retain the 
terminal group aromaticity for good pqs inhibition. 
In order to investigate the head group ring-size effects on pqs inhibition, the linker and 
tail group were kept constant as for 19, whilst the head group were changed to single 
ring systems (Table 6, scaffold C). The resulting compounds 103 and 104 lost activity. 
Both the 5-bromine substituted and unsubstituted 5-methyl-5H-[1,2,4]triazino[5,6-
b]indole head group can be important pqs inhibition in terms of shape complementarity 
and lipophilicity. With a smaller molecular size, the single ring system analogues can 
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have a different occupancy for the PqsR LBD compared with the 5-methyl-5H-
[1,2,4]triazino[5,6-b]indole analogues. Reducing the ring size also significantly 
changes the lipophilicity reflected by CLogP values decreasing from 3.95 (19) to 2.40 
(103) and 3.40 (104). Loss of lipophilicity can affect cell penetration and ultimately 
influence pqs biological activity. Therefore, it appears important to possess a 
hydrophobic centroid on the compounds scaffold to retain pqs inhibition.  
2.2.5 Concept validation investigation for the three essential structure features 
and their effects on pqs inhibition  
In the previous pharmacophore investigation, it was shown that structural features 
including a hydrophobic head group, flexible linker and aryl tail group are essential for 
the 5-methyl-5H-[1,2,4]triazino[5,6-b]indole analogues to retain pqs inhibition.  
Based on these results, it was decided to use a reversed fragment-based lead 
discovery method (FBLD) to investigate key structure features and their influences on 
pqs inhibition. In doing so, the drug-sized scaffold of 5-methyl-5H-[1,2,4]triazino[5,6-
b]indole analogues was deconstructed into fragments, which contain key structure 
features and bioreporter assay and biophysical methods were used to detect ligand-
protein interactions (Figure 29).  
It was hypothesised that the tricyclic head or aryl tail group fragments should show 
lower pqs inhibition and/or ΔTm values and along with the growing of these fragments 
to drug-sized compounds (350 < MWt. < 500), the compounds in vitro and biophysical 
profiles should improve correspondingly. 
 




Figure 29. Schematic diagram for the use of FBLD methods in investigation of the 
essential structure features of 5-methyl-5H-[1,2,4]triazino[5,6-b]indole analogues and 
their effects on pqs inhibition. 
The head group fragments 105 was inactive against PAO1-L and PA14 in cell-based 
bioreporter assays, whilst 105 weakly stabilized PqsR protein observed as an increase 
of ΔTm of 0.1 °C at 500 µM (Table 6). Incorporating a CH2COO(t-Butyl) linker, the 
resulting analogue 32 strongly stabilized the PqsR LBD protein observed as a 2.0 °C 
(500 µM) and 1.36 °C (250 µM) increase of Tm values. Incorporating a CH2COOH 
linker, 35 weakly destabilized the protein observed as -0.3 °C ΔTm value (500 µM). 
Introducing the aryl tail group, the corresponding N-phenyl analogue of 38 was inactive 
against PAO1-L and PA14 but strongly stabilized the protein observed as 1 °C ΔTm 
value (500 µM).  
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Table 6. The in vitro and biophysical data for compound 105, 32, 35, and 38 
 
Entry R1 
Remaining Activity (%)a,b,c,d, f ΔTm: (± °C) a,e, f 
PAO1 PA14 500 (µM) 
250 
(µM) 
DMSO - 100 ± 8.37 100 ± 3.87 0 0 
Sen19 - 26.20 ± 10.33 24.57 ± 3.87 +14.2 +14.2 
105 CH3 NA NA +0.1 0 
32 CH2COO(t-Butyl) NA NA +2.0 +1.4 
35 CH2COOH NA NA -0.3 -0.1 
38 N-CH2CONH-phenyl 80.26 ± 23.75 NA +1.0 +1.0 
aData shown are mean values obtained from three independent experiments 
performed in triplicates. b% Remaining Activity (RA%) screening at single 
concentration (10 μM) in triplicates. c The inhibitory effect evaluated using PAO1-
LmCTX::PpqsA-lux and PA14mCTX::PpqsA-lux reporter assays. Remaining activity 
(RA%) values below 50%, compounds were regarded as active. RA% values do not 
have a linear relationship with IC50. dNA : not active. e Thermal shift assay (TSA, oC) 
at two ligand concentrations (250 and 500µM) in triplicates. f-: not available.  The 
determination of analogues RA% was conducted by Dr. Fadi Soukarieh. Compound 
105 used in this assay were synthesised by project students.  
 
2.3 Conclusion  
In this work, a novel series of 1,2,4-triazino[5,6-b]indole-3-thiol derivatives were 
synthesized and shown to be PqsR antagonists in bioreporter assays. X-ray 
crystallography results on key compounds demonstrated ligand target interactions. A 
straightforward synthesis of 5-methyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol derivatives 
was reported with overall good yields. 8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-
b]indole-3-thiol derivatives displayed an overall improved  pqs inhibition compared to 
the corresponding des-bromo analogues. 
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Introducing aromatic substituents onto the tail group led to a significant increase in pqs 
inhibition and the corresponding pyridin-2-yloxy analogue 69 was more active than the 
literature compound 7. The X-ray crystal structure of 69-PqsR LBD complex was 
obtained, which provided insights into the ligand binding mechanism. Further 
investigations around pharmacophores for the 5-methyl-5H-1,2,4-triazino[5,6-
b]indole-3-thiol analogues suggested that the tricyclic head group, unsubstituted linker 
and tail group aromaticity are essential for pqs inhibitory activity.  
In this chapter, fragment-based methods were used for a concept validation 
experiment where the 5-methyl-5H-1,2,4-triazino[5,6-b]indole-3-thiol analogues’ 
scaffold were firstly deconstructed into fragments. Assisted by TSA method it was 
noticed that along with the growing of these fragments to drug-size compounds, the 
corresponding analogues showed improved biophysical profile. These results 
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Chapter III: Using in silico, in vitro and biophysical methods 
for the fragment-based hit identification and optimization 
for PqsR inhibition 
3.1 Introduction and project aim  
Fragment-based lead discovery approaches have become an important lead 
discovery technique for both established and new drug targets in the last 20 years. 
87,124,170,171 However, FBLD methods have not been widely applied in the identification 
of PqsR antagonists with only three publications at the time of writing this thesis. 
152,172,173  
In the last chapter, a fragment-based lead discovery (FBLD) method was applied in a 
concept validation experiment where the 5-methyl-5H-1,2,4-triazino[5,6-b]indole-3-
thiol analogue scaffold was deconstructed into fragments. Growing the fragments 
(MWt < 300) to drug-sized compounds (300 < MWt < 500) afforded a corresponding 
improvement in in vitro pharmacological and biophysical profiles. This finding suggests 
the fragment-based method can be applied for PqsR antagonist identification. In this 
chapter, a fragment hit identification and optimization workflow are presented (Figure 
30). 




Figure 30. A fragment hit identification, optimization, and evolution workflow. In silico 
methods were used for fragment library screening against PqsR LBD followed by a 
manual inspection step where fragment hit candidates were then determined. The 
selected fragments were then subjected to fragment screening using bioreporter 
assay and biophysical methods, which allowed for the identification of fragment hits. 
Fragment hits were then advanced to hit exploration to optimise binding interactions 
before being subjected to the fragment evolution step.  
3.2 Using an in silico method for fragment screening against PqsR 
LBD 
Biophysical, bioreporter assay and in silico methods are commonly used in fragment 
library screening.174,102,175 In this work, an in silico method requiring less resource and 
time investment 126,176,177,178 was chosen to be the primary virtual screening method.  
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The previous 5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thiol analogues suffer from 
poor solubility believed to be due to the hydrophobic aryl head group. It was decided 
to introduce more sp3 character to this region to improve both compound solubility and 
novelty. The selection of fragment libraries for the virtual screening were therefore 
tailored to sp3 character rich fragment libraries. 
3.2.1 Selection of five fragment libraries for virtual screening   
Four fragment libraries from the Enamine company were selected for virtual screening, 
which were: 3D-shape diverse fragment library, essential fragment library, single 
pharmacophore library, and sp3 rich fragment library.  
The essential fragment library from Enamine contains 320 fragments, which stems 
from literature-reported fragments and molecules with determined protein-ligand 
crystallography data. All the fragments in this library have been tested for water 
solubility and chemically stability, and therefore are suitable for secondary biophysical 
or bioreporter assay screening. 
The Ro3 fragment library is the world’s largest collection of fragments, which contains 
2,725,753 fragments. It should be noticed that in this library, toxicophores and 
chemically reactive motifs were removed to yield better “lead-like” compounds at a 
later stage.  
The single pharmacophore fragment library contains 1,500 compounds in which 
fragments have a single polar group or one motif for ligand-protein interaction. 
Fragments in this library tend to have lower synthetic complexity compared with the 
previously mentioned fragment libraries and therefore are more likely to be 
synthetically accessible in the later follow-up fragment growing stage.  
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The sp3 rich fragment library contains 50,272 fragments, in which the Fsp3 cut-off score 
was set at 0.47 and has become the largest and most diverse commercial sp3 
character rich fragment library.It has been shown that a higher Fsp3 value can lead to 
an increased clinical success rate, which may relate to improved solubility and better 
occupancy of the biological targets of interest. 107,179 
 F12! 	= 	 "#$	&'()$*	+,	-.!/0*)+&-"#$	1+102	&'()$*	+,	/0*)+&-  (4) 
3.2.2 Selection of optimal fragment starting points based on the virtual 
screening results 
Docking studies were performed on Maestro using HTVS (High-throughput virtual 
screening) mode against PqsR LBD crystal structure (PDB code: 4JVD; force field: 
OPLS3e). 
 
Figure 31. The histogram of docking scores for all molecules screened. Fragments 
tend to have low affinity to the biological targets reflecting as higher docking scores. 
Most of the fragments screened for this work displayed docking scores in a range from 












































































































































































































Docking scores for screened fragments
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A manual inspection step of high-scoring fragments was introduced. Fragments with 
a docking score lower than -6.5 were manually filtered based on their synthetic 
complexity, the possibility for further chemical modification and their commercial price, 
which ultimately afforded 7 promising fragment starting points 106-112 (Figure 32).  
 
Figure 32. Seven high-scoring fragments from virtual screening 106-112 and the 
fragment extract from the 5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thiol analogues 
(29). The boxes highlight functionalities from which fragment elaboration can take 
place.  
Fragments 106-112 displayed good fragment-likeness according to the Ro3 and good 
physicochemical profiles. In particular, the low lipophilic nature of these fragments is 
beneficial in the later fragment-to-lead modification process (Table 7). Fragments 106-
112 are all commercially available and have suitable functional groups for further 
elaboration including carboxylic acid (R-COOH), thiol (R-SH), amine (R-NH2), and 
alcohol (R-OH) groups.  
Table 7. Fragments physicochemical properties and molecular docking scores 
Comp. Docking score CLogPa MWt. HBD/HBA 
106 -6.683 1.042 165.21 1/2 
107 -7.815 0.645 207.23 1/3 
108(S) -6.760 1.194 177.20 1/2 
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Comp. Docking score CLogPa MWt. HBD/HBA 
108(R) -7.164 1.194 177.20 1/2 
109 -6.890 1.973 173.17 0/3 
110 -7.009 0.400 163.14 0/4 
111 -7.001 1.746 196.22 0/3 
112 -6.571 1.844 270.09 0/3 
29 -7.156 2.310 216.26 1/3 
a Calculation of CLogP using software ChemDraw Professional 16.0. Calculation of 
HBD/A using software MarvinSketch 20.11 at pH 7.4.  
Fragments 106-112 showed good docking scores (Maestro, HTVS mode) in a range 
from -6.571 to -7.815 and all fragments were predicted to fit into the same region in 
PqsR LBD (Figure 33a). Fragment 29 is extracted from the head group of 69 which is 
a potent PqsR inhibitor from our previous work and was included as a reference 
fragment in the docking study (Figure 33j). Some fragments selected from the virtual 
screening have better docking scores and CLogP values than 29, which gave us conf 
idence to continue with these fragments.  
The secondary screening using the bioreporter assay, TSA and ITC methods were 
performed on 106-112 and 29 to confirm fragments binding to PqsR protein.  




Figure 33. The predicted compound binding mode for 106-112 in the PqsR LBD (a-i) 
(Maestro, PDB: 4jvd). (a)  Fragments 106-112 were predicted to fit into the same 
region in PqsR LBD. (b-i) Fragments 106-112 were predicted to have hydrogen 
bonding interactions within local environment.  106 and 112 were predicted to form a 
hydrogen bond with Gln194. Fragment 107, 108, 109, 110, 111 can act as HBAs and 
have a hydrogen bond interaction with Leu197. Fragment 108 is a chiral molecule and 
the R enantiomer was predicted to have hydrogen bond interactions with both Leu197 
and Ile236, whilst the S enantiomer can only have a hydrogen bonding with Leu197. 
Hydrogen bonds are shown as yellow dash lines. The ligand scaffolds were 
represented in grey. (j) The scaffolds for compound 69 and 29.  
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3.3 Using bioreporter assay and biophysical methods for the 
secondary screening on the selected fragments (106-112 and 29) 
As introduced in the first chapter, fragments tend to weakly bind to biological targets 
with affinity values in a range from micromolar (µM) to millimolar (mM), which is a 
challenge in identifying weak binders. An inappropriate screening method can lead to 
either false positives or a low hit rate. In this work multiple methods, including 
bioreporter assay, TSA and ITC methods were used to cross validate fragment 
candidates in order to yield high quality hits.  
3.3.1 Bioreporter assay and TSA screening results on the selected fragments 
The mCTX::PpqsA-lux-based bioreporter was used for the evaluation of the fragments 
pqs inhibition against PAO1-L strain. PAO1-L culture was treated with a 50 µM 
fragment solution and fragments showing a pqs activity reduction greater than 30% 
(i.e. RA% < 70%) were regarded as being weakly active. Results showed that only 
106, 107 and 108 were weakly active against PAO1-L in the initial spot test, however 
these results could not be repeated in later experiments Table 8.  
TSA was then introduced to detect fragment and protein interactions. As previously 
described, SYPRO™ Orange was used as the fluorescent dye to monitor PqsR LBD 
thermal stability. When ΔTm is higher than 0.3 °C at 500 µM ligand concentration, it 
can be inferred that the fragment strongly binds to the protein reflected by a significant 
thermal stability change. 
Fragment 106 strongly stabilized the protein reflected by the observed increase of 
0.5 °C ΔTm value compared with the DMSO reference (Table 8). Compound 29 
strongly destabilized the protein displayed negative ΔTm values of -7.7 °C and -
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14.4 °C at 250 µM and 500 µM ligand concentrations, respectively. Compounds 107 
(ΔTm = - 0.3 °C) and 112 (ΔTm = - 0.4 °C) moderately destabilized the protein, which 
could attribute to  the fragment stabilising the unfolded protein or protein 
aggregation.131 Fragments 108-111 did not show a large ΔTm change at the testing 
concentrations and were not progressed further. 
Table 8. Fragments 106-112 and 29 RA% and TSA screening results 
Structure Comp. 
Remaining Activity 
(%)a,b, c,d,e ΔTm (±°C)
e 
Initial 
screening Repeats 500 (µM)
a,e 250 (µM)a,e 
DMSO  100% 100% 0 0 
 
106 71.2 ± 6.5 NA + 0.5 + 0.4 
 
107 67.9 ± 3.5 NA - 0.3 - 
 
108 70.8 ± 4.2 NA - 0.2 - 
 
109 NA - + 0.1 - 0.1 
 
110 NA - + 0.1 + 0.3 
 
111 NA - 0 + 0.1 
 
112 NA - - 0.4 - 0.1 
 
29 NA - - 14.4 - 7.7 
aData shown are mean values obtained from three independent experiments 
performed in triplicates. b% Remaining Activity (RA%) screening at single 
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concentration (50 μM) in triplicates. c The inhibitory effect evaluated using PAO1-
LmCTX::PpqsA-lux reporter assays. Remaining activity (RA%) values below 70%, 
fragments were regarded as active. RA% values do not have a linear relationship with 
IC50. dNA : not active. e”-“: not available. fThermal shift assay (TSA, °C) at two ligand 
concentrations (500 and 250 µM) in duplicates or triplicates.  The determination of RA% 
was conducted by Dr. Fadi Soukarieh and repeated by me. The determination of TSA 
(± °C) was conducted in collaboration with William Richardson.  
3.3.2 ITC experiment on 106 and 108  
In order to determine the thermodynamic parameters of 106 binding to PqsR protein, 
ITC experiments were conducted by titrating 5 mM of 106 in the presence of 200 µM 
PqsR protein solution. The data analysis was conducted in Origin software and the 
resulting binding thermograms for 106 are shown in Figure 34. 
As the titration progressed, the ligand binding sites became saturated, reflected by the 
peak of heat changes becoming smaller and at the end of the titrations, a great portion 
of the binding site was saturated leaving only the heat of dilution. This result confirmed 
the binding of 106 to PqsR protein with an average dissociation constant (Kd) value of 
864.5 µM based on the two titrations. The average change of enthalpy (ΔH) was 6.18 
kcal/mol and the stoichiometry (N) was closed to 1. This allowed further calculation of 
the Gibbs free energy change (ΔG) and entropic contribution to binding (-TΔS) 
according to equations 5 and 6, which gave an average ΔG value of 4.18 kcal/mol 
and -TΔS as 2 kcal/mol. 
                                                        	∆3 = −RTln56                                                     (5) 
                                                      			∆3 = 	∆7 − T∆8                                                  (6)                             
Where R indicates the gas constant, 8.314 J k-1mol-1 and T indicates temperature in 
Kelvin. 
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In general, a favourable enthalpy change can result from hydrogen and van der Waals 
bonding interactions within the ligand binding site, whilst unfavourable entropy 
contribution (the positive  -TΔS value) can be attributed to unfavourable hydrophobic 
effect and ligand flexibility180,181. The positive -TΔS and negative ΔH values of 106 
suggest that the binding of 106 to PqsR LBD was mainly enthalpically driven (Figure 
34C). 
The enthalpically favourable and entropy unfavourable binding of 106 to PqsR LBD 
can be attributed to the flexible alcohol group on 106. This alcohol group was predicted 
to have a hydrogen bonding interaction with Gln194 in the docking study, whilst the 
rotatable methylene bond can lead to the entropic penalty.  
It has been widely accepted that ligands with favourable enthalpic binding signatures 
are optimal for hit selection as it is easier to increase the entropic contribution but 
harder to improve enthalpic contribution in later hit-to-lead optimization processes. 
181,182 As such, fragment 106 showing an enthalpically preferred binding towards PqsR 
protein was selected as hit.  






Figure 34. ITC results for 106 in duplicate. (A) and (B) showed the raw data output: 
the injection peaks (on the top) and the integrated data (on the bottom). The duplicates 
were using the same experimental setting up by titrating 5 mM 106 in the presence of 
200 µM PqsR protein solution. (C) indicated the thermodynamic parameters for 106.  
The determination of 106 binding to PqsR using ITC was conducted by William 
Richardson.  
Binding interaction was not observed when titrating 2 mM of 108 in the presence of 50 
µM PqsR protein, therefore 108 was not progressed further (Figure 35).  
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X-ray crystallography methods were also applied to fragments 106 and 107 in order 
to obtain detailed fragment binding mode to guide later fragment evolution however 
no fragment-protein complex was obtained. Ultimately, 106 showing a clear binding to 
PqsR protein in both TSA and ITC experiments and along with 107 displayed 
promising TSA results were selected as the hit compounds and progressed to hit 
modification stage. 
 
Figure 35. ITC experiment results for 108. (A) showed the raw data output and (B) 
showed the integrated data. ITC was conducted by William Richardson.  
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3.4 Hit optimization I: fragment hit 107 exploration 
Hit exploration is essential in terms of  sampling chemical space around the initial 
fragment hits and also enable the optimization of existing molecules or explore new 
binding interactions within the ligand binding site.  
3.4.1 The design of hit exploration study for fragment 107 
Fragment 107 contains a 3-hydroxyphenyl ring and a morpholine ring linked through 
an amide bond in which the 3-hydroxyl group was predicted to hydrogen bond with 
Gln194 in docking studies. The hit exploration study initially focused on exploring the 
electrostatic requirements of ring A by changing the hydroxyl group substitution 
position or replacing the 3-hydroxyl group with other functional groups (Scaffold A, 
113-117 and 119-126 Figure 36 I). Through functionalization of the ring B on 107 or 
replacing it with other six membered ring system, the effect of the ring B was also 
investigated (Scaffold A, 118b-d, Figure 36 I). 
Fragment 141 with a different linker was designed to investigate the effect of the amide 
bond to ligand binding to PqsR protein (Scaffold B, 141, Figure 36 I).  
A retrosynthetic analysis was applied to 4-benzoylmorpholine analogues (scaffold A 
and B Figure 36 II). This indicated that scaffold A and B can be synthesized from 
simple building blocks through well documented reactions such as amide bond 
formation and reductive amination, which provided confidence to build a small 
fragment library. 
 




Figure 36. Fragment 107 optimization scheme (I) and retrosynthetic analysis of 
scaffold A, B and C (II).  
3.4.2 The synthesis of designed analogues  
The forward synthetic scheme for the majority of designed analogues was depicted in 
Scheme 7. Fragments 113, 115-117, 119-127 were achieved by amide coupling 
reactions where substituted benzoic acids 128-140 were subjected to a wide range of 
secondary amines, using HATU as coupling reagent to give targeted analogues 113, 
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115-117, 119-127.  Analogues 119a, 127, 119b-d were then treated with BBr3 to 
demethylate the aryl methyl ethers to give analogues 107, 114, 118b-d.   
Scheme 7. Preparation of targeted compound 107, 113-127. 
 
aReagents and conditions: (a) various amines, HATU, DMAP, NMP, DIPEA, rt;(b) BBr3, 
DCM, rt. 
The preparation of 141 is represented in Scheme 8. 3-Hydroxybenzaldehyde (142) 
and morpholine were subjected to reductive amination using NaBH(OAc)3 as reducing 
reagent in THF to give 141.  
Scheme 8. Preparation of targeted compound 141. 
 
aReagents and conditions: (a) 142, morpholine, NaBH(OAc)3, HOAc, THF, rt.  
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3.4.2 The results for the hit exploration study around 107 
The mCTX::PpqsA-lux-based bioreporter assay and TSA methods were applied for the 
evaluation of fragment pqs inhibition and ligand binding to PqsR protein in this hit 
exploration study. For the PAO1-LmCTX::PpqsA-lux reporter assays, PAO1-L strain 
was treated with a 50 µM fragment solution in DMSO/PPS buffer and fragments 
showing a pqs activity reduction greater than 70% (i.e. RA% < 70%)  were regarded 
as being active. In TSA, the PqsR protein was treated with a fragment solution at 500 
µM ligand concentration in the presence of the environmental sensitive fluorescent 
dye, SYPRO™ Orange.  
The hit exploration study initially focused on modifying ring A, whilst the linker and ring 
B were kept consistent as a morpholine ring as in 107 (Table 9, compounds 113-117, 
119a, 120-126). Removal of the hydroxyl group (113) or changing the hydroxyl group 
from the meta-(107) to the ortho- (114) position, caused compound to exhibit no 
inhibition against PAO1-L at 50 µM screening concentration. When replacing the 
meta-hydroxyl group with a meta-methoxy group, 119a weakly stabilized the protein, 
observed as a 0.1°C increase for ΔTm. The 3,4-dimethoxy substituted analogue 124 
weakly stabilized the protein (ΔTm = + 0.1°C), whilst the 4-hydroxy-3-methoxy 
substituted analogue 123 weakly destabilized the PqsR protein (ΔTm = - 0.1°C. The 
3, 5-di-substitued analogues 120-122 and 125 were inactive in the bioreporter assay, 
whilst 125 (R1= 3,5-diOMe) and 122 (R1= 3-OMe-5-Me) weakly destabilized PqsR 
protein observed as a 0.1°C decrease of ΔTm. The 3,4,5-trimethoxy substituted 
analogue 126 weakly stabilized PqsR protein observed by an increase of ΔTm value 
for 0.2 °C. Replacing the 3-hydroxyl group with halogen atoms, including chlorine (115, 
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117) and fluorine (116) caused the resulting analogues to show no inhibition against 
PAO1-L at 50 µM screening concentration.  
The hit exploration study then focused on modifying ring B and the linker, whilst ring 
A was kept consistent as a 3-hydroxyphenyl ring (Table 10, compounds 118b-d). 
Replacing the morpholine ring (107) with 4-methylpiperazine (118b) or piperidine 
(118c), caused no pqs inhibition at screening concentrations. Introducing methyl 
groups to R2 proved unsuccessful as 118d was inactive in the bioreporter assay. 
Replacing the amide linker with a methylene linker as in 141 caused a loss of binding 
to the PqsR protein (ΔTm = 0°C) 
Further hit exploration study was focused on modifying ring B, whilst kept ring A 
consistent as 3-methoxyphenyl group (compounds 119b-g). Fragments where ring B 
was a 4-methylpiperazinyl (119b) or piperidinyl (119c) showed no pqs inhibitory 
activity. Introducing HBA (an alcohol group) on ring B, 119e weakly destabilized PqsR, 
which was observed as a 0.2°C decrease of ΔTm. Fragment 119g containing a 
piperazine-2,6-dione ring B weakly destabilized PqsR observed as a 0.3°C decrease 
of ΔTm. Introducing a piperazin-2-one ring as ring B, 119f weakly stabilized PqsR 
protein observed as an increase in ΔTm value for 0.3 °C.  
Through the hit exploration study around 107, no fragment was found to display 
improved in vitro and biophysical profiles, except analogues 119g and 119f that were 
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Table 9. The hit exploration study around fragment 107 
 






DMSO    100.0% 0 
107 A 3-OH 11 NA - 0.3 
113 A H Ring 1 NA / 
114 A 2-OH Ring 1 NA / 
115 A 3-Cl Ring 1 NA / 
116 A 3-F Ring 1 NA / 
117 A 4-Cl Ring 1 NA / 
118b A 3-OH Ring 2 NA / 
118c A 3-OH Ring 3 NA / 
118d A 3-OH Ring 4 NA / 
119a A 3-OMe Ring 1 NA + 0.1 
119b A 3-OMe Ring 2 NA / 
119c A 3-OMe Ring 3 NA / 
119d A 3-OMe Ring 4 NA / 
119e A 3-OMe Ring 5 NA - 0.2 
119g A 3-OMe Ring 7 NA - 0.3 
119f A 3-OMe Ring 6 NA + 0.3 
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120 A 3-OMe-5-F Ring 1 NA / 
121 A 3-OMe-5-Cl Ring 1 NA / 
122 A 3-OMe-5-Me Ring 1 / - 0.1 
123 A 3-OMe-4-OH Ring 1 NA - 0.1 
124 A 3,4-di-OMe Ring 1 NA + 0.1 
125 A 3,5-di-OMe Ring 1 NA - 0.1 
126 A 3,4,5-trimethoxy Ring 1 NA + 0.2 
141 B / / NA 0 
aData shown are mean values obtained from three independent experiments 
performed in triplicates. b% Remaining Activity (RA%) screening at single 
concentration (50 μM) in triplicates. cThe inhibitory effect evaluated using PAO1-
LmCTX::PpqsA-lux reporter assays. Remaining activity (RA%) values below 70%, 
fragments were regarded as active. RA% values do not have a linear relationship with 
IC50. dNA : not active. e”/“:Not available. fThermal shift assay (TSA, oC) at 500 µM 
ligand concentrations in duplicates or triplicates. The determination of TSA (± oC) was 
conducted in collaboration with William Richardson.  
3.5 Hit optimization II: hit exploration around fragment 106 
The influence of the key structural features of fragment binding to PqsR protein was 
investigated by introducing a methyl group onto the existing linker (Figure 37, 
compound 143) or replacing the alcohol group with a primary amine group (Figure 37, 
144). Some close analogues of 106 with low synthetic complexity were also 
investigated (Figure 37, 145a-c and 146b) in order to find fragments with improved 
binding affinity compared to 106.  
 




Figure 37. The design of the hit exploration around 106.  
3.5.1 The synthesis of designed analogues  
Analogues with the benzothiazole core group (145a-c) were synthesized as outlined 
in Scheme 9. Substituted 2-aminobenzothiazoles (146a-c) were subjected to 
acetylation using acetic anhydride in the presence of DIPEA to give target analogues 
145a-c. 
Scheme 9 Preparation of targeted compound 145a-c 
 
aReagents and conditions: acetic anhydride, DIPEA, DMF, 60°C, ~80%-90%. 
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3.5.2 The results for the hit exploration study around 106 
In the hit exploration study around 106, TSA and ITC methods were applied for the 
evaluation of the fragments binding to PqsR protein. 
By introducing a methyl group on to the linker, fragment 143 may have lost the ability 
to form key binding interaction towards PqsR as there was no observable change of 
the ΔTm value.  
Replacing the alcohol group with a tertiary amine group, 144 destabilized the PqsR 
protein observed as a decrease of ΔTm value of 0.2 °C at 500 µM screening 
concentration.  
The benzothiazole analogue 145a strongly stabilized the protein observed as an 
increase of ΔTm value for 1.1 °C at 500 µM ligand concentration. Further introducing 
bromine atoms at the 5 (145b) or 6 (145c) positions of the benzothiazole ring, 
stabilized the protein observed as increase of ΔTm values for 1.9 and 1.1 °C at 500 
µM ligand concentration, respectively.  
Table 10. The hit exploration study around fragment 106 
 
ID Scaffold R1 X R2 R3 
ΔT (±°C)a,b Kd (µM) 
500 µM 250 µM No.1 No.2 
DMSO      0 0   
106 A H OH / / + 0.5 + 0.4 844 885 
143 A CH3 OH / / 0 0 / / 
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ID Scaffold R1 X R2 R3 
ΔT (±°C)a,b Kd (µM) 
500 µM 250 µM No.1 No.2 
144 A H NH2 / / -0.2 0 / / 
145a B / / H COCH3 + 1.1 + 0.5 356 409 
145b B / / 5-Br COCH3 + 1.9 / / / 
145c B / / 6-Br COCH3 + 1.1 / 39.5 / 
146b B / / 5-Br H / / 142 75 
aThermal shift assay (TSA, oC) at 500 µM and 250 µM ligand concentrations in 
duplicates. b”/“: not available. The determination of TSA (± oC) was conducted in 
collaboration with William Richardson. Kd values was obtained from ITC experiment.  
ITC experiment was conducted to further confirm the binding interactions and 
determine thermodynamic parameters of 145a, 145c and 146b to PqsR protein.  
When titrating 5 mM 145a in the presence of 200 µM PqsR protein solution, it 
confirmed the binding of 145a to PqsR with an average Kd value of 382.5 µM based 
on two titrations. The average change of enthalpy (ΔH) was 6.6 kcal/mol and the 
average values of Gibbs free energy change (ΔG) was 4.6 kcal/mol, whilst the average 
-TΔS value was calculated as 1.9 kcal/mol (Figure 38).180,181 








Figure 38. ITC results for 145a in duplicates (A) and (B) including the injection peaks 
(on the top), the integrated data (at the bottom). The ITC experiment was designed 
and conducted by William Richardson.  
Titrating 5 mM 145c in the presence of 250 µM PqsR protein solution confirmed the 
binding of 145c to PqsR protein with a Kd value as 39.5 µM and ΔH value was 2.20 
kcal/mol. It was noticed that the N value was 3.5. In general, the high N value can 
result from multiple binding sites on the protein, ligand solubility issue and the selection 
of an inappropriate binding model. As there is only one ligand binding site on the PqsR 
protein, the high N value may attribute to the poor solubility of 145c in the testing buffer 
or multiple binding interactions occurred in the same pocket (Figure 39).  




Figure 39. ITC results for 145c: (A) the injection peaks (on the top), the integrated 
data (at the bottom). The ITC experiment was designed and conducted by William 
Richardson. 
In order to improve the aqueous solubility of the bromo-substituted benzothiazole 
analogues, the free amine analogue (146b) was used in the ITC experiment instead 
of the corresponding acetamide (145b). Titrating 5 mM of 146b in the presence of 250 
µM PqsR protein solution confirmed the binding of 146b to PqsR protein with an 
average Kd value of 108 µM based on two titrations. The ΔH was 20.5 kcal/mol and N 
was 1. Further calculation gave an average ΔG value as 5.43 kcal/mol and -TΔS as 
15.1 kcal/mol (Figure 40). 









Figure 40. ITC results for 146b:  the injection peaks (A), the integrated data (B) and 
the thermodynamic parameters (C). The ITC experiment was designed and conducted 
in collaboration with William Richardson.  
3.6 Conclusion 
In this work, a novel workflow combining in silico, bioreporter assay and biophysical 
methods in fragment library screening and hit validation and optimisation was carried 
out.  
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Virtual screening was selected as the primary screening method followed by a manual 
inspection step on the high docking scoring fragments where fragments were 
assessed based on synthetic complexity.  
The selected fragments 106-112 were subjected to bioreporter assay, TSA, and/or 
ITC methods for the validation of fragment binding to PqsR protein.183  
Compounds 106 and 107 with confirmed binding interactions were regarded as initial 
hits and advanced to hit exploration study and led to fragments 145a, 145c and 146b 
with improved binding affinity.  
All the synthesised fragments were collected to build a small fragment library which 
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Chapter IV: Using fragment-based method for the discovery 
of novel PqsR antagonists for the treatment of P. 
aeruginosa infections 
4.1 Introduction and aim 
In the last chapter, through a virtual screening of fragment libraries against PqsR LBD 
followed by TSA and ITC screening, fragments 106, 144, 145a and 146b were 
identified following confirmation of ligand binding interaction with PqsR protein and 
desirable hit-likeness (Figure 41).  
 
Figure 41. Structure of fragment hits 106, 144, 145a and 146b and all compounds 
follows Ro3.  
In this chapter, fragment evolution methods including fragment growing, linking, and 
merging methods were applied to fragments 106, 144, 145a and 146b for the 
identification of lead-like PqsR inhibitors (Figure 42).  




Figure 42. Schematic representation of fragment hit evolution methods. Scheme I 
illustrated fragment evolution strategy for 106: fragment 106 was advanced through a 
fragment growing method by intruding a range of alkyl chains at R1. Scheme II 
illustrated fragment evolution strategies for fragment 144, 145a, and 146b:  structure 
extraction of the tail groups of the 5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thiol 
analogues to give fragments followed by fragment linking or merging with fragments 
144, 145a and 146b.  
The crystal structure of PqsR LBD with two bound 2-methyl-2, 4-pentanediol (MPD) 
molecules in two sub-pockets (pocket 1 and 2) has been reported (Figure 43). This 
finding suggested that PqsR LBD can be occupied by two small ligands at the same 
time and inspired us to explore fragments bind to these two adjacent pockets at the 
same time.  
It was hypothesized that  low affinity fragments bind to a sub-pocket of PqsR LBD may 
not be able to be detected by TSA or bioreporter assays, whilst these weak binding 
interactions may cause a subtle conformational change of the ligand binding pocket. 
This subtle conformational change of PqsR LBD may enhance the binding of a second 
fragment to another sub-pocket. In doing so, these two fragments can functionalize as 
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synergistic combinations observed as the fragment cocktails displaying a greater 
effect in bioreporter assay and biophysical experiments than the single fragments.  
In this work, a synergistic experiment assisted by TSA and mCTX::PpqsA-lux based 
bioreporter assay was designed for the identification of synergistic fragment pairs.  
 
Figure 43. Crystal structure of PqsR LBD with two bound MPD molecules in PqsR 
LBD (pocket 1 and 2).11 The scaffold of MPD was represented in purple (PDB 
code :4jvc). 
4.2 Advancing 106 through a fragment growing method 
Fragment 106 weakly stabilized the PqsR protein observed as a 0.5 °C decrease of 
DTm at 500 µM screening concentration in TSA. However, growing fragment 106 by 
introducing a methyl group at R1, affording fragment 143 led to no observable DTm 
change in TSA (Figure 44).  
Natural hydroxyquinoline-based agonist PQS and the benzothiazole analogues such 
as 106 both contain a bicyclic core and alcohol groups (Figure 44) and the biological 
activity of the hydroxyquinoline analogues is alkyl chain length dependent. Shortening 
the heptyl side chain of PQS decreases agonist potency in the PAO1 strain, whilst, 
lengthening the heptyl side chain to either an octyl or nonyl chain maintains potent 
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agonism. It was also demonstrated that replacing the linear heptyl chain in PQS with 
aromatic substituents (147a and 147b) abolished agonist activity.156,184–186  
Based on the scaffold similarity between the benzothiazole analogues and PQS, it was 
hypothesized that the pqs inhibition of the benzothiazole analogues can also be alkyl 
chain length dependent. A fragment growing method was applied to 106 by 
lengthening the alkyl chain at R1, which led to the design of compounds 148a-d (Figure 
44).  
 
Figure 44. Structure comparison between the hydroxyquinoline and benzothiazole 
analogues. 
4.2.1 The synthesis of designed analogues 143, 148a-d 
The forward synthetic scheme for the benzo[d]thiazol-2-yl-1-ol analogues 143 and 
148a-d is shown in Scheme 10. Benzothiazole-2-carboxaldehyde 151 was subjected 
to Grignard reactions to give the secondary alcohols 143, and 148a-d in which the 
Grignard reagents 150b-d were prepared from bromides 149b-d reacting with Mg 
under an inert atmosphere of N2.  
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Scheme 10 Preparation of compounds 143 and 148a-d 
 
a Reagents and conditions: (i) Mg, I2, THF, N2, reflux; (ii) CH3MgBr or CH3(CH2)2MgBr 
or 150a-d, THF, N2, rt.  
4.2.2 Bioreporter assay and TSA screening results for designed analogues 143 
and 148a-d 
Lengthening the alkyl chain from a methyl group (143) to a propyl chain (148a) 
destabilized the PqsR protein as evidenced by a negative ΔTm value of -0.4 °C at 500 
µM ligand concentration (Table 11). Introducing a hexyl (148b) or heptyl (148c) chain 
at R1, strongly stabilized the protein observed as an increase of ΔTm value of 0.9 °C 
for both compounds. Compounds 148b and 148c also showed pqs inhibition in the 
PAO1-LmCTX::PpqsA-lux reporter assay observed as RA% values of 60% and 63% 
at 50 μM screening concentration, respectively. 
Table 11. Analogues 56, 84, 108, 109 110 and 111 physiochemical properties, RA% 
and TSA screening results 
 
ID R1 MWt. CLogP RA%a,b,c ΔTm (±oC)d 
106 H 165.21 1.042 105.18 ± 2.29 +0.5 
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ID R1 MWt. CLogP RA%a,b,c ΔTm (±oC)d 
143 CH3 179.04 1.35 94.66 ± 7.17 0 
148a CH3(CH2)2 207.29 2.41 93.52 ± 8.42 -0.4 
148b CH3(CH2)5 249.37 4.00 59.98 ± 6.08 +0.9 
148c CH3(CH2)6 263.40 4.53 63.44 ± 8.89 +0.9 
148d Phenyl(CH2)4 297.42 4.36 64.37 ± 6.46 -0.3 
aData shown are mean values obtained from three independent experiments 
performed in triplicates. The data are shown as mean ± standard deviation (SD) b% 
Remaining Activity (RA%) were obtained through PAO1-LmCTX::PpqsA-lux reporter 
assay screening at single concentration (50 μM) in triplicates. c Remaining activity 
(RA%) values below 70%, fragments were regarded as active. RA% values do not 
have a linear relationship with IC50. dThermal shift assay (TSA, oC) at 500 µM ligand 
concentrations in duplicates. The determination of TSA (± oC) was conducted in 
collaboration with William Richardson.  
The high CLogP values of 148b-c might well contribute to the improved pqs inhibition 
in the bioreporter assay. Higher lipophilicity can improve ligand binding affinity to 
biological targets and ligand penetration ratio through biological membranes,187–189 
lengthening the alkyl chain leads to an increase in ligand lipophilicity which might 
ultimately affect pqs inhibition.  
Truncation of the linear alkyl side chain in combination with the addition of a terminal 
aryl group led the discovery of 148d, which retained pqs inhibition with a RA% of 64% 
at 50 μM screening concentration in the bioreporter assay against PAO1-L. Compound 
148d also weakly destabilized the PqsR protein reflected as a 0.3 °C (500 µM) 
decrease of DTm in TSA. Compared with the hydroxyquinoline analogues (PQS, 147a-
b) which have limited tolerance for introducing aromatic tail groups, the benzothiazole 
analogues may have better tolerance for R1 variation in terms of pqs inhibition.  
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4.3 Extract fragments from the 5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thiol analogues 
In the SAR study around the 5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thiol 
analogues, it was noticed that variations of the terminal aryl tail groups led to pqs 
inhibitory activity difference (Figure 45).  
It was surmised that the aryl tail groups of 38, 19, 65, 69 and 79 contribute to the 
observed differences in pqs inhibition. These compounds were then subjected to 
structure deconstruction (Figure 45), which led to the design of fragments 152a-d, 81 
and 82.  
 
Figure 45.  A FBLD scheme starting from structure extraction of the tail groups of the 
5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thiol analogues to give fragments 81, 82, 
and 152a-d. Compounds 38, 19, 65, 69 and 79 were drug-sized PqsR antagonists, 
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which share identical head and linker groups but displayed different in vitro profiles. It 
was hypothesised that fragments extracted from the tail group of the 5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thiol analogues may also bind to the PqsR LBD and 
possess a similar binding mode as the tail groups of the original drug-sized molecules. 
4.3.1 The synthesis of designed fragments 152a-c 
The synthetic route for 152a-c are summarized in scheme 11. The 4-substitued 
anilines 153a-b and 74 were subjected to acetylation using acetic anhydride to give 
152a-c. Fragment 81 and 82 were synthetic intermediates from previous series. 
Scheme 11 Preparation of designed fragments 152a-c 
 
aReagents and conditions: (i) acetic anhydride, DCM, 40oC. 
4.3.2 The screening of fragments 152a-d, 81 and 82 using TSA 
As compounds 19 and 65 were equally potent in the bioreporter assay, it was 
hypothesised that 152a and 152b originating from the tail groups of 19 and 65 should 
display similar biophysical and bioreporter assay screening profiles. Surprisingly, the 
two fragments displayed divergent TSA results. Fragment 152a strongly stabilized the 
PqsR protein reflected by an observed increase of ∆Tm value for 1.1 oC, whilst 152b 
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Table 12. Fragments 81, 82, 152a-d TSA screening results 
ID Structure CLogP ΔTm (±
oC)a,b 
500 µM 250 µM 
DMSO   0 0 
152a 
 
2.13 +1.1 +1.1 
152b 
 
0.58 +0.2 +0.2 
152c 
 
1.76 -0.7 -0.3 
82 
 
4.29 -0.8 -0.5 
81 
 
2.91 -0.3 -0.2 
152d 
 
2.11 +0.2 +0.1 
152e  
 
2.34 +5.3 +3.5 
152f 
 
2.27 +1.3 +0.9 
aThermal shift assay (TSA, oC) at 500 µM and 250 µM ligand concentrations in 
duplicates. bThe determination of TSA (± oC) was conducted in collaboration with 
William Richardson.  
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Fragment 152c originating from compound 69, strongly destabilized the PqsR protein 
reflected by an observed decrease of ΔTm value for 0.7 °C. Fragmentation of 79 led 
to the identification of 82 which strongly destabilized PqsR protein observed as a 
decrease of ΔTm value for 0.8 oC at 500 µM ligand concentration. Further 
deconstruction of 82 led to the identification of fragments 81 and 152d, where 81 
weakly destabilized the protein and 152d weakly stabilized the protein at 500 µM 
ligand concentration in TSA.  
These results suggested that electron deficient aromatic ring systems, such as 
fragment 152a can be preferable in terms of increasing PqsR protein thermal stability. 
In order to prove this assumption, fragments 152e and 152f with strong electron 
withdrawing groups (nitro groups and halogen atoms) were screened using TSA 
method and both fragments strongly stabilized the PqsR protein. With similar CLogP 
values, fragments 152e displayed higher ΔTm value than 152f, which may attribute to 
more electron deficient nature of 152e.  
Fragment 152a strongly stabilized the PqsR protein and was progressed for ITC 
experiment to determine the thermodynamic parameters. 
4.3.3 Determination of the thermodynamic parameters of 152a using ITC 
Titrating 1 mM 152a in the presence of 250 µM PqsR protein solution confirmed the 
binding of 152a to PqsR protein with a binding affinity (Kd) value as 30.0 µM. The ΔH 
was observed as - 4.97 kcal/mol and N was 1 (Figure 46). This allowed further 
calculation for the average values of ΔG as 6.08 kcal/mol and -TΔS as 1.2 kcal/mol. 
The negative ΔH and -TΔS values indicates favourable entropic and enthalpic binding 
signatures of 152a. Considering the favourable entropic and enthalpic binding 
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signatures and the strong binding interaction to PqsR protein, 152a was selected as a 
promising fragment candidate for fragment linking and merging methods. 
 
Figure 46. ITC results for 152a: (A) the injection peaks (B) the integrated data (C) the 
thermodynamic parameters. The ITC experiment was designed and conducted by 
William Richardson.  
4.4 Applying fragment linking and merging methods between strong 
PqsR fragment binders benzothiazole analogues (145a and 146b) 
and 152a 
The binding thermodynamic parameters of the amino benzothiazole analogues (145a, 
146b) and 152a to PqsR protein was previously confirmed through ITC experiments. 
However, X-ray co-crystal structures for these fragments bound to PqsR LBD are still 
not determined. Fragment linking, and merging methods were applied to fragments 
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pairs 145a with 152a and 146b with 152a and led to the design of compounds 
154a,c,d and 154b respectively (Figure 47). Due to time limitation, only 154a and 
154b were synthesized.  
 
Figure 47. Schematic representation of the fragment linking and merging strategy 
between 145a with 152a and 146b with 152a. Kd values were obtained from ITC 
experiments. There are multiple merging strategies can be applied between fragments 
145a and 152a and examples were displayed as 154a, 154c and 154d, however due 
to time limitation only compound 154a was synthesized.  
Compound 154a was predicted to bind to the PqsR LBD where the 2-
aminobenzothiazole group is predicted to act as a HBD through hydrogen bonding 
with Leu207. Compound 154b could bind to the same PqsR ligand binding site where 
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the amino group could hydrogen bond with Leu207 and the 4-chlorophenyl group is 
predicted to partake in a face to edge π-stacking interaction with Tyr258 (Figure 48).  
 
Figure 48. Predicted binding modes of compound 154a (a) and 154b (b) in PqsR 
LBD. Hydrogen bonds are shown as yellow dash lines. π-stacking interaction is 
shown as blue dash lines. The ligand scaffolds were represented in red (154a) and 
green (154b). 
4.4.1 The synthesis of designed compounds 154a and 154b 
The preparation of the 2-aminobenzothiazole analogues 154a and 154b is 
represented in Scheme 12. Intermediate N-formamides 146a-b were firstly 
deprotonated by NaH under an inert atmosphere of N2 and then reacted with the 
electrophile 2-bromo-N-(4-chlorophenyl)acetamide (91) through nucleophilic 
substitution to give compounds 154a-b.  
Scheme 12 Preparation of 154a and 154b  
 
aReagents and conditions: (i) acetic anhydride, formic acid, 40oC, N2. (ii) 91, NaH, 
DMF, 0oC to rt. 
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4.4.2 The biophysical and in vitro profiles of compounds 154a-b 
Merging fragments 145a and 152a led to the design and synthesis of compound 154a 
which was inactive in the bioreporter assay against PAO1-L. Applying a fragment 
linking method between two strong PqsR binders 146b and 152a led to the discovery 
of 154b. Compound 154b showed a RA% value of 34% at 10 µM screening 
concentration against PAO1-L in the mCTX::PpqsA-lux based bioreporter assay, 
which also strongly stabilized PqsR protein observed as an increase of ΔTm value for 
1.9 oC at 500 µM ligand concentration in TSA.  
Table 13. The biophysical and bioreporter assay screening profiles for 
compound 174 and 175  
 
Compd. R1 RA%a,b ΔT (±oC)c,d 
154a H 86.40 ± 6.03 / 
154b Br 33.92 ± 2.92 + 1.9 
aThe inhibitory effect evaluated using PAO1-LmCTX::PpqsA-lux reporter assay at 
single concentration (10 μM) in triplicates. bThe data are shown as mean ± standard 
deviation (SD). cThermal shift assay (TSA, oC) at 500 µM ligand concentrations in 
duplicates.d”/” indicates Not available. The determination of TSA (± oC) was conducted 
in collaboration with William Richardson. 
4.5 Fragment linking strategy between a weak binder 144 and a 
strong binder 152a 
Fragment 144 weakly destabilized the PqsR protein observed as a decrease of ΔTm 
value for 0.2 °C at 500µM ligand concentration in TSA. A fragment linking strategy was 
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applied to between fragments 144 and 152a, which led to the design of compounds 
156a-c with different linkers (Figure 49).  
 
Figure 49. Schematic representation of the fragment linking strategy between 144 and 152a 
through different linkers.  
Compounds 156a-c share a high scaffold similarity and were predicted to bind to the 
same region in the PqsR LBD. The 4-chlorophenyl groups of compounds 156a-b can 
insert deeply in the pocket, whilst 156c may flip in the pocket with the 4-chlorophenyl 
group pointing outside (Figure 50). 
 
Figure 50. Predicted binding modes of compound 156a (A), 156b (B) and 156c (C) 
in PqsR LBD. Hydrogen bonds are shown as yellow dash lines. π-tacking interaction 
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is shown as blue dash lines. The unfavourable clash is shown as orange dash line. 
The ligand scaffolds were represented in orange (156a), red (156b) and green 
(156c). 
4.5.1 The synthesis of designed compound 156a-c 
The preparation for 156a-c is outlined in Scheme 13. Compound 153a was subjected 
to amide coupling to react with Boc-glycine, Boc-proline and N-Boc-piperidine-4-
carboxylic acid using HATU as coupling reagent to give compounds 157a-c. After the 
acidic treatment of 157a-c using 4M HCl in dioxane, the resulting analogues 158a-c 
were then subjected to reductive amination with benzo[d]thiazole-2-carbaldehyde 
using NaBH(OAc)3 as reducing reagent to give analogues 156a-c.  
Scheme 13 Preparation of 156a-c 
 
aReagents and conditions: (i) HATU, DIPEA, DMAP, NMP, rt. (ii) 4M HCl in 1,4-
dioxane, rt, >100%; (iii) benzo[d]thiazole-2-carbaldehyde, NaBH(OAc)3, HOAc, THF, 
rt, N2. 
4.5.2 The bioreporter assay screening results for compound 156a-c 
Fragments 144 and 152a were linked through a range of linkers, including linear alkyl 
linker and ring systems and the resulting analogues 156a-c were subjected to the 
PAO1-LmCTX::PpqsA-lux reporter assay for the assessment of pqs inhibition. Whilst 
compounds 156a-c were predicted to bind to PqsR LBD in docking studies, these 
compounds unfortunately proved inactive in the later bioreporter assay (Figure 51). 




Figure 51. Inhibitory effect of 156a-c through the PAO1-LmCTX::PpqsA-lux reporter 
assay. Remaining activity (RA%) values below 50%, compounds were regarded as 
active. Compounds 156a-c were screened at single concentration (10 μM) in 
triplicates. The data is shown as mean ± standard deviation (SD) 
4.6 Exploration of synergistic combinations assisted by the 
mCTX::PpqsA-lux-based bioreporter assay and TSA 
As mentioned previously, it was hypothesized that PqsR LBD can be occupied by two 
small ligands at the same time and these two fragments can functionalize as 
synergistic combinations observed as the fragment cocktails displaying a greater 
effect in bioreporter assay and biophysical experiments than the single fragments. In 
order to explore fragment synergistic combinations, experiments were designed using 
the mCTX::PpqsA-lux-based bioreporter assay and TSA method.  
The mCTX::PpqsA-lux-based bioreporter assay was incorporated for the assessment 
of single fragments and fragment combinations pqs inhibition. Statistical analysis was 
introduced to compare the pqs inhibition differences between single fragment 
solutions and fragment cocktails solutions. Statistical analysis between three or more 



















Structure ID RA% CLogP
156a 103.52 ± 3.81 2.64
156b 101.61 ± 7.86 3.51
156c 92.38 ± 8.33 3.79
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comparisons test with a single pooled variance. A p-value lower than 0.05 is 
considered to represent a significant difference. Statistical analysis was performed 
using GraphPad Prism version 8.1.2 (GraphPad Software, Inc., La Jolla, CA, USA). 
Fragments 81, 105, 107, 108 and 125 were selected from the in-house fragment library 
for the exploration of fragment synergistic combinations (Figure 52). All fragments 
showed no pqs inhibition observed as pqs activity reduction less than 10% (i.e. RA% > 
90%) in the mCTX::PpqsA-lux-based bioreporter assay at 50 μM  screening 
concentration (Table 14).  
For the determination of fragment pairs pqs inhibition, PAO1-L was treated with 50 µM 
final concentration of the cocktail fragment solutions, which was prepared from two 
evenly mixed fragment solutions. In this work, fragment pairs: 81 and 108, 81 and 107, 
81 and 105, 81 and 125 were screened accordingly.  
 
Figure 52. Fragments selected for synergistic exploration.  
It was surprisingly to notice that the fragment cocktail containing 81 and 108 showed 
pqs inhibition with a RA% value of 62% Table 14, which was more potent than single 
fragment solutions (Figure 53).  




Figure 53. The inhibitory effect of single fragments 81 and 108 and the fragment 
cocktail containing both 81 and 108 through the PAO1-LmCTX::PpqsA-lux reporter 
assay at single concentration (50 μM) in triplicates. Ordinary one-way ANONA was 
used for statistical analysis, **P < 0.01; ***P < 0.001. The data are shown as mean ± 
standard deviation (SD). 
The same group of the fragment pairs were screened again using TSA for the 
assessment of fragments thermal stability to PqsR protein Table 14. Surprisingly, the 
fragment combination of 81 and 108 with the strongest pqs inhibition did not influence 
the thermal stability of PqsR protein observed as 0 °C ΔTm value. The divergent 
screening results for fragment pairs 81 and 108 in biophysical and bioreporter assays 
suggested that the two fragments may bind to different biological targets. The 
combination of 81 and 105 strongly destabilized the protein reflected by the observed 
decrease of ΔTm value of 1.7 °C. 
Table 14. TSA and in vitro screening results for fragment combinations  
No. Structure RA%a,b,c ΔT (±oC)d 
DMSO  100.00% 0 
105 
 
101.60 ± 2.49  +0.1 
81 
 
112.54 ± 4.08 -0.3 
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No. Structure RA%a,b,c ΔT (±oC)d 
108 
 
101.41 ± 1.37 -0.2 
107 
 
110.32 ± 1.82 -0.3 
    
125 
 
104.34 ± 1.38 -0.1 
81 + 108 
 
61.66 ± 9.66 0.0 
81 + 107 
 
71.56 ± 9.88 -0.4 
81 + 105 
 
73.41 ± 13.43 -1.7 
81 + 125 
 
83.10 ± 7.21 0.0 
aData shown are mean values obtained from three independent experiments 
performed in triplicates. bThe data are shown as mean ± standard deviation (SD) b% 
Remaining Activity (RA%) screening at single concentration (50 μM) in triplicates. cRA% 
values below 70%, compounds were regarded as active dThermal shift assay (TSA, 
oC) at 500 µM ligand concentrations in duplicates. The determination of TSA (± oC) 
was conducted in collaboration with William Richardson  
4.7 Conclusion 
Fragment 106 was advanced through a fragment growing method, with the resulting 
compounds 148b-d showing improved pqs inhibition in the PAO1-LmCTX::PpqsA-lux 
reporter assay. Application of a fragment linking strategy between 146b and 152a led 
to the design of compound 154b, which showed pqs inhibition in the mCTX::PpqsA-
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lux based bioreporter assay observed as 34% RA% at 10 µM screening concentration 
against PAO1-L. 
Synergistic fragment combinations were explored and fragment pairs 81 and 108, 81 
and 105 showed improved in vitro or biophysical profiles in combination than in single 
fragments. Unfortunately, due to COVID time restrictions further planned work could 
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Chapter V: Conclusions and future work 
5.1 Conclusions  
 P. aeruginosa, a nosocomial pathogen, has become a serious public health threat 
due to its high mortality and morbidity rates. 1,2,3,4 Current treatment for P. aeruginosa 
infections remains as antibiotics, despite the wide spread of multi-drug-resistant P. 
aeruginosa demonstrating resistance to nearly all antibiotics. 190 191,192 The pqs system 
is not vital for bacteria survival and the inhibition of pqs system is able to attenuate 
pathogenicity of P. aeruginosa. 5,6,10  The pqs system transcriptional regulator PqsR, 
also known as MvfR 10 is key in regulating virulence factors. PqsR mutants display 
significantly attenuated pathogenicity in multiple animal models. 11 Therefore, PqsR 
antagonists are regarded as a promising alternative to antibiotics. 12 In this work, 
different hit-to-lead optimisation methods were applied for the identification of novel 
PqsR antagonists to overcome P. aeruginosa infections.  
5.1.1 A classic hit-to-lead optimization process to find PqsR antagonists  
In chapter II, a hit-to-lead optimization process was presented starting from hit 
compound 19 obtained from a virtual screening. This was developed into lead 
compound 69, which displays enhanced pqs inhibition in both PAO1-L and PA-14 
strains (Figure 54). 




Figure 54. The schematic representation of the hit-to-lead optimization process 
starting from 19 to the potent lead compound 69. The pqs inhibitory effect evaluated 
using PAO1-LmCTX::PpqsA-lux and PA14mCTX::PpqsA-lux reporter assays. 
The X-ray co-crystal structure of 69 in complex with PqsR LBD was determined 
(Figure 55A) and revealed that the sulfur atom presented in the linker region locked 
the overall conformation allowing 69 to bend and accommodate into the hydrophobic 
pocket. The amide linker present in 69 hydrogen bonds with Leu207, whilst the 4-
(pyridin-2-yloxy)phenyl tail group points outside the pocket and has a π-stacking 
interaction with Tyr258 with a 4.55 Å distance. Interestingly, the pyridinyl side chain of 
compound 69 had a better overlap with Tyr258 compared with the phenyl side chain of 
7 (Figure 55B). Compound 7 is the only reported PqsR antagonist displaying in vivo 
activity in a mouse lung infection model. 193 The better overlapping with Tyr258 may 
indicate a stronger π stacking interaction with 69 compared to 7, which may result in 
greater pqs inhibition of 69. 




Figure 55. (A) X-ray co-crystal structure of 69 bound to PqsR ligand binding domain 
with a resolution of 3.2 Å. The scaffold structure of 69 shown in green while nitrogen, 
oxygen, and sulfur atoms presented in blue, red, and yellow. The protein structure 
shown in grey and residues Tyr258 and Leu207 labelled in black. (B) The comparison of 
69 and 7 in complex with PqsR LBD. The ligands scaffolds are presented in blue (7) 
and yellow (69). The π stacking of 7 is slightly off the edge compared with 69.  
The pharmacophore for the 5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thiol 
analogues were also investigated through SAR studies which suggested that the 
tricyclic head group, flexible linker, and aromatic tail group were key in retaining 
analogous pqs inhibition (Figure 56). 




Figure 56. The schematic representation for the pharmacophores of the 5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thiol analogues  
Assisted by TSA analysis, a concept validation experiment was conducted and it 
showed that gradually introducing key building blocks i.e. linker groups and tail groups, 
to the head group, the resulting compounds showed improved biophysical profiles in 
TSA (Figure 57).  
 
Figure 57. Schematic representation of the concept validation experiment. Growing 
of fragments to the drug-sized molecule 38, analogues biophysical profile improved 
correspondingly.  
5.1.2 PqsR antagonist fragment hit identification and optimisation  
Fragment-based lead discovery approaches have become an important lead 
discovery technique for both well-characterized or new drug targets in the last 20 years. 
87,124,170,171 However, FBLD methods have not been widely applied in identification of 
PqsR antagonists with only three publications so far (at the time of writing). 152,172,173  
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In chapter III, fragment-based methods were used for the discovery of new PqsR 
antagonists including fragment hit identification, optimisation, and evolution (Figure 
58).  
 
Figure 58. The workflow of fragment-based method in fragment hit identification and 
optimisation.  ITC experiment was used for the determination of Kd for 106. Thermal 
shift assay (TSA, °C) was incorporated to determine fragments biophysical profiles 
where fragments were screened at 250 µM, 500 µM ligand concentrations in 
duplicates or triplicates.  
In this work, a virtual screening on the PqsR ligand binding domain (LBD) against four 
fragment libraries was firstly conducted through a high-throughput virtual screening 
mode (PDB code: 4JVD; Maestro, force field: OPLS3e). After a manual inspection 
step on high scoring fragments (docking score < -6.5), seven promising fragments 
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106-112 were selected for further in vitro and biophysical screening (Figure 59). 
Fragment 106 showing a clear binding to PqsR protein in both TSA and ITC 
experiments and was selected along with 107 also displaying promising results in TSA, 
progressed to hit modification stage. 
 
Figure 59. The structure of initial seven fragment hit candidates.  
Fragment 106 and 107 were progressed to hit exploration studies leading to the 
discovery of 149, 151 and 152 displaying improved ligand binding interactions against 
PqsR protein in TSA and ITC experiment (Figure 60). Fragments 106, 149, 151 and 
152 with confirmed binding affinities were progressed to hit-to-lead optimization. In 
addition, a small in-house library by collecting all the fragments the group and 
synthesized so far were built, which will be used to screen against other biological 
targets.  
Figure 60. TSA and ITC results for fragment 106, 149, 151 and 152. Fragments were 
screened at 500 µM ligand concentration to obtain ΔTm values. Kd values were 
obtained from ITC experiments. 
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5.1.3 Using fragment growing, linking, and merging methods advancing PqsR 
antagonist fragment hits.   
Fragment hits 106, 144, 145a and 146b were evolved to drug-sized molecules (350 < 
MWt. < 500) through fragment growing, linking, and merging methods (Figure 61).  
 
Figure 61. Structure of fragment hits 106, 144, 145a and 146b.A fragment growing 
method was applied on 106 and through lengthening the alkyl chain at R1 (Figure 62) 
compounds 148b-d were discovered, showing improved biophysical profiles and pqs 
inhibition in the PAO1-LmCTX::PpqsA-lux reporter assay.   
 
Figure 62. Schematic representation of fragment growing strategy on 106. PAO1-
LmCTX::PpqsA-lux reporter assay was used for the evaluation of compounds pqs 
inhibition screened at 50 µM ligand concentration. Thermal shift assay (TSA, °C) was 
conducted for the determination of analogues biophysical profiles and compounds 
were screened at 500 µM ligand concentrations in duplicates. “NA” indicates not active. 
Fragment linking and merging methods were applied on 2-benzothiazolamine 
analogues (145a-b and 144) with 152a leading to the design and synthesis of 154a-b, 
and 156a-c (Figure 63). 
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Fragment linking between 145b and 152a led to the design and synthesis of 
compound 154b, which showed pqs inhibition in the bioreporter assay against PAO1-
L observed as a RA% value of 34% at 10 µM screening concentration. Compound 
154b also strongly stabilized PqsR protein observed as an increase of ΔTm value for 
1.9 oC at 500 µM ligand concentration in TSA. 
 
Figure 63. The schematic illustration of structure deconstruction of 38 to 152a 
functionalized as a promising fragment growing vector followed by fragment linking 
and merging strategies with fragments 145a-b and 144.  
Fragment synergistic combinations were also explored and two pairs of fragment pairs 
(107 and 108, 171 and 105) demonstrated better in vitro and/or biophysical profiles in 
combinations than the single fragments (Figure 64).  
 
Figure 64. The structure of fragments 81, 108, and 105. 
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5.2 Future work 
In previous work, fragment-based methods were used for the identification of PqsR 
antagonist fragments and some fragment hits were advanced to lead-like molecules 
(350 < Mwt <500) displaying pqs inhibition in PAO1-LmCTX::PpqsA-lux reporter assay.  
Unfortunately, due to COVID time restrictions some planned work could not be 
completed and will therefore be proposed here. 
5.2.1 Further modification on compound 154b 
Through a fragment linking strategy between 146b and 152a, compound 154b was 
identified showing moderate pqs inhibition in the PAO1-LmCTX::PpqsA-lux reporter 
assay observed as 34% RA% at 10 μM screening concentration. 
In continuation of this work, the IC50 value of 154b in PAO1-LmCTX::PpqsA-lux 
reporter assay should be determined followed by SAR studies around 154b to further 
optimise pqs inhibition (Figure 65). The X-ray crystallography and biophysical assays 
should also conduct on selected analogues. For the lead compound the metabolic 
stability test and in vivo assays should also be considered.  
 
Figure 65. Schematic representation of the proposed SAR study on 154b. Compound 
154b showed pqs in the bioreporter assay observed as a RA% value of 34% at 10 µM 
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screening concentration against PAO1-L. Compound 154b stabilized PqsR protein 
observed as an increase of ΔTm value for 1.9 oC at 500 µM ligand concentration in 
TSA. The SAR study around the tail group of 154b could start from removal of the 
chorine atom (160a). The following design for this SAR study could be guided by 
Topliss tree, which is a non-mathematical strategy widely used for the exploration of 
substituents on a benzene ring or substituted phenyl ring.194–196 The SAR study of the 
head group could start from changing the substituted position of the bromine atom or 
replacing the bromine to other halogen atoms (160d-e).  
5.2.2 Further modification on 148d 
Through a fragment growing method on 106, compound 148d was identified 
displaying moderate pqs inhibition against PAO1-L with a RA% value of 64%. Also, 
compound 148d weakly destabilized the PqsR protein reflected as a 0.3 °C (500 µM) 
decrease of DTm in TSA. In the recent experiment, it showed confirmed pqs inhibition 
with an IC50 value of 150.9 μM, which provided some confidence in continuation of this 
work. In order to further improve pqs inhibition, compound 148d can be subjected to 
an SAR study, which is proposed in Figure 66. If resulting analogues showed 
significant increasing pqs inhibition, the X-ray crystallography and biophysical assays 
should also conduct on selected analogues. For the lead compound the metabolic 
stability test and in vivo assays should also be considered. 
 
Figure 66. Schematic representation of the proposed SAR study on 167. The design 
for this SAR study would be guided by Topliss tree and the examples for the SAR 
study around the tail group of 148d were presented as 161a-d. The experiment for the 
determination of 148d IC50 value was recently conducted by William Richardson and 
compound 148d showed an IC50 value of 150.9 μM in PAO1-LmCTX::PpqsA-lux 
reporter assay.  
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5.2.3 Advancing synergistic pairs 
In the previous work, fragment pairs 81 and 108, 81 and 105 were identified 
demonstrating better in vitro and/or biophysical profiles in combinations than the single 
fragments. It would be interesting to explore the fragment binding modes through X-
ray crystallography experiment. These fragment pairs can also act good starting points 
for fragment linking methods to be advanced to drug-sized molecules. In continuation 
of this work, the fragment linking method can be applied to these two pairs of 
fragments.  
Both 81 and 108 have multiple HBDs and HBAs including amines and carboxylic acid 
groups, which can be pharmacophores and key for bioactivity. These functional 
groups can also act as chemical elaboration points offering straightforward routes to 
linkage. In order to investigate the influence of these structural features on pqs 
inhibition, fragments 81 and 108 were linked through different linkers (Figure 67, 
scheme I, 162a-c).  
 
Figure 67. Schematic representation of the proposed fragment linking methods: 
fragment pair 81 and 108 Scheme I, fragment pair 81 and 105 Scheme II.  A direct 
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linking between the tertiary amine of 81 and the carboxylate acid of 108 led to 
analogue 162c. Adding a simple linker between the secondary amine on the 1,2,3,4-
tetrahydroisoquinoline core of 108 and tertiary amine of 81, the resulting analogue 
162a keeps the 3-carboxylic acid group. Replacing the carboxylic acid group with a 
methyl carboxylate group led to the design of analogue 162b. The proposed fragment 
linking strategy on fragment pair 81 and 105 led to the design of compound 162d.  
Although fragment pair 81 and 105 destabilized the PqsR protein, it would be 
interesting to link this fragment pair and analysis the biophysical profile of the resulting 
compound 162d.  
5.2.4 Finding dual PqsA/R or PqsA inhibitors through fragment-based methods 
The quorum sensing (QS) system in P. aeruginosa is highly interconnected and 
complicated. Inhibition of multiple signalling cascades in the QS system is more 
efficient in terms of attenuating P. aeruginosa pathogenicity.185,197–199  PqsA is the key 
enzyme for the biosynthesis of the signalling molecules HHQ and PQS in the QS 
system and the inhibition of PqsA can significantly attenuate the generation and 
secretion of P. aeruginosa virulence factors. 7,200–202 The crystal structure of PqsA has 
been recently published, which provides some confidence to investigate dual PqsA/R 
or PqsA inhibitors.  
In order to find fragments targeting PqsA and/or PqsR proteins, screening of an in-
house fragment library against PqsA and PqsR proteins through TSA was conducted. 
Fragment 152d, 81, 146c and 163 were shown to change the thermal stability for both 
PqsA and PqsR proteins (Figure 68). Through using TSA, some fragments 119a, 119f, 
119d, 105, 123 and 164 were identified to strongly destabilize the PqsA protein and 
had a minimal influence on the thermal stability of PqsR protein (Figure 69). When 
fragments bind to the protein unfolded form or cause protein aggregation, it causes 
protein destabilization reflecting as negative ΔTm values. Advancing these fragments 
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can be challenging and orthogonal screening is required to cross validate these 
fragments. 
 
Figure 68. Fragments influenced thermal stability for both PqsA and PqsR. Fragments 
were screened at 500 µM or 1 mM ligand concentrations in triplicates for the 
determination of ΔTm values in TSA. This TSA was conducted by William Richardson. 
In the TSA for the screening of fragments against PqsA protein, it was noticed that 
PqsA protein have low tolerance to DMSO and the native ligand of PqsA protein 
anthranilate acid stabilised the protein with an increase of ΔTm value of 1.0 °C. These 
results suggested that TSA may not be suitable for the PqsA screening and orthogonal 
screening is required to cross validate all the fragment hits mentioned.  
 
Figure 69. Fragments influence thermal stability for PqsA protein. Fragments were 
screened at 500 µM or 1 mM ligand concentrations in triplicates for the determination 
of ΔTm values in TSA. This TSA was conducted by William Richardson. 
 




6.1 Microbiological Experiments 
6.1.1 PqsR bioreporter assay 
6.1.1.1 Bacterial strains 
The P. aeruginosa strains used in the thesis are listed in Supplementary table 1.  
Supplementary table 1. Bacterial strains used in the thesis  
Strain Description   Reference/origin  
PAO1-L Wild type P. aeruginosa from 
Université de Lausanne, 
Switzerland  




PAO1-L with the reporter 
construction PpqsA-luxCDABE 
inserted in the specific attB site 
of the Chromosome. 203 TcR 
(plasmid with tetracycline 
resistance gene) 
[203] 
Soukarieh et al. 
 
PA14 Wild type UCBPP-PA14 Rahme et al., 1995 
PA14 miniCTX::PpqsA-lux PA14 with chromosomal mini-
CTX::PpqsA-luxCDABE; TcR 
Soukarieh et al. 
6.1.1.2 Preparing bacterial cultures for single concentration PqsR bioreporter 
assays 
Overnight culture of strains PAO1-L miniCTX::PpqsA-lux  and PA14 miniCTX::PpqsA-
lux in separate universal containers were created.  Each universal container contains 
a single colony of strains, 5 mL LB medium and Gentamicin at 20 µg/mL. Cultural 
overnight at 37 oC with shaking at 200 r.p.m. The optical density at 600 nm (OD600) for 
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the overnight culture was determined on the next day. Strains were prior to use when 
OD600 was approximately 2.5. Strains PAO1-L and PA14 stocks solution (20 mL) were 
prepared by diluting the overnight culture with fresh LB medium in universal containers 
to OD600 of 0.02.   
6.1.1.3 Bioluminescence reporter gene assay for 50 µM singe concentration spot 
test  
50 mM tested compound stock solution in DMSO was diluted to 100 µM by adding 1 
µL of stock solution to 500 µL LB medium in an Eppendorf. Adding 100 µL of the 
diluted compound solution to three wells of a Grenier 96 well flat black plate to obtain 
results in triplicates. To each of wells containing 100 µL tested compound was added 
100 µL PAO1-L or PA14 stock culture to give final 50 µM concentration. The plate was 
run by a luminometer-spectrometer (Tecan GENios Pro) at 37oC for 24 h to 30 h 
monitoring a kinetic cycle (OD600) and luminescence every 30 min.  
The readouts of the OD600 and luminescence were taken from the peak of the 
luminescence and normally observed between 8 to 9 h. The results were normalized 
against the native control containing 0.1% DMSO to give remaining active data.  
A similar methodology was applied for the 50 µM singe concentration spot test for 
synergistic combinations. Fragments were diluted to 200 µM by adding 2 µL of stock 
solution to 500 µL LB medium in an Eppendorf. Two 50 µL of 200 µM fragment 
solutions were added to the same well of a Grenier 96 well to give a final 100 µM 
mixed solution and this step was repeated three time to give results in triplicates. To 
each of wells containing 100 µL mixed solution was added 100 µL PAO1-L or PA14 
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stock culture to give final 50 µM concentration and the plate was run by a luminometer-
spectrometer (Tecan GENios Pro) using the same script as mentioned before.  
In order to remove cytotoxicity compounds, the bacteria growth curve should be 
monitored and compared with DMSO control. Compounds inhibition to LuxABCDE 
protein should also be determined in order to eliminate false positives. 
6.2 Biophysical experiments 
6.2.1 Thermal shift assay (TSA) 
The melting temperature (Tm) of PqsR94-309 in the presence and absence of inhibitors 
was determined using 96-well fluorescence-based thermal shift assay. The 10 mM 
DMSO fragments stocks were diluted to 5 mM and 2.5 mM using DMSO. The 
Mastermix contains 500 µL of 1.5 mg/mL PqsR94-309 and 500 µL 40 ´ SYPRO™ 
Orange Protein Gel Stain (5,000X Concentrate in DMSO, ThermoFisher). 10 µL of the 
Mastermix was dispensed into each well of a MicroAmp 96-well qPCR plate and 
followed by pipetting of 35 µL of buffer and 5 µL of diluted fragments stocks to give a 
final compound concentration of 500 µL and 250 µL at 10% (v/v) DMSO.  For DMSO 
positive control, 5 µL of DMSO was dispensed into the mixture of 10 µL Mastermix 
and 35 µL buffer. For the negative control, 5 µL Sypro orange was mixed with 40 µL 
buffer and 5 µL DMSO to ensure compounds did not interference with the dye. Each 
compound and control groups were assessed in duplicate or triplicate. The plate was 
sealed with MicroAmp optical adhesive film and centrifuged at 300 r.m.p for 3 minutes. 
The plate was incubated for 5 minutes at 30oC in the Real-time PCR instrument 
(Applied Biosystems 7500 instrument) with a step size of 1oC/min. Data was analysed 
using NAMI software package to determine Tm values. The DTm values were 
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calculated as DTm = Tm (compound) – Tm (DMSO control). Buffer solution was 
prepared by William Richard containing 50 mM Tricine, 500 mM sodium chloride, and 
10% Glycerol (pH = 8.5) and screened compounds stocks were prepared as 10 mM 
in DMSO.  
6.2.2 Isothermal titration calorimetry (ITC) 
ITC titrations were performed to detect direct binding between PqsR94-309 and 
fragments using MicroCal PEAQ-ITC (Malvern). Fragment DMSO stock solutions 
were diluted with the experimental buffer resulting a final DMSO concentration of 10% 
(v/v). The buffer used for dilution and protein purification was provided by William 
Richard (Buffer: 20 mM Tricine-NaOH (pH = 8), 250 mM NaCl and 2.5% Glycerol).  
Using Malvern’s software, the cell and syringe were washed before each titration. ITC 
measurements were routinely performed the using pre-defined 19 injections method 
with a single 0.4 µL injection, followed by 18, 2 µL injections.  
The sample cell was load with 25 µM PqsR94-309 with a final DMSO concentration of 
10% (v/v) in buffer where the protein sample and buffer were provided by William 
Richard. The syringe was loaded with 500 µM compound solution in buffer with a final 
DMSO concentration of 10% (v/v). To correct for heats of dilution, the buffer solution 
was titrated into protein solution to correct the base line of the final titrating base line.  
6.3 Molecular Docking  
6.3.1 Protein structure preparation  
The X-ray crystal structure of PqsR LBD in complex with native agonist NHQ (PDB 
code: 4JVD) was used as protein template and prepared with Protein Preparation 
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Wizard in Maestro (Schrödinger, LLC, 2017, New York, NY) using default setting in 
which waters were deleted, hydrogens were added, and bond orders were assigned.  
6.3.2 Grid generation  
Prepared protein structure was used to general Glide scoring grid for later docking 
study using Receptor Grid Generation. The scoring grid box was generated based on 
the centroid of workspace ligand in a default size.  
6.3.3 Ligand preparation 
Fragment libraries and compounds were prepared using LipPrep with Epik 
(Schrödinger, LLC, 2017, New York, NY) to generate lowest energy conformations for 
each compound in desalt and tautomeric state. The targeted pH was set as 7.5 ± 0.2 
to generate protonation state.  
6.3.4 Molecular Docking  
Two scoring protocols were used for the docking: Glide HTVS (high throughput virtual 
screening) and Glide SP (standard precision) in default parameters using the force 
field is OPLS3. The screening of fragment libraries was used Glide HTVS and the 
drug-sized molecules was used Glide SP. The number of poses for each ligand was 
set to 5 and the top three poses was saved based on Glide docking scores and 
reported.  
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6.4 Chemistry experimental section 
6.4.1 General chemistry 
Reagents and anhydrous solvents were purchased from Sigma Aldrich, Alfa Aesar 
and Fisher Scientific and were used without further purification. Nuclear magnetic 
resonance: 1H-NMR and 13C-NMR, were obtained at room temperature using a Bruker 
AV400, spectrometer operating at 400 MHz. The samples were prepared in 
deuterated solvent: DMSO-d6 and chloroform-d. Chemical shifts (δ) were recorded in 
ppm and coupling constants (J) were recorded in Hz. The spectra were analyzed using 
MestReNova12.0.1 software. Mass spectrometry: Analytical HPLC were performed on 
a Shimadzu UFLCXR system coupled to an Applied Biosystems API2000. Two 
columns thermostated at 40oC were used. Column one: Phenomenex Gemini-NX 
3µm-110A C18, 50x2mm Column two: Phenomenex Luna 3µm (PFP2) 110A, 50x2 
mm. Column three: Waters X terra MS C8 2.5µm, 4.6x30 mm. Flow rate 0.5mL/min. 
UV detection at 220 (channel2) and 254nm (channel1). SHORT Gradient: Pre-
equilibration run for one min at 5% B; then method run: 5 to 98% solvent B in 2min, 
98% B for 2min, 98 to 5% B in 0.5min then 5% for one min. LONG Gradient: Pre-
equilibration run for one min at 5% B; then method run: 5% B for 0.5min, 10 to 98% 
solvent B in 8min, 98% B for 2min, 98 to 5% B in 0.5min then 5% B for one min. 
Solvent A: 0.1% Formic Acid in water; solvent B: 0.1% Formic Acid in MeCN. 
Chromatography: Thin-layer chromatography (TLC) was performed, UV light and 
standard TLC stains were used to visualise the Merck Silica gel 60 Å F254 plates. 
Retention factors (Rf) in a given solvent system are reported to two decimal places. 
Compounds were purified via column chromatography using either a Thompson pump 
or normal phase Interchim Puriflash pre-packed cartridges consisting of 50 μM silica, 
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or a glass column using Merck Geduran silica gel 60 Å (230-240 μm) Column size 
selected was generally 40-60 times the loading amount. 
6.4.2 Synthesis 
General Procedure 1: Preparation of 1-methyl-2, 3-indolinediones 26-28  
 
 
To a solution of 2,3-indolinediones 23-25 in anhydrous DMF (10 mL/mmol) at 0oC 
under N2 protection, NaH 60% dispersion in mineral oil (1.1 equiv) was added in one 
portion. The mixture was stirred for 45 minutes followed by addition of iodomethane 
(1.4 equiv). The mixture was then slowly warmed up to room temperature and stirred 
for further 6 hours. The mixture was poured into Sat. NH4Cl (100 mL) and stirred 
vigorously for 10 minutes. The resulting suspension was extracted with ethyl acetate 
(50 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, 
and concentrated. The crude compound was purified by column chromatography 
(eluent PET/EtOAc 5:1) to give the desired compound. 
 
Reaction code: liu180-007 
1-Methylindoline-2,3-dione (26) was prepared according to general procedure 1 
starting from 2,3-indolinedione (23) (3.00 g, 20.40 mmol). The crude product was 
purified by column chromatography (eluent PET/EtOAc 5:1) to give an orange solid 
(3.03 g, 92%): 1H NMR (400 MHz, DMSO-d6) δ 7.67 (td, J = 7.8, 1.4 Hz, 1H, H-2), 7.53 
(dd, J = 7.5, 1.5 Hz, 1H, H-4), 7.20 – 7.06 (m, 2H, H-3 and H-5), 3.14 (s, 3H, H-1). 13C 
NMR (101 MHz, DMSO-d6) δ 183.9, 158.6, 151.82, 138.64, 124.69, 123.65, 117.82, 
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111.02, 26.47. LCMS m/z calc. for C9H7NO2 [M]+: 161.1, found 161.1 with tR 2.48 min, 
purity 95%. 
 
Reaction code: liu180-005 
5-Bromo-1-methylindoline-2,3-dione (27) was prepared according to general 
procedure 1 starting from 5-bromo-2,3-indolinedione (24) (5.00 g, 22.12 mmol). The 
crude product was purified by column chromatography (eluent PET/EtOAc 5:1) to give 
an orange solid (3.91 g, 73 %): 1H NMR (400 MHz, DMSO-d6) δ 7.86 (dd, J = 8.4, 2.1 
Hz, 1H, H-3), 7.70 (d, J = 2.1 Hz, 1H, H-2), 7.13 (d, J = 8.4 Hz, 1H, H-4), 3.14 (s, 3H, 
H-1). 13C NMR (101 MHz, DMSO-d6) δ 182.69, 158.31, 150.75, 140.25, 126.95, 
119.65, 115.33, 113.19, 26.60. LCMS m/z calc. for C9H6BrNO2 [M]+: 241.2, found 
240.2 with tR 2.52 min, purity 95%. 
 
Reaction code: liu180-137 
5-Methoxy-1-methylindoline-2,3-dione (28) was prepared according to general 
procedure 1 starting from 5-methoxyindoline-2,3-dione (25) (2.00g, 11.29 mmol). The 
crude product was purified was purified by column chromatography (eluent 
PET/EtOAc 5:1) to give an orange solid (1.89 g, 88 %): 1H NMR (400 MHz, DMSO-d6) 
δ 7.26 (dt, J = 8.6, 2.7 Hz, H-4), 7.13 (q, J = 2.4 Hz, 1H, H-2), 7.11 – 7.04 (m, 1H, H-
3), 3.78 (s, 3H, H-5), 3.12 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 184.20, 
158.65, 156.22, 145.67, 124.31, 118.30, 112.06, 109.59, 56.36, 26.50. LCMS m/z calc. 
for C10H9NO3 [M]+: 191.1, found 191.1 with tR 2.28 min, purity 95%. 
General procedure 2 Preparation of 5-methyl-5H-[1,2,4]triazino[5,6-b]indole-3-
thiols 29-31  
 




A mixture of 1-methyl-2, 3-indolinediones 26-28, thiosemicarbazide (1.1 equiv) and 
K2CO3 (1.5 equiv) in the mixture of 70% dioxane and 30% water 10 mL/mmol was 
refluxed for 16 hours. On cooling, the mixture was filtered and concentrated. The 
mixture was diluted with water (10 mL) and recrystallized in acetic acid. The crude 
compounds were used directly for next steps without further purification. 
 
Reaction code: liu180-49 
5-Methyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol (29) was prepared according to 
general procedure 2 starting from 1-methylindoline-2,3-dione (26) (1.63 g, 10.055 
mmol). The product was obtained as an orange solid (0.99 g, 45%): 1H NMR (400 
MHz, DMSO-d6) δ 14.56 (s, 1H, H-1), 8.05 (d, J = 7.6 Hz, 1H, H-6), 7.76 – 7.61 (m, 
2H, H-3 and H-4), 7.41 (td, J = 7.5, 1.1 Hz, 1H, H-5), 3.67 (s, 3H, H-2). 13C NMR (101 
MHz, Chloroform-d) δ 177.36, 132.43, 124.32, 122.77, 110.81, 20.78. LCMS m/z calc. 
for C10H8N4S [M]+: 216.3, found 216.2 with tR 2.22 min, purity 95 %. 
 
Reaction code: liu180-17 
8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol (30) was prepared 
according to general procedure 2 starting from 5-bromo-1-methylindoline-2,3-dione 
(27) (1.00 g, 4.16 mmol). The product was obtained as an orange solid (1.23 g, 86%): 
1H NMR (400 MHz, DMSO-d6) δ 14.68 (s, 1H, H-1), 8.22 (d, J = 2.0 Hz, 1H, H-5), 7.88 
(dd, J = 8.6, 2.0 Hz, 1H, H-4), 7.64 (d, J = 8.7 Hz, 1H, H-3), 3.65 (s, 3H, H-2). 13C NMR 
(101 MHz, DMSO-d6) δ 179.98, 148.73, 143.62, 134.82, 134.34, 124.39, 119.89, 
115.89, 113.99, 21.54. LCMS m/z calc. for C10H7BrN4S[M]+: 295.2, found 295.1 with 
tR 2.47 min, purity 95%. 




Reaction code: liu180-189 
8-Methoxy-5-methyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol (31) was prepared 
according to general procedure 2 starting from 5-methoxy-1-methylindoline-2,3-dione 
(28) (1.519 g, 7.9449 mmol). The product was obtained as an orange solid (1.89 g, 
96.7%): 1H NMR (400 MHz, DMSO-d6) δ 13.49 (s, 1H, H-1), 7.55 (app.d, J = 8.9 Hz, 
2H, H-6 and H-3), 7.27 (d, J = 8.8 Hz, 1H, H-4), 3.85 (s, 3H, H-5), 3.62 (s, 3H, H-2). 
13C NMR (101 MHz, DMSO-d6) δ 179.77, 172.55, 156.48, 148.34, 138.44, 135.63, 
119.34, 118.64, 112.76, 56.34, 21.68. LCMS m/z calc. for C11H10N4OS [M]+: 246.3, 
found 246.3 with tR 2.31 min, purity 85%.  
*Apparent multiples indicants coupling constants accidentally coincide (abbreviate as 
app.) 
General Procedure 3 Preparation of tert-butyl 2-((5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetates 32-34  
 
 
Under the protection of N2, tert-Butyl bromoacetate (1.0 equiv.) was added dropwise 
to a suspension of 5-methyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiols (29-31) (1 equiv) 
and triethylamine (1.1 equiv) in anhydrous toluene (5 mL/mmol) at 0oC. Reaction 
mixture was allowed slowly warm up to room temperature and stirred for 3 hours. 
Reaction mixture was quenched by water and stirred at room temperature for further 
5 minutes. The mixture was then dilute with water and then extracted by EtOAc (50 
mL × 3). The organic layers were combined and washed with brine and dried over 
Na2SO4. The crude compound was purified by column chromatography. 
 
Rui Ling Liu                                                                             University of Nottingham  
138 
 
Reaction code: liu180-55 
tert-Butyl 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetate (32) was 
prepared according to general procedure 3 starting from 5-methyl-5H-
[1,2,4]triazino[5,6-b]indole-3-thiol (29) (0.40 g, 1.83 mmol). The crude product was 
purified by column chromatography (eluent PET/EtOAc 4:1) to give a white solid (0.37 
g, 62%): 1H NMR (400 MHz, DMSO-d6) δ 8.36 (d, J = 7.6 Hz, 1H, H-5), 7.79 (app.d, J 
= 4.1 Hz, 2H, H-3 and H-2), 7.51 (m, 1H, H-4), 4.10 (s, 2H, H-6), 3.83 (s, 3H, H-1), 
1.42 (s, 9H, H-7). 13C NMR (101 MHz, Chloroform-d) δ 168.04, 166.84, 146.43, 141.42, 
141.14, 130.74, 122.90, 122.12, 118.01, 109.84, 82.07, 34.54, 28.03, 27.22. LCMS 
m/z calc. for C16H18N4O2S [M]+: 330.2, found 330.4 with tR 2.91 min, purity 95%. 
 
Reaction code: liu180-21  
tert-Butyl 2-((8-bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetate 
(33) was prepared according to general procedure 3 starting from 8-bromo-5-methyl-
5H[1,2,4]triazino[5,6-b]indole-3-thiol (30) (0.15 g, 0.53 mmol). The crude product was 
purified by column chromatography (eluent PET/EtOAc 4:1) to give a yellow solid (0.19 
g, 88%): 1H NMR (400 MHz, DMSO-d6) δ 8.52 (d, J = 2.0 Hz, 1H, H-4), 7.94 (dd, J = 
8.7, 2.0 Hz, 1H, H-3), 7.78 (d, J = 8.7 Hz, 1H, H-2), 4.11 (s, 2H, H-5), 3.81 (s, 3H, H-
1), 1.42 (s, 9H, H-6). 13C NMR (101 MHz, Chloroform-d) δ 167.92, 167.77, 146.62, 
140.30, 140.13, 133.43, 125.09, 119.92, 116.10, 111.39, 82.22, 34.61, 28.02, 27.41. 
LCMS m/z calc. for C16H17BrN4O2S [M]+: 408.0, found 408.3 with tR 3.05 min, purity 
95%. 
 
Reaction code: liu180-207 
tert-Butyl 2-((8-methoxy-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetate 
(34)  was prepared according to general procedure 3 starting from 8-methoxy-5-
methyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol (31) (0.80 g, 3.25 mmol). The crude 
product was purified by column chromatography (eluent PET/EtOAc 4:1) to give a 
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yellow solid (0.6481g, 55.39%): 1H NMR (400 MHz, DMSO-d6) δ 7.86 (d, J = 2.5 Hz, 
1H, H-4), 7.71 (d, J = 8.9 Hz, 1H, H-2), 7.39 (dd, J = 8.9, 2.6 Hz, 1H, H-3), 4.09 (s, 2H, 
H-5), 3.91 (s, 3H, H-7), 3.79 (s, 3H, H-1), 1.42 (s, 9H, H-7). 13C NMR (101 MHz, 
DMSO-d6) δ 168.22, 166.59, 156.29, 146.38, 141.35, 136.43, 119.93, 118.35, 112.68, 
104.66, 81.63, 56.34, 34.25, 28.15, 27.83. LCMS m/z calc. for C17H20N4O3S [M]+: 
360.2, found 360.4 with tR 2.91 min, purity 95%. 
General Procedure 4 Preparation of 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetic acids 35-37  
 
tert-butyl 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetates (32-34) (1 equiv) 
were dissolved in small amount of DCM (2 mL/mmol), 4M HCl in dioxane (excess) was 
added to the suspension. The mixture was then allowed to stir at room temperature 
overnight. Solvent was removed under vacuum to yield light yellow solid. The crude 
product was washed with diethyl ether and DCM and was used directly for next steps 
without further purification. 
 
Reaction code: 180-61 
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (35) was prepared 
according to general procedure 4 starting from tert-butyl 2-((5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetate (32) (0.40 g, 1.21 mmol). The product was 
obtained as a yellow solid (280 mg, 84.34%): 1H NMR (400 MHz, DMSO-d6) δ 8.34 (d, 
J = 7.7 Hz, 1H, H-5), 7.79 (app. d, J = 4.0 Hz, 2H, H-2 and H-3), 7.51 (m, 1H, H-4), 
4.10 (s, 2H, H-6), 3.83 (s, 3H, H-1)13C NMR (101 MHz, DMSO-d6) δ 170.50, 166.81, 
146.54, 142.14, 131.47, 123.40, 121.92, 117.75, 111.70, 79.46, 33.58, 27.81. LCMS 
m/z calc. for C12H10N4O2S [M]+: 274.3, found 274.3 with tR 2.40 min, purity 95%.  




Reaction code: liu180-35 
2-((8-bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (36) was 
prepared according to general procedure 4 starting from tert-butyl 2-((8-bromo-5-
methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetate (33) (0.54 g, 1.32 mmol). The 
product was obtained as a yellow solid (0.38 g, 81.7%): 1H NMR (400 MHz, DMSO-
d6) δ 8.50 (d, J = 2.0 Hz, 1H, H-4), 7.94 (dd, J = 8.7, 2.0 Hz, 1H, H-3), 7.78 (d, J = 8.7 
Hz, 1H, H-2), 4.14 (s, 2H, H-5), 3.81 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 
168.10, 146.66, 140.93, 133.76, 124.20, 119.65, 115.51, 115.49, 113.88, 81.73, 34.30, 
28.15. LCMS m/z calc. for C12H9BrN4O2S [M]+: 354.2, found 353.19 with tR 2.63 min, 
purity 95%. 
 
Reaction code: liu180-209 
2-((8-Methoxy-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acid (37) 
was prepared according to general procedure 4 starting from tert-butyl 2-((8-methoxy-
5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetate 34 (0.54 g, 1.32 mmol). The 
product was obtained as a yellow solid (0.38 g, >100%): 1H NMR (400 MHz, DMSO-
d6) δ 7.76 (d, J = 2.5 Hz, 1H, H-4), 7.65 (d, J = 8.9 Hz, 1H, H-1), 7.35 (dd, J = 8.8, 2.5 
Hz, 1H, H-3), 4.14 (s, 2H, H-5), 3.88 (s, 3H, H-7), 3.75 (s, 3H, H-1). 13C NMR (101 
MHz, DMSO-d6) δ 170.39, 166.31, 156.34, 146.32, 141.06, 136.56, 120.00, 118.20, 
112.72, 104.77, 56.32, 33.57, 27.88.  LCMS m/z calc. for C13H12N4O3S [M]+: 43, found 
304.3 with tR 2.46 min, purity 85%. 
General Procedure 5 Preparation of 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)-N-phenylacetamides  
 




2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetic acids (1 equiv), HATU (3 
equiv), DMAP (0.1 equiv) and amines (1 equiv) was dissolved in 1mL/mmol anhydrous 
NMP and stirred at room temperature for 5 minutes before addition of DIPEA (6 equiv). 
The mixture was allowed to stir at room temperature for overnight. The reaction was 
monitored by TLC and quenched by addition of water. The reaction mixture was stirred 
for 5 minutes and the diluted with water and was extracted by EtOAc three times and 
the combined organic layers were combined and washed with Sat. NaHCO3 and brine 
and dried over Na2SO4. The crude product was purified by column chromatography. 
 
Reaction code: liu180-71 
N-(4-chlorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (19) was prepared according to general procedure 5 starting from 
using 35 (0.050 g, 0.18 mmol) and 4-Chloroaniline (0.023 g, 0.18 mmol). The crude 
product was purified by column chromatography (eluent PET/EtOAc 2:1) to give a 
white solid (0.022 g, 31%): 1H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H, H-7), 8.32 
(d, J = 7.9 Hz, 1H, H-5), 7.81 – 7.72 (m, 2H, H-2 and H-3), 7.71 – 7.63 (m, 2H, H-8 
and H-11), 7.48 (td, J = 6.9, 5.9, 2.2 Hz, 1H, H-4), 7.42 – 7.33 (m, 2H, H-9 and H-10), 
4.28 (s, 2H, H-6), 3.77 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 167.07, 166.92, 
146.51, 142.05, 141.40, 138.50, 131.38, 129.19, 127.37, 123.32, 121.86, 121.11, 
117.71, 111.62, 35.99, 27.72. LCMS m/z calc. for C18H14ClN5OS [M]+: 383.3, found 
383.85 with tR 2.84 min, purity 95%.  
 



























1.0 equiv X= H, Br, OMe
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2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-phenylacetamide (38) was 
prepared according to general procedure 5 starting from using 35 (0.050 g, 0.18 mmol) 
and aniline (0.017 g, 0.18 mmol).  The crude product was purified by column 
chromatography (eluent PET/EtOAc 2:1) to give a white solid (0.013g, 20%): 1H NMR 
(400 MHz, DMSO-d6) δ 10.42 (s, 1H, H-7), 8.33 (d, J = 7.8 Hz, 1H, H-5), 7.81 – 7.72 
(m, 2H, H-8 and H-12), 7.66 – 7.58 (m, 2H, H-9 and H-11), 7.49 (ddd, J = 8.1, 5.2, 3.0 
Hz, 1H, H-3), 7.32 (app. t, J = 7.9 Hz, 2H, H-2 and H-4), 7.11 – 7.02 (m, 1H, H-10), 
4.28 (s, 2H, H-6), 3.79 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 167.17, 166.70, 
146.54, 142.07, 141.40, 139.56, 131.39, 129.27, 123.83, 123.34, 121.88, 119.57, 
117.74, 111.65, 36.01, 27.75. LCMS m/z calc. for C18H15N5OS [M]+: 349.3, found 349.4 
with tR 2.72 min, purity 95%. 
 
Reaction code: liu180-93 
N-(3-chlorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (40)  was prepared according to general procedure 5 starting from 
35 (0.040 g, 0.15 mmol) and 3-Chloroaniline ( 0.019 g, 0.15 mmol). The crude product 
was purified by column chromatography (eluent PET/EtOAc 2:1) to give white solid 
(0.013 g, 23%): 1H NMR (400 MHz, DMSO-d6) δ 10.62 (s, 1H, H-7), 8.34 (d, J = 7.8 
Hz, 1H, H-5), 7.84 (t, J = 2.0 Hz, 1H, H-8), 7.78 (app. d, J = 3.9 Hz, 2H, H-3 and H-
11), 7.54 – 7.43 (m, 2H, H-2 and H-10), 7.36 (t, J = 8.1 Hz, 1H, H-4), 7.18 – 7.05 (m, 
1H, H-9), 4.29 (s, 2H, H-6), 3.78 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 167.19, 
167.01, 146.55, 142.11, 141.46, 140.98, 133.60, 131.42, 131.02, 123.56, 123.35, 
121.91, 119.00, 117.94, 117.74, 111.67, 36.01, 27.74. LCMS m/z calc. for 
C18H16ClN5OS [M]+: 383.4, found 383.85 with tR 2.87 min, purity 95%. 
 
Reaction code: liu180-99 
N-(3,4-Dichlorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (41) was prepared according to general procedure 5 using 35 
(0.070 g, 0.25 mmol) and 3,4-Dichloroaniline (0.041 g, 0.25 mmol). The crude product 
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was purified by column chromatography (eluent PET/EtOAc 2:1) to give a white solid 
(0.005 g, 5%): 1H NMR (400 MHz, DMSO-d6) δ 10.73 (s, 1H, H-7), 8.33 (d, J = 7.8 Hz, 
1H, H-5), 8.02 (d, J = 2.4 Hz, 1H, H-8), 7.84 – 7.74 (m, 2H, H-3 and H-10), 7.60 (d, J 
= 8.8 Hz, 1H, H-9), 7.56 – 7.43 (m, 2H, H-2 and H-4), 4.29 (s, 2H, H-6), 3.78 (s, 3H, 
H-1). 13C NMR (101 MHz, DMSO-d6) δ 167.37, 166.94, 146.55, 142.12, 141.48, 
139.62, 131.53, 131.44, 131.28, 125.26, 123.37, 121.91, 120.72, 119.61, 117.74, 
111.69, 36.00, 27.75. LCMS m/z calc. for C18H14Cl2N5OS [M+H]+: 418.3, found 418.2 
with tR 2.95 min, purity 95%. 
 
 
Reaction code: liu180-141 
N-(2-Methoxyphenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (42) was prepared according to general procedure 5 using 35 
(0.070 g, 0.26 mmol) and 2-methoxyaniline (0.031 g, 0.26 mmol). The crude product 
was purified by column chromatography (eluent PET/EtOAc 2:1) to give a yellow solid 
(0.0245 g, 51%): 1H NMR (400 MHz, DMSO-d6) δ 9.70 (s, 1H, H-7), 8.35 (d, J = 7.7 
Hz, 1H, H-5), 8.10 – 8.00 (m, 1H, H-11), 7.78 (app. q, J = 5.2, 3.8 Hz, 2H, H-2 and H-
3), 7.50 (ddd, J = 8.1, 5.2, 3.1 Hz, 1H, H-4), 7.10 – 6.98 (m, 2H, H-9 and H-10), 6.96 
– 6.82 (m, 1H, H-8), 4.31 (s, 2H, H-6), 3.81 (s, 3H, H-12), 3.78 (s, 3H, H-1). 13C NMR 
(101 MHz, DMSO-d6) δ 167.14, 166.92, 149.42, 146.54, 142.19, 141.55, 131.53, 
127.77, 124.70, 123.44, 121.92, 121.30, 120.78, 117.74, 111.70, 111.49, 35.64, 28.56, 
27.78. LCMS m/z calc. for C20H18N5O3S [M]+: 370.3, found 379.44 with tR 2.80 min, 
purity 95%. 
 
Reaction code: 180-143 
N-(4-Methoxyphenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (43) was prepared according to general procedure 5 using 36 
(0.070 g, 0.26 mmol) and 4-methoxyaniline (0.031 g, 0.26 mmol). The product was 
obtained as a yellow solid (0.095 g, 98 %): 1H NMR (400 MHz, DMSO-d6) δ 10.27 (s, 
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1H, H-7), 8.32 (d, J = 7.7 Hz, 1H, H-5), 7.88 – 7.70 (m, 2H, H-2 and H-3), 7.56 – 7.51 
(m, 2H, H-8 and H-11), 7.48 (ddd, J = 2.6, 5.6, 8.1 Hz, 1H, H-4), 6.96 – 6.71 (m, 2H, 
H-9 and H-10), 4.25 (s, 2H, H-6), 3.79 (s, 3H, H-12), 3.72 (s, 3H, H-11). 13C NMR (101 
MHz, DMSO-d6) δ 167.20, 166.15, 155.75, 146.45, 142.06, 141.37, 132.70, 131.38, 
123.33, 121.86, 121.13, 117.75, 114.37, 111.64, 38.71, 35.88, 27.74. LCMS m/z calc. 
for C19H17N5O2S [M]+: 379.2, found 379.44 with tR 2.70 min, purity 95%. 
 
Reaction code: liu195-43/ 180-147 
N-(3,4-Dimethoxyphenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (44) was prepared according to general procedure 5 using 35 
(0.070 g, 0.26 mmol) and 4-methoxyaniline (0.039 g, 0.26 mmol). The crude product 
was purified by column chromatography (eluent PET/EtOAc 2:1) to give white solid 
(0.003 g, 3 %): 1H NMR (400 MHz, DMSO-d6) δ 10.28 (s, 1H, H-7), 8.30 (d, J = 7.7 
Hz, 1H, H-5), 7.81 – 7.68 (m, 2H, H-2 and H-8), 7.47 (ddd, J = 2.4, 5.8, 8.0 Hz, 1H, H-
3), 7.35 (d, J = 2.4 Hz, 1H, H-10), 7.12 (dd, J = 2.4, 8.6 Hz, 1H, H-4), 6.90 (d, J = 8.7 
Hz, 1H, H-9), 4.25 (s, 2H, H-6), 3.78 (s, 3H, H-1), 3.72 (d, J = 0.9 Hz, 6H, H-11 and H-
12). 13C NMR (101 MHz, DMSO-d6) δ 167.19, 166.20, 149.03, 146.52, 145.36, 142.04, 
141.36, 133.18, 131.36, 123.32, 121.84, 117.72, 112.56, 111.62, 111.47, 104.72, 
56.18, 55.81, 35.96, 27.74. LCMS m/z calc. for C20H20N5O3S [M+H]+: 410.5, found 
410.2 with tR 2.62 min, purity 95%. 
 
Reaction code: liu180-115 
N-(4-fluorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (45) was prepared according to general procedure 5 using 35 
(0.070 g, 0.26 mmol) and 4-Fluoroaniline (0.028 g, 0.26 mmol). The crude product was 
purified by column chromatography (eluent PET/EtOAc 2:1) to give a white solid 
(0.030 g, 32%): 1H NMR (400 MHz, DMSO-d6) δ 10.48 (s, 1H, H-7), 8.33 (d, J = 7.8 
Hz, 1H, H-5), 7.86 – 7.71 (m, 2H, H-8 and H-11), 7.69 – 7.59 (m, 2H, H-2 and H-3), 
7.49 (ddd, J = 8.0, 5.3, 2.9 Hz, 1H, H-4), 7.16 (app. t, J = 8.9 Hz, 2H, H-9 and H-10), 
Rui Ling Liu                                                                             University of Nottingham  
145 
 
4.27 (s, 2H, H-6), 3.78 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 167.12, 166.64, 
158.50 (d, J = 240.3 Hz, 1JCF), 146.54, 142.08, 141.41, 135.96, 131.40, 123.34, 121.88, 
121.34 (d, J = 8.0 Hz, 3JCF), 117.74, 115.85 (d, J = 22.3 Hz), 111.65, 27.74. LCMS m/z 
calc. for C18H14FN5OS [M+H]+: 367.1, found 367.40 with tR 2.75 min, purity 95%. 
 
Reaction code: liu180-127 
N-(4-Bromophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (46) was prepared according to general procedure 5 using 35 
(0.070 g, 0.26 mmol) and 4-bromoaniline (0.044 g, 0.26 mmol). The crude product was 
purified by column chromatography (eluent PET/EtOAc 2:1) to give a white solid 
(0.030 g, 27%): 1H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H, H-7), 8.33 (d, J = 7.7 
Hz, 1H, H-5), 7.89 – 7.72 (m, 2H, H-2 and H-3), 7.69 – 7.57 (m, 2H, H-8 and H-9), 
7.55 – 7.43 (m, 3H, H-4 and H-9 and H-10), 4.28 (s, 2H, H-6), 3.77 (s, 3H, H-1). 13C 
NMR (101 MHz, DMSO-d6) δ 167.08, 166.94, 146.55, 142.10, 141.43, 138.92, 132.11, 
131.42, 123.36, 121.90, 121.50, 117.75, 115.40, 111.68, 36.01, 27.75. LCMS m/z calc. 
for C18H14BrN5OS [M]+: 429.0, found 428.31with tR 2.87 min, purity 95%. 
 
Reaction code: 180-149 
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(p-tolyl)acetamide (47) 
was prepared according to general procedure 5 using 35 (0.070 g, 0.26 mmol) and 4-
methoxyaniline (0.027 g, 0.26 mmol). The crude product was purified by column 
chromatography (eluent PET/EtOAc 2:1) to give a white solid (0.032 g, 35 %): 1H NMR 
(400 MHz, DMSO-d6) δ 10.33 (s, 1H, H-7), 8.29 (d, J = 7.8 Hz, 1H, H-5), 7.74 (app. d, 
J = 6.8 Hz, 2H, H-4 and H-3), 7.49 (app. dd, J = 17.2, 7.7 Hz, 3H, H-2 and H-8 and 
H11), 7.12 (app. d, J = 8.0 Hz, 2H, H-9 and H-10), 4.26 (s, 2H, H-6), 3.76 (s, 3H, H-
1), 2.25 (s, 3H, H-12). 13C NMR (101 MHz, DMSO-d6) δ 167.19, 166.43, 146.48, 
142.00, 141.33, 137.06, 132.74, 131.33, 129.63, 123.29, 121.82, 119.58, 117.70, 
111.57, 35.98, 27.72, 20.91. LCMS m/z calc. for C19H18N5OS [M]+: 363.1, found 
363.44 with tR 2.78 min, purity 95%. 




Reaction code: liu180-77 
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4-
(trifluoromethoxy)phenyl)acetamide (48) was prepared according general 
procedure 5 starting from 35 (0.050 g, 0.18 mmol) and 4-(trifluoromethoxy)aniline 
(0.032 g, 0.18 mmol). The crude product was purified by column chromatography 
(eluent PET/EtOAc 2:1) to give a white solid (0.005 g, 6%): 1H NMR (400 MHz, DMSO-
d6) δ 10.63 (s, 1H, H-7), 8.33 (d, J = 7.9 Hz, 1H, H-5), 7.84 – 7.62 (m, 4H, H-2, -3, -8 
and -11), 7.49 (ddd, J = 8.1, 5.3, 2.8 Hz, 1H, H-4), 7.34 (app. d, J = 8.6 Hz, 2H, H-9 
and H-10), 4.29 (s, 2H, H-6), 3.78 (d, J = 1.7 Hz, 3H, H-1). 13C NMR (101 MHz, DMSO-
d6) δ 178.30, 167.05, 167.00, 146.55, 142.10, 141.44, 144.06, 138.74, 131.41, 123.35, 
122.18, 121.90, 120.92, 117.74, 111.66, 35.95, 27.75. LCMS m/z calc. for 
C19H14F3N5O2S [M]+: 433.4, found 433.41 with tR 2.91 min, purity 95%.  
 
Reaction code: liu180-185 
3-(2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)acetamido)benzamide (50) 
was prepared  according  to general procedure 5 using  35 (0.10 g, 0.36 mmol)  and  
3-aminobenzamide (0.050 g, 0.36 mmol). The crude product was purified by column 
chromatography (eluent DCM/0.7 M MeOH 20:1) to give a grey solid (0.055 g, 34%): 
1H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H, H-7), 8.29 (d, J = 7.7 Hz, 1H, H-5), 8.10 
(t, J = 1.9 Hz, 1H, H-8), 7.94 (s, 1H, H-9), 7.84 – 7.75 (m, 1H, H-3), 7.76 – 7.68 (m, 
2H, H-12), 7.56 (dt, J = 7.7, 1.3 Hz, 1H, H-2), 7.46 (ddd, J = 8.0, 6.0, 2.2 Hz, 1H, H-4), 
7.38 (app. dd, J = 17.4, 9.5 Hz, 2H, H-10 and H-11), 4.29 (s, 2H, H-6), 3.76 (s, 3H and 
H-1). 13C NMR (101 MHz, DMSO-d6) δ 168.27, 167.10, 166.90, 146.50, 142.02, 
141.37, 139.56, 135.63, 131.36, 129.11, 123.30, 122.58, 122.29, 121.84, 119.21, 
117.70, 111.59, 35.97, 27.72. LCMS m/z calc. for C19H16N6O2S [M+H]+: 393.3, found 
393.44 with tR 2.44 min, purity 95%. 




Reaction code: liu180-83 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-
phenylacetamide (51) was prepared according to general procedure 5 starting from 
using 36 (0.050 g, 0.14 mmol) and aniline (0.013 g, 0.14 mmol). The crude product 
was purified by column chromatography (eluent PET/EtOAc 2:1) to give a white solid 
(0.015 g, 25%): 1H NMR (400 MHz, DMSO-d6) δ 10.42 (s, 1H, H-6), 8.49 (d, J = 1.9 
Hz, 1H, H-4), 7.93 (app. dd, J = 8.7, 2.0 Hz, 1H, H-3), 7.76 (d, J = 8.7 Hz, 1H, H-2), 
7.62 (app. d, J = 7.9 Hz, 2H, H-7 and H-11), 7.32 (t, J = 7.9 Hz, 2H, H-8 and H-10), 
7.06 (t, J = 7.4 Hz, 1H, H-9), 4.29 (s, 2H, H-5), 3.78 (s, 3H, H-1). 13C NMR (101 MHz, 
DMSO-d6) δ 167.96, 166.60, 146.71, 140.94, 140.52, 139.54, 133.69, 132.07, 129.27, 
129.14, 124.16, 123.84, 119.71, 119.57, 115.44, 113.85, 36.03, 27.91. LCMS m/z calc. 
for C18H14BrN5OS [M]+: 429.2, found 428.3 with tR 2.87 min, purity 95%. 
 
Reaction code: liu180-91 and 195-45 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(3-
chlorophenyl)acetamide (53) was prepared according to general procedure 5 
starting from using 36 ( 0.050 g, 0.14 mmol) and 3-Chloroaniline (0.018 g, 0.14 mmol). 
The crude product was purified by column chromatography (eluent PET/EtOAc 2:1) to 
give a white solid (0.010g, 15.4%): 1H NMR (400 MHz, DMSO-d6) δ 10.63 (s, 1H, H-
7), 8.50 (d, J = 1.9 Hz, 1H, H-4), 7.93 (dd, J = 8.7, 2.0 Hz, 1H, H-3), 7.84 (t, J = 2.1 
Hz, 1H, H-8), 7.76 (d, J = 8.6 Hz, 1H, H-2), 7.52 – 7.45 (m, 1H, H-11), 7.35 (d, J = 8.1 
Hz, 1H, H-9), 7.16 – 7.07 (m, 1H, H-10), 4.29 (s, 2H, H-6), 3.77 (s, 3H, H-1). LCMS 
m/z calc. for C18H13BrClN5OS [M]+: 464.2, found 472.7 with tR 2.98 min, purity 95%. 
 




Reaction code: liu180-31/45 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4-
chlorophenyl)acetamide (54) was prepared according to general procedure 5 
starting from using 36 ( 0.050 g, 0.1415 mmol) and 4-Chloroaniline (0.020 g, 0.1562 
mmol). The crude product was purified by column chromatography (eluent PET/EtOAc 
2:1) to give a white solid (0.010 g, 15%): 1H NMR (400 MHz, DMSO-d6) δ 10.57 (s, 
1H, H-7), 8.50 (d, J = 2.0 Hz, 1H, H-4), 7.93 (dd, J = 8.7, 2.0 Hz, 1H, H-3), 7.76 (d, J 
= 8.7 Hz, 1H, H-2), 7.72 – 7.60 (m, 2H, H-8 and H-11), 7.42 – 7.34 (m, 2H, H-9 and 
H-10), 4.28 (s, 2H, H-6), 3.77 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 167.86, 
166.82, 146.71, 140.96, 140.55, 138.49, 133.71, 129.20, 127.38, 124.18, 121.11, 
119.71, 115.45, 113.86, 36.01, 27.90.  LCMS m/z calc. for C18H13BrClN5OS [M+H]+ : 
462.3, found 462.75 with tR 2.91 min, purity 95%. 
 
Reaction code: liu180-97 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(3,4-
dichlorophenyl)acetamide (55) was prepared according to general procedure 5 
using 36 (0.070 g, 0. 20 mmol) and 3,4-dichloroaniline (0.035 g, 0.21 mmol). The crude 
product was purified by column chromatography (eluent PET/EtOAc 2:1) to give white 
solid (0.005 g, 5%): 1H NMR (400 MHz, DMSO-d6) δ 10.73 (d, J = 7.6 Hz, 1H, H-6), 
8.50 (d, J = 1.9 Hz, 1H, H-4), 8.02 (d, J = 2.3 Hz, 1H, H-7), 7.94 (dd, J = 8.7, 1.9 Hz, 
1H, H-9), 7.76 (d, J = 8.7 Hz, 1H, H-3), 7.60 (d, J = 8.8 Hz, 1H, H-2), 7.53 (dd, J = 8.9, 
2.4 Hz, 1H, H-8), 4.29 (s, 2H, H-5), 3.76 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) 
δ 167.37, 166.94, 146.55, 142.12, 141.48, 139.62, 131.53, 131.44, 131.28, 125.26, 
123.37, 121.91, 120.72, 119.61, 117.74, 111.69, 36.00, 27.75. LCMS m/z calc. for 
C18H12BrCl2N5OS [M]+: 497.1, found 497.19 with tR 3.06 min, purity 95%. 




Reaction code: liu180-139 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(2-
methoxyphenyl)acetamide (56) was prepared according to general procedure 5 
using 36 (0.070 g, 0.20 mmol) and 2-methoxyaniline (0.023 g, 0.20 mmol). The crude 
product was purified by column chromatography (eluent PET/EtOAc 2:1) to give a 
yellow solid (0.026 g, 28%): 1H NMR (400 MHz, DMSO-d6) δ 9.69 (s, 1H, H-6), 8.51 
(d, J = 2.0 Hz, 1H, H-4), 8.03 (dd, J = 1.5, 8.0 Hz, 1H, H-10), 7.94 (dd, J = 2.0, 8.7 Hz, 
1H, H-3), 7.77 (d, J = 8.7 Hz, 1H, H-2), 7.11 – 6.96 (m, 2H, H-7 and H-8), 6.89 (ddd, 
J = 1.9, 6.9, 8.5 Hz, 1H, H-9), 4.32 (s, 2H, H-5), 3.80 (app. d, J = 2.5 Hz, 6H, H-1 and 
H-11). 13C NMR (101 MHz, DMSO-d6) δ 167.72, 167.01, 149.48, 141.05, 140.66, 
133.81, 127.75, 124.74, 124.19, 121.40, 120.77, 119.70, 115.53, 113.89, 111.50, 
56.10, 35.69, 27.93. LCMS m/z calc. for C19H16BrN5O2S [M]+: 459.3, purity 95%. 
 
Reaction code: liu180-133 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4-
methoxyphenyl)acetamide (57) was prepared according to general procedure 5 
using 36 (0.070 g, 0.20 mmol) and 4-methoxyaniline (0.023 g, 0.20 mmol). The crude 
product was purified by column chromatography (eluent PET/EtOAc 2:1) to give a light 
yellow solid (0.017 g, 18%): 1H NMR (400 MHz, DMSO-d6) δ 10.28 (s, 1H, H-6), 8.49 
(d, J = 2.0 Hz, 1H, H-4), 7.93 (dd, J = 8.7, 2.0 Hz, 1H, H-3), 7.76 (d, J = 8.7 Hz, 1H, 
H-2), 7.56 – 7.49 (m, 2H, H-7 and H-10), 6.93 – 6.85 (m, 2H, H-8 and H-9), 4.25 (s, 
2H, H-5), 3.78 (s, 3H, H-11), 3.72 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 168.03, 
166.05, 155.76, 146.72, 140.94, 140.50, 133.68, 132.69, 124.15, 121.13, 119.72, 
115.44, 114.38, 113.85, 38.72, 35.90, 27.92. LCMS m/z calc. for C19H16BrN5O2S [M]+: 
458.3, found 458.33 with tR 2.87 min, purity 95%. 




Reaction code: liu180-113 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4-
fluorophenyl)acetamide (58) was prepared according to general procedure 5 using 
36 (0.070 g, 0.20 mmol) and 4-Fluoroaniline (0.022g, 0.20 mmol). The crude product 
was purified by column chromatography (eluent PET/EtOAc 2:1) to give a white solid 
(0.027g, 30%): 1H NMR (400 MHz, DMSO-d6) δ 10.48 (s, 1H, H-6), 8.49 (d, J = 2.0 
Hz, 1H, H-4), 7.92 (dd, J = 8.7, 2.0 Hz, 1H, H-3), 7.75 (d, J = 8.7 Hz, 1H, H-2), 7.68 – 
7.57 (m, 2H, H-7 and H-10), 7.16 (app. t, J = 8.9 Hz, 2H, H-8 and H-9), 4.27 (s, 2H, H-
5), 3.77 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 167.91, 166.55, 146.71, 140.95, 
140.54, 135.92, 133.70, 124.17, 121.38, 121.30, 119.70, δ 115.85 (d, J = 22.4 Hz, 
2JCF)., 115.45, 113.85, 35.93, 27.90. LCMS m/z calc. for C18H13BrFN5OS [M]+: 446.3, 
found 446.30 with tR 2.88 min, purity 95%. 
 
Reaction code: liu180-131 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4-
bromophenyl)acetamide (59) was prepared according to general procedure 5 using 
36 (0.070 g, 0.20 mmol) and 4-bromoaniline (0.034 g, 0.20 mmol). The crude product 
was purified by column chromatography (eluent PET/EtOAc 2:1) to give a yellow solid 
(0.007g, 7%): 1H NMR (400 MHz, DMSO-d6) δ 10.57 (s, 1H, H-6), 8.49 (d, J = 2.0 Hz, 
1H, H-4), 7.93 (dd, J = 8.7, 2.1 Hz, 1H, H-3), 7.76 (d, J = 8.7 Hz, 1H, H-2), 7.64 – 7.56 
(m, 2H, H-7 and H-10), 7.55 – 7.44 (m, 2H, H-8 and H-9), 4.28 (s, 2H, H-5), 3.76 (s, 
3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 167.08, 166.95, 146.55, 142.10, 141.44, 
138.92, 132.11, 131.42, 123.36, 121.91, 121.50, 117.75, 115.39, 111.68, 36.01, 27.75. 
LCMS m/z calc. for C18H13Br2N5OS [M]+: 507.2, found 507.20 with tR 2.87 min, purity 
95%. 




Reaction code: liu180-151 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(p-
tolyl)acetamide (60) was prepared according to general procedure 5 using 36 (0.070 
g, 0.20 mmol) and 2-methoxyaniline (0.030 g, 0.20 mmol). The crude product was 
purified by column chromatography (eluent PET/EtOAc 2:1) to give a white solid 
(0.015 g, 12 %): 1H NMR (400 MHz, DMSO-d6) δ 10.34 (s, 1H, H-6), 8.47 (d, J = 2.0 
Hz, 1H, H-2), 7.91 (dd, J = 8.7, 2.0 Hz, 1H, H-3), 7.74 (d, J = 8.7 Hz, 1H, H-4), 7.51 
(app. d, J = 8.4 Hz, 2H, H-7 and H-10), 7.12 (app. d, J = 8.1 Hz, 2H, H-8 and H-9), 
4.27 (s, 2H, H-5), 3.77 (s, 3H, H-1), 2.25 (s, 3H, H-11). 13C NMR (101 MHz, DMSO-
d6) δ 168.00, 166.33, 146.69, 140.91, 140.49, 137.05, 133.67, 132.74, 129.63, 124.14, 
119.70, 119.58, 115.44, 113.84, 36.00, 27.91, 20.92. LCMS m/z calc. for 
C19H17BrN5OS [M+H]+: 442.1, found 442.1 with tR 2.95 min, purity 95%. 
 
Reaction code: liu180-51 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4-
(trifluoromethoxy)phenyl)acetamide (61) was prepared according to general 
procedure 5 starting from using 36 (0.050 g, 0.14 mmol) and 4-
(trifluoromethoxy)aniline (0.021 mL, 0.16 mmol). The crude product was purified by 
column chromatography (eluent PET/EtOAc 2:1) to give a white solid (0.007 g, 9%): 
1H NMR (400 MHz, DMSO-d6) δ 10.63 (s, 1H, H-6), 8.48 (d, J = 2.0 Hz, 1H, H-4), 7.92 
(dd, J = 8.7, 2.0 Hz, 1H, H-2), 7.83 – 7.64 (m, 3H, H-3, -7 and -10), 7.34 (app. d, J = 
8.6 Hz, 2H, H-8 and H-9), 4.29 (s, 2H, H-5), 3.77 (d, J = 5.3 Hz, 3H, H-1). 13C NMR 
(101 MHz, DMSO-d6) δ 167.83, 167.00, 166.91, 146.70, 142.09, 140.95, 140.56, 
138.73, 133.70, 124.16, 122.18, 120.93, 119.69, 119.33, 115.45, 113.85, 111.66, 
35.97, 27.74. LCMS m/z calc. for C19H13BrF3N5O2S [M+H]+: 512.1, found 512.31 with 
tR 3.05 min, purity 95%. 




Reaction code: liu180-267 
N-(4-chlorophenyl)-2-((8-methoxy-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (62) was obtained according to general procedure 5  using 37 (0.10 
g, 0.33 mmol) and 4-chloroaniline (0.046 g, 0.36 mmol). The crude product was 
purified by column chromatography (eluent PET/EtOAc 2:1) to give a white solid 
(0.020 g, 15%): 1H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H, H-6), 7.84 (d, J = 2.8 
Hz, 1H, H-4), 7.67 (app. dd, J = 11.3, 8.7 Hz, 3H, H-2, -7 and -10 ), 7.44 – 7.31 (m, 
3H, H-3, -8, and -9), 4.26 (s, 2H, H-5), 3.90 (s, 3H, H-1), 3.74 (s, 3H, H-11). 13C NMR 
(101 MHz, DMSO-d6) δ 166.96, 166.92, 156.25, 146.43, 141.38, 138.51, 136.45, 
129.20, 127.36, 121.10, 119.87, 118.37, 112.67, 104.68, 56.32, 35.96, 27.76. LCMS 
m/z calc. for C19H17ClN5O2S [M]+: 413.3, found 413.88 with tR 2.86 min, purity 95%. 
 
Reaction code: 195-105 
N-(4-(cyanomethyl)phenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (65) was obtained according to general procedure 5 using 
35(0.080 g, 0.0.29 mmol) and 2-(4-aminophenyl)acetonitrile (0.043 g, 0.32 mmol). The 
crude product was purified by column chromatography (eluent PET/EtOAc 2:1) to give 
a white solid (58.9 mg, 52%): 1H NMR (400 MHz, DMSO-d6) δ 10.52 (d, J = 10.1 Hz, 
1H, H-7), 8.29 (d, J = 7.7 Hz, 1H, H-5), 7.95 (s, 1H, H-8), 7.78 – 7.68 (m, 2H, H-3 and 
H-11), 7.67 – 7.60 (m, H, H-2), 7.46 (ddd, J = 1.8, 6.5, 8.0 Hz, 1H, H-4), 7.30 (app. d, 
J = 8.3 Hz, 2H, H-9 and H-10), 4.27 (s, 2H, H-12), 3.97 (s, 2H, H-6), 3.76 (s, 3H, H-
1).13C NMR (101 MHz, DMSO-d6) δ 167.12, 166.85, 146.49, 142.01, 141.34, 138.94, 
131.39, 129.04, 126.39, 123.33, 121.84, 120.00, 119.81, 117.67, 111.58, 35.96, 27.70, 
22.30. LCMS m/z calc. for C20H17N6OS [M+H]+: 389.4, found 389.3 with tR 2.66 min, 
purity> 95%. 




Reaction code: liu180-195 
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4-
phenoxyphenyl)acetamide (66) was prepared according to general procedure 5 
using 35 (0.10 g, 0.36 mmol)  and 4-phenoxyaniline (0.067 g, 0.36 mmol). The crude 
product was purified by column chromatography (eluent PET/EtOAc 2:1) to give a 
white solid (0.094 g, 58%): 1H NMR (400 MHz, DMSO-d6) δ 10.45 (s, 1H, H-7), 8.35 – 
8.27 (m, 1H, H-5), 7.82 – 7.71 (m, 2H, H-2 and H-3), 7.70 – 7.60 (m, 2H, H-8 and H-
11), 7.48 (ddd, J = 8.1, 5.6, 2.6 Hz, 1H, H-4), 7.40 – 7.31 (m, 2H, H-13 and H-15), 7.13 
– 7.05 (m, 1H, H-14), 7.04 – 6.92 (m, 4H, H-9, -10, -13 and -15), 4.28 (s, 2H, H-6), 
3.79 (s, 3H, H-1).  13C NMR (101 MHz, DMSO-d6) δ 174.23, 166.53, 142.06, 141.39, 
135.47, 131.38, 130.43, 123.46, 123.32, 121.86, 121.29, 119.98, 118.34, 117.74, 
111.63, 35.93, 27.75. LCMS m/z calc. for C24H19N5O2S [M]+: 442.3, found 441.51 with 
tR 2.95 min, purity 95%. 
 
Reaction code: liu180-197 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4-
phenoxyphenyl)acetamide (67) was obtained according to general procedure 5  
using 36 ( 0.10 g, 0.28 mmol) and 4-phenoxyaniline (0.052 g, 0.28 mmol). The crude 
product was purified by column chromatography (eluent PET/EtOAc 2:1) to give a 
white solid (0.027 g, 18%): 1H NMR (400 MHz, DMSO-d6) δ 10.46 (s, 1H, H-6), 8.47 
(d, J = 2.0 Hz, 1H, H-4), 7.91 (dd, J = 8.7, 2.0 Hz, 1H, H-3), 7.74 (d, J = 8.7 Hz, 1H, 
H-2), 7.68 – 7.58 (m, 2H, H-7 and H-10), 7.42 – 7.29 (m, 2H, H-12 and H-14), 7.13 – 
7.07 (m, 1H, H-13), 7.05 – 6.90 (m, 4H, H-8, -9, -11, -15), 4.28 (s, 2H, H-5), 3.78 (s, 
3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 166.43, 157.78, 152.30, 146.68, 140.92, 
140.51, 135.45, 133.67, 130.43, 124.13, 123.47, 121.29, 119.97, 119.68, 118.35, 
115.44, 113.83, 35.96, 27.92. LCMS m/z calc. for C24H18BrN5O2S [M]+: 521.2, found 
520.41 with tR 3.06 min, purity 95%. 




Reaction code: liu180-269 
2-((8-Methoxy-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4-
phenoxyphenyl)acetamide (68) was obtained according to general procedure 5 
using 36 (0.10 g, 0.33 mmol) and 4-phenoxyaniline (0.067 g, 0.36 mmol). The crude 
product was purified by column chromatography (eluent PET/EtOAc 2:1) to give a 
white solid (0.063 g, 41%): 1H NMR (400 MHz, DMSO-d6) δ 10.45 (s, 1H, H-6), 7.84 
(d, J = 2.5 Hz, 1H, H-4), 7.76 – 7.58 (m, 3H, H-2, -12 and -14), 7.37 (app. td, J = 8.3, 
7.8, 2.5 Hz, 3H, H-13, -7 and -10), 7.10 (t, J = 7.4 Hz, 1H, H-3), 7.05 – 6.89 (m, 4H, 
H-11, -15, -8, -9), 4.26 (s, 2H, H-5), 3.90 (s, 3H, H-1), 3.77 (s, 3H, H-16). 13C NMR 
(101 MHz, DMSO-d6) δ 166.99, 166.56, 157.79, 156.25, 152.28, 146.44, 141.36, 
136.45, 135.47, 130.43, 123.46, 121.28, 119.98, 119.85, 118.38, 118.35, 112.66, 
104.67, 56.32, 35.91, 27.78. LCMS m/z calc. for C25H21N5O3S [M]+: 471.4, found 
471.54 with tR 2.96 min, purity 95%. 
General procedure 6 Preparation of 2-bromo-N-phenylacetamides  
 
Anilines (1 equiv) was dissolved in DCM (5 mL/mmol) followed by addition of Et3N (1.5 
equiv) and bromoacetyl chlorides (1 equiv) at 0oC under N2 protection. Reaction 
mixture was allowed slowly warm up to room temperature. Reactions were monitored 
by TCL. Once the reaction finished, solvent was removed under vacuum and crude 
product was used directly without further purification.  
 
Reaction code: liu180-177 
2-Bromo-N-(2-chlorophenyl)acetamide (64) was prepared according to general 
procedure 6 using 2-chloroaniline (63) (0.30 g, 2.35 mmol) and 2-bromoacetyl chloride 
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(0.37 g, 2.35 mmol). The crude product was obtained as a white crystal (0.19 g, 33% 
crude yield) 
 
Reaction code: liu180-227 
2-Bromo-N-(4-chlorophenyl)propanamide (87) was prepared according to general 
procedure 6 using 4-chloroaniline (0.50 g, 3.94 mmol) and 2-bromoacetyl chloride 
(0.67 g, 3.94 mmol). The crude product was purified by column chromatography 
(eluent PET/EtOAc 5:1) to give a white solid (0.24 g, 24%): 1H NMR (400 MHz, DMSO-
d6) δ 10.46 (s, 1H, H-3), 7.72 – 7.55 (m, 2H, H-4 and H-7), 7.54 – 7.22 (m, 2H, H-5 
and H-6), 4.69 (q, J = 6.7 Hz, 1H, H-2), 1.75 (d, J = 6.6 Hz, 3H, H-1). 13C NMR (101 
MHz, DMSO-d6) δ 168.08, 138.00, 129.26, 127.86, 121.32, 44.73, 21.76. LCMS m/z 
calc. for C9H9BrClNO [M]+: 263.0, found 262.53 with tR 2.74 min, purity 95%. 
 
Reaction code: liu180-245 
2-Bromo-N-(4-chlorophenyl)-2-methylpropanamide (88) was prepared according 
to general procedure 6 using 4-chloroaniline (0.20 g, 1.57 mmol) and 2-bromo-2-
methylpropanoyl bromide (0.36 g, 1.57 mmol). The crude product was purified by 
column chromatography (eluent PET/EtOAc 5:1) to give a white solid (0.53 g, >100%): 
1H NMR (400 MHz, DMSO-d6) δ 9.93 (s, 1H, H-3), 7.72 (app. dd, J = 8.6, 1.9 Hz, 2H, 
H-4 and H-7), 7.38 (app. dt, J = 8.7, 1.8 Hz, 2H, H-5 and H-6), 2.00 (s, 6H, H-1 and 
H-2). 13C NMR (101 MHz, DMSO-d6) δ 169.93, 138.07, 128.92, 128.07, 122.48, 60.93, 
31.16, 30.94. 6. LCMS m/z calc. for C10H11BrClNO [M]+: 277.1, found 276.56 with tR 
2.88 min, purity 95%. 
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5-Methyl-5H-[1,2,4]triazino[5,6-b]indoles-3-thiols (1 equiv) was dissolved in 5 
mL/mmol of DCM and Et3N (1.5 equiv) was added to the suspension followed by 
addition of 2-bromo-N-phenylacetamides (1 equiv) at 0oC under N2. Reaction mixture 
was allowed slowly warm up to room temperature and stir for 4 hours. The reaction 
was monitored by TCL. Once the reaction finished, solvent was removed under 
vacuum. The crude product was purified by column chromatography. 
 
Reaction code: liu180-181 
N-(2-chlorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (39) was prepared according to general procedure 7 using 2-
bromo-N-(2-chlorophenyl)acetamide (64) (0.10 g, 0.41 mmol) and 5-methyl-5H-
[1,2,4]triazino[5,6-b]indole-3-thiol (29) (0.088 g, 0.41 mmol). The crude product was 
purified by column chromatography (eluent PET/EtOAc 2:1) to give a white solid 
(0.029 g, 18%): 1H NMR (400 MHz, DMSO-d6) δ 9.93 (s, 1H, H-7), 8.34 (d, J = 7.7 Hz, 
1H, H-5), 7.87 – 7.73 (m, 3H, H-2, -3, -11), 7.50 (app. ddd, J = 7.7, 5.1, 2.4 Hz, 2H, H-
8 and H-10), 7.40 – 7.25 (m, 1H, H-9), 7.18 (td, J = 7.7, 1.6 Hz, 1H, H-4), 4.35 (s, 2H, 
H-6), 3.81 (s, 3H, H-1). 13C NMR (101 MHz, DMSO-d6) δ 167.33, 166.90, 146.55, 
142.14, 141.50, 135.29, 131.47, 129.94, 127.99, 126.66, 125.83, 123.39, 121.93, 
117.74, 111.68, 35.43, 27.85. LCMS m/z calc. for C18H14ClN5OS [M]+: 383.2, found 
383.85with tR 2.82 min, purity 95%. 
 
Reaction code: liu180-191 
2-((8-Bromo-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(2-
chlorophenyl)acetamide (52) was prepared according to general procedure 7 using 
bromo-N-(2-chlorophenyl)acetamide (64) (0.100 g, 0.3387 mmol) and 30 (0.083 g, 
0.3387 mmol). The crude product was purified by column chromatography (eluent 
PET/EtOAc 2:1) to give a white solid (0.053 g, 35%): 1H NMR (400 MHz, DMSO-d6) δ 
9.94 (s, 1H, H-6), 8.50 (t, J = 2.8 Hz, 1H, H-4), 7.93 (dt, J = 9.3, 2.7 Hz, 1H, H-3), 7.88 
– 7.64 (m, 2H, H-2 and H-10), 7.50 (dd, J = 7.9, 1.6 Hz, 1H, H-9), 7.43 – 7.25 (m, 1H, 
H-7), 7.23 – 7.08 (m, 1H, H-8), 4.36 (app. d, J = 3.3 Hz, 2H, H-5), 3.80 (s, 3H, H-1). 
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13C NMR (101 MHz, DMSO-d6) δ 167.71, 167.22, 146.72, 140.99, 140.61, 135.28, 
133.76, 129.96, 127.98, 126.70, 126.29, 125.94, 124.20, 119.69, 115.50, 113.88, 
35.45, 28.00. LCMS m/z calc. for C18H13BrClN5OS [M]+: 463.0, found 462.75 with tR 
3.01 min, purity 95%. 
 
Reaction code: liu180-235 
N-(4-chlorophenyl)-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)propanamide (92) was prepared according to general procedure 7 using 87 
(0.20 g, 0.93 mmol) and 29 (0.24 g, 0.93 mmol). The crude product was purified by 
column chromatography (eluent PET/EtOAc 2:1) to give a white solid (0.083 g, 22%): 
1H NMR (400 MHz, DMSO-d6) δ 10.61 (s, 1H, H-7), 8.30 (d, J = 7.7 Hz, 1H, H-5), 7.75 
(app. d, J = 5.9 Hz, 2H, H-2 and H-3), 7.68 (app. d, J = 8.6 Hz, 2H, H-8 and H-11), 
7.47 (ddd, J = 8.0, 6.0, 2.3 Hz, 1H, H-4), 7.38 (app. d, J = 8.8 Hz, 2H, H-9 and H-10), 
4.85 (q, J = 7.0 Hz, 1H, H-6), 3.77 (s, 3H, H-1), 1.68 (d, J = 7.1 Hz, 3H, H-12). 13C 
NMR (101 MHz, DMSO-d6) δ 170.55, 166.85, 146.49, 142.08, 141.47, 138.40, 131.42, 
129.19, 127.53, 123.33, 121.88, 121.25, 117.71, 111.61, 45.12, 27.76, 18.65. LCMS 
m/z calc. for C19H16ClN5OS [M]+: 397.2, found 397.8 with tR 3.03 min, purity 95%. 
 
Reaction code: liu180-225 
tert-Butyl 2-methyl-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)propanoate: To a solution of tert-butyl 2-((5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)acetate (29) (0.30 g, 0.91 mmol) in anhydrous DMF (10 mL) at 0oC 
under N2 protection, NaH 60% dispersion in mineral oil (0.11 g, 2.72 mmol) was added 
in one portion. The mixture was stirring for 45 minutes followed by addition of 
iodomethane (0.64 g, 4.54 mmol) dropwise. The mixture was then slowly warmed up 
to room temperature and stirred for overnight. The mixture was poured into Sat. NH4Cl 
(60 mL) and stirred vigorously for 10 minutes. The resulting suspension was extracted 
with EtOAc (30 mL × 3). The combined organic layers were washed with brine, dried 
over Na2SO4, and concentrated. The crude compound was purified by column 
chromatography to give a white solid (0.17 g, 52 % yield): 1H NMR (400 MHz, DMSO-
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d6) δ 8.35 (dt, J = 7.7, 1.0 Hz, 1H, H-5), 7.86 – 7.73 (m, 2H, H-2 and H-3), 7.50 (ddd, 
J = 8.0, 5.6, 2.6 Hz, 1H, H-4), 3.80 (s, 3H, H-1), 1.71 (app. s, 6H, H-6 and H-7), 1.31 
(s, 9H, H-8). 13C NMR (101 MHz, DMSO-d6) δ 172.64, 167.06, 146.27, 141.99, 141.11, 
131.39, 123.36, 121.90, 117.84, 111.64, 80.83, 51.95, 27.88, 27.83, 26.52. LCMS m/z 
calc. for C18H22N4O2S [M]+: 358.2, found 358.46 with tR 3.03 min, purity 95%. 
 
Reaction code: liu180-229 
2-Methyl-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)propanoic acid: 
tert-butyl 2-methyl-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)propanoate (0.064 g, 0.18 mmol) were dissolved in DCM (3 mL), and 4 mL 
4M HCl in dioxane (excessive) was added to the suspension. The mixture was then 
allowed to stir at room temperature for 24 hours. Solvent removed under vacuum to 
give light yellow solid. The crude compound was washed with diethyl ether and DCM 
and was used directly for the next step without further purification (0.038 g, 70% ): 1H 
NMR (400 MHz, DMSO-d6) δ 8.32 (d, J = 7.7 Hz, 1H, H-5), 7.84 – 7.71 (m, 2H, H-2 
and H-3), 7.49 (ddd, J = 8.0, 5.7, 2.4 Hz, 1H, H-4), 3.80 (s, 3H, H-1), 1.73 (app. s, 6H, 
H-7 and H-8). 13C NMR (101 MHz, DMSO-d6) δ 175.34, 167.06, 146.30, 142.07, 
141.02, 131.47, 123.40, 121.91, 117.79, 111.66, 51.64, 27.83, 26.60. LCMS m/z calc. 
for C14H14N4O2S [M]+: 302.1, found 302.35 with tR 2.55 min, purity 90%. 
 
Reaction code: liu180-265 
6.4.2.4 Preparation of N-(4-chlorophenyl)-2-methyl-2-((5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)propanamide (93) 
Method 1: N-(4-chlorophenyl)-2-methyl-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)propanamide was prepared according to general procedure 5 using 2-methyl-
2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)propanoic acid. 
Method 2: To a solution of 5-methyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol (29) (0.100 
g, 0.46 mmol) in anhydrous DMF (10 mL) at 0 oC under N2 protection, NaH 60% 
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dispersion in mineral oil (0.020g, 0.51 mmol) was added in one portion. The mixture 
was stirred for 45 minutes followed by addition of 2-bromo-N-(4-chlorophenyl)-2-
methylpropanamide (88) (0.128 g, 0.46 mmol). The mixture was then slowly warmed 
up to room temperature and stirred for overnight. The mixture was poured into Sat. 
NH4Cl (60 mL) and stirred vigorously for 10 minutes. The resulting suspension was 
extracted with EtOAc (30 mL × 3). The combined organic layers were washed with 
brine, dried over Na2SO4, and concentrated.  The crude product was purified by 
column chromatography(eluent PET/EtOAc 3:1) to give a yellow solid (0.140 g, 74% ): 
1H NMR (400 MHz, DMSO-d6) δ 9.98 (s, 1H, H-6), 8.29 (dt, J = 7.8, 1.0 Hz, 1H, H-5), 
7.85 – 7.62 (m, 4H, H-2, -3, -7 and -10), 7.45 (ddd, J = 8.0, 6.7, 1.5 Hz, 1H, H-4), 7.38 
– 7.17 (m, 2H, H-8 and H-9), 3.73 (s, 3H, H-1), 1.81 (app. s, 6H, H-11 and H-12). 13C 
NMR (101 MHz, DMSO-d6) δ 172.39, 166.56, 146.24, 141.98, 141.26, 138.68, 131.44, 
128.76, 127.36, 123.33, 122.25, 121.90, 117.71, 111.60, 52.77, 27.78, 26.61. LCMS 
m/z calc. for C20H18ClN5OS [M]+: 411.2, found 411.91 with tR 2.99 min, purity 95%. 
Preparation of tert-butyl 4-(2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamido)piperidine-1-carboxylate  
 
Reaction code: liu195-003/ liu180-281 
tert-Butyl 4-(2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamido)piperidine-1-carboxylate (99) was prepared according to general 
procedure 5 using 35 (0.100 g, 0.36 mmol) and tert-butyl 4-aminopiperidine-1-
carboxylate (0.073 g, 0.36 mmol). The crude compound was purified by column 
chromatography (eluent PET/EtOAc 3:1) to give a yellow solid (0.150 g, 90 %): 1H 
NMR (400 MHz, DMSO-d6) δ 8.34 (d, J = 7.7 Hz, 1H, H-7), 8.26 (d, J = 7.7 Hz, 1H, H-
5), 7.84 – 7.70 (m, 2H, H-2 and H-3), 7.50 (ddd, J = 3.5, 4.8, 8.0 Hz, 1H, H-4), 4.04 (s, 
2H, H-6), 3.88- 3.71 (m, 6H, H-1 and H-13, H-9, H-10), 2.86 (app. d, J = 10.1 Hz, 2H, 
H-9 and H-10), 1.73 (app. dd, J = 3.8, 13.0 Hz, 2H, H-8 and H-11), 1.40 (s, 9H, H-12), 
1.35 – 1.20 (m, 2H, H-8 and H-11). 13C NMR (101 MHz, DMSO-d6) δ 167.28, 166.83, 
154.38, 142.05, 131.37, 123.34, 121.87, 117.77, 111.65, 79.12, 48.95, 46.69, 34.95, 
30.58, 28.54, 27.82. LCMS m/z calc. for C22H28N6O3S [M+H]+: 457.5, found 457.1 with 
tR 2.76 min. 




Reaction code: liu195-009 
Preparation of 2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(piperidin-
4-yl)acetamide (100). 99 (0.352 g, 0.77 mmol) was dissolved in DCM (5 mL), 3 mL 
4M HCl in dioxane (excessive) was added, and the reaction mixture was allowed to 
stir at room temperature for 6 hours. The reaction was monitored by TCL. Once the 
reaction finished, solvent was removed under vacuum, 7 N NH3 in Methanol (10 mL) 
was added, the solvent was allowed to stir at room temperature for 3 hours. Solvent 
was removed under vacuum. The crude product was purified by column 
chromatography (eluent DCM: 0.7 N NH3 in MeOH (10:1). A grey solid (0.14 g, 51%). 
1H NMR (400 MHz, Chloroform-d) δ 8.48 – 8.40 (m, 1H, H-7), 7.75 (td, J = 1.2, 7.7 Hz, 
1H, H-5), 7.59 – 7.47 (m, 3H, H-2, -3 and -4), 3.99 (s, 2H, H-6), 3.97 – 3.91 (m, 1H, 
H-8), 3.87 (s, 3H, H-1), 3.15 (app. d, J = 12.9 Hz, 2H, H-10 and H-12), 2.85 – 2.73 (m, 
2H, H-10 and H-12), 1.98 (app. d, J = 13.6 Hz, 2H, H-9 and H-13), 1.60 – 1.39 (m, 2H, 
H-9 and H-13 ). 13C NMR (101 MHz, Chloroform-d) δ 168.51, 166.77, 146.52, 142.00, 
131.37, 123.37, 122.66, 117.96, 110.06, 45.66, 43.78, 34.74, 30.55, 27.47. LCMS m/z 
calc. for C17H20N6OS [M+H]+: 357.4, found 357.2 with tR 1.95 min. 
 
Preparation of 2-bromo-N-cyclohexylacetamide 96 Cyclohexanamine (0.200g, 
2.02 mmol) was dissolved in 10 mL DCM, Et3N (0.224 g, 2.22 mmol) was added at 0 
oC  under N2, followed by addition of 2-bromoacetyl chloride (0.32 g, 2.02 mmol). 
Reaction mixture was allowed to warm up to room temperature and stirred for 4 hours 
and monitored by TLC. Once the reaction finished, solvent was removed under 
vacuum and crude product was used directly for the next step without purification.  
 
Reaction code: liu180-291 




yl)thio)acetamide (98). 29 (0.100 g, 0.46 mmol) was dissolved in 5 mL DCM at 0 oC, 
Et3N (0.051 g, 0.51 mmol) was added followed by addition of 96 (0.102 g, 0.46 mmol). 
Reaction was allowed warm up to room temperature and stirred for 4 hours and 
monitored by TLC. Solvent was removed under vacuum and the crude product was 
purified by column chromatography (eluent PET/EtOAc 3:1) to give a white solid 
(0.153 g, 94%). 1H NMR (400 MHz, DMSO-d6) δ 8.33 (dd, J = 7.7, 0.9 Hz, 1H, H-7), 
8.14 (d, J = 7.9 Hz, 1H, H-5), 7.89 – 7.66 (m, 2H, H-2 and H-3), 7.49 (ddd, J = 8.0, 4.8, 
3.5 Hz, 1H, H-4), 4.03 (s, 2H, H-6), 3.83 (s, 3H, H-1), 3.55 (td, J = 9.6, 8.5, 3.7 Hz, 1H, 
H-8), 1.81 – 1.71 (m, 2H, H-6), 1.67 (app. dt, J = 12.0, 3.4 Hz, 2H, H-9 and 13), 1.55 
(app. d, J = 12.4 Hz, 2H, H-9 and 13), 1.33 – 1.05 (m, 6H, H-10, 11, and 12). 13C NMR 
(101 MHz, DMSO-d6) δ 167.39, 166.48, 146.53, 142.04, 141.28, 131.34, 123.33, 
121.86, 117.78, 111.65, 48.50, 35.02, 32.82, 27.82, 25.65, 24.97. LCMS m/z calc. for 
C18H21N5OS+[M]+: 355.2, found 355.4 with tR 2.75 min, purity 95%. 
 
Reaction code: liu195-019 
Preparation of tert-butyl (4-chlorophenyl)(methyl)carbamate. To a solution of tert-
butyl (4-chlorophenyl) carbamate (1.00 g, 4.39 mmol) in anhydrous DMF (12 mL) at 
0oC under N2 protection, NaH 60% dispersion in mineral oil (0.210 g, 5.27 mmol) was 
added in one portion. The mixture was stirring for 45 minutes followed by addition of 
iodomethane (0.935 g, 6.59 mmol) dropwise. The mixture was then slowly warmed up 
to room temperature and stirred for overnight. The mixture was poured into Sat. NH4Cl 
(60 mL) and stirred vigorously for 10 minutes. The resulting suspension was extracted 
with EtOAc (50 mL × 3). The combined organic layers were washed with brine, dried 
over Na2SO4, and concentrated. The crude compound was purified by column 
chromatography (eluent PET/EtOAc 5:1) to give a clear oil (1.00 g, 94%). 1H NMR 
(400 MHz, DMSO-d6) δ 7.43 – 7.36 (m, 2H, H-2 and H-6), 7.34 – 7.26 (m, 2H, H-3 and 
H-5), 3.17 (s, 3H, H-1), 1.40 (s, 9H, H-7). 13C NMR (101 MHz, DMSO-d6) δ 153.96, 
142.84, 129.70, 128.84, 127.50, 80.34, 37.29, 28.35. Purity >95%. 
 
Preparation of 4-chloro-N-methylaniline: tert-butyl (4-
chlorophenyl)(methyl)carbamate (1.00 g, 4.15 mmol) were dissolved in DCM (5 mL), 
3 mL 4M HCl in dioxane (excessive) was added. The mixture was then allowed to stir 
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at room temperature for 24 hours. Solvent removed under vacuum to give a white solid 
as HCl salt. The 4-chloro-N-methylaniline. HCl then dissolved in DCM and added 
excessive Et3N to neutralize the HCl salt. Solvent removed under vacuum and the 
crude product (brown oil) was used directly for the next step without further purification. 
 
Reaction code: liu195-27 
Preparation of 2-bromo-N-(4-chlorophenyl)-N-methylacetamide (90). The 
preparation for 90 was based on general procedure 6. 4-chloro-N-methylaniline 
(0.10 g, 0.71 mmol) were dissolved in DCM (5 mL) at room temperature. Et3N (0.079 
g, 0.78 mmol) was added followed by addition of 2-bromopropanoyl chloride (0.12 g, 
0.71 mmol). Reaction was stirred for 4 hours and monitored by TLC. Solvent was 
removed under vacuum and the crude product was purified by column 
chromatography. (eluent PET/EtOAc 6:1) to give a grey solid (149 mg, 76%). 1H NMR 
(400 MHz, Chloroform-d) δ 7.44 (app. d, J = 8.3 Hz, 2H, H-3 and H-6), 7.26 (app. d, J 
= 8.2 Hz, 2H, H-4 and H-5), 4.24 (q, J = 6.6 Hz, 1H, H-2), 3.28 (s, 3H, H-7), 1.74 (d, J 
= 6.7 Hz, 3H, H-1). 13C NMR (101 MHz, Chloroform-d) δ 169.47, 141.35, 134.42, 
130.22, 128.64, 38.78, 38.13, 21.74. LCMS m/z calc. for C10H11BrClNO [M+H]+: 277, 
found 278.1 with tR 2.80 min, purity> 95%. 
 
Reaction code: liu195-23 
N-(4-chlorophenyl)-N-methyl-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)acetamide (94) was prepared according to general procedure 7 using 2 2-
bromo-N-(4-chlorophenyl)-N-methylacetamide 89 (0.050 g, 0.19 mmol) and 29 (0.041 
g, 0.19 mmol). The crude product was purified by column chromatography (eluent 
PET/EtOAc 1:1) to give a white solid (32.5 mg, 43%): 1H NMR (400 MHz, DMSO-d6) 
δ 8.32 (d, J = 7.8 Hz, 1H, H-5), 7.78 (app. d, J = 4.1 Hz, 2H, H-2 and H-3), 7.65 – 7.35 
(m, 5H, H-4, -7, -8, -9, -10), 4.05 (app. d, J = 22.3 Hz, 2H, H-6), 3.76 (s, 3H, H-1), 3.23 
(s, 3H, H-11). 13C NMR (101 MHz, DMSO-d6) δ 170.55, 166.85, 146.49, 142.08, 
141.47, 138.40, 131.42, 129.19, 127.53, 123.33, 121.88, 121.25, 117.71, 111.61, 
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45.12, 27.76, 18.65. LCMS m/z calc. for C19H16ClN5OS [M]+: 397.2, found 397.8 with 
tR 3.03 min, purity 95%. 
 
Reaction code: liu195-31 
N-(4-chlorophenyl)-N-methyl-2-((5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)propanamide (95) was prepared according to general procedure 7 using 29 
(0.050 g, 0.23 mmol) and 90 (0.064 g, 0.23 mmol). Reaction was allowed warm up to 
room temperature and stirred for overnight and monitored by TLC. Solvent was 
removed under vacuum and the crude product was purified by column 
chromatography (eluent PET/EtOAc 1:1) to give a grey solid (59 mg, 76%). 1H NMR 
(400 MHz, DMSO-d6) δ 8.33 (d, J = 7.7 Hz, 1H, H-5), 7.79 (app. d, J = 3.8 Hz, 2H, H-
2 and H-3), 7.69 – 7.40 (m, 3H, H-4, -7, -10), 7.36 (app. d, J = 8.0 Hz, 2H, H-8 and H-
9), 4.80 (q, J = 6.9 Hz, 1H, H-6), 3.70 (s, 3H, H-1), 3.20 (s, 3H, H-11), 1.51 (d, J = 6.9 
Hz, 3H, H-12). 13C NMR (101 MHz, DMSO-d6) δ 171.18, 170.94, 166.01, 146.30, 
142.40, 142.15, 141.44, 132.85, 131.49, 130.07, 129.96, 123.38, 121.91, 117.69, 
111.61, 55.39, 44.54, 37.69, 27.62, 24.57, 22.19, 19.31. LCMS m/z calc. for 
C20H19ClN5OS [M+H]+: 412.2, found 412.2 with tR 2.90 min, purity> 95%. 
 
Reaction code: liu195-75 
Preparation of tert-butyl (4-hydroxyphenyl)carbamate (72). 4-aminophenol (0.50 
g, 4.58 mmol) were dissolved in DCM (10 mL) at room temperature. (Boc)2O (1.20 g, 
5.50 mmol) was added followed by addition of Et3N (0.69 g, 6.87 mmol). Reaction was 
stirred for overnight and monitored by TLC. Solvent was removed under vacuum and 
diluted with water (50 mL). The resulting suspension was extracted with EtOAc (30 
mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, 
and concentrated. The crude compound was purified by column chromatography 
(eluent PET/EtOAc 4:1) to give a white solid (493.8 mg, 52%). 1H NMR (400 MHz, 
Chloroform-d) δ 7.36 (app. d, J = 8.8 Hz, 2H, H-2 and H-5), 7.14 – 7.02 (m, 2H, H-4 
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and H-3), 6.52 (s, 1H, H-6), 1.57 (s, 9H, H-7). 13C NMR (101 MHz, Chloroform-d) δ 
152.72, 152.03, 146.47, 135.95, 121.68, 119.36, 83.44, 28.34. LCMS m/z calc. for 
C11H15NO3 [M+H]+: 210.2, found 210.2 with tR 2.52 min, purity> 95%. 
 
Reaction code: liu 195-83 
Preparation of tert-butyl (4-(pyridin-2-yloxy)phenyl)carbamate (73). tert-butyl (4-
hydroxyphenyl)carbamate (72) (0.1 g, 0.48 mmol), 2-bromopyridine (0.091 g, 0.58 
mmol), the ligand ( 0.012 g, 0.096 mmol), CuI (0.010 g, 0.048 mmol) and K3PO4 (0.20 
g, 0.96 mmol) were dissolved in DMSO (10 mL) under the protection of N2, the reaction 
was then heated under 90 oC for overnight and monitored by TLC. Once the reaction 
was finished, then it was allowed to cool to room temperature. The reaction mixture 
was diluted with water (50 mL). The resulting suspension was extracted with EtOAc 
(30 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, 
and concentrated. The crude compound was purified by column chromatography 
(eluent PET/EtOAc 5:1) to give a colorless oil (27.5 mg, 20%).  1H NMR (400 MHz, 
Chloroform-d) δ 8.21 (ddd, J = 0.8, 2.0, 5.0 Hz, 1H, H-9), 7.69 (ddd, J = 2.1, 7.2, 8.3 
Hz, 1H, H-7), 7.40 (app. d, J = 8.4 Hz, 2H, H-4 and H-3), 7.17 – 7.06 (m, 2H, H-2 and 
H-5), 7.00 (ddd, J = 1.0, 5.0, 7.2 Hz, 1H, H-8), 6.89 (dt, J = 0.9, 8.3 Hz, 1H, H-6), 6.56 
(s, 1H, H-10), 1.54 (s, 9H, H-11). 13C NMR (101 MHz, Chloroform-d) δ 163.95, 152.87, 
149.37, 147.59, 139.52, 135.18, 121.84, 118.30, 111.18, 82.88, 28.35. LCMS m/z 
calc. for C16H17N2O3 [M+H]+: 287.1, found 287.2 with tR 2.85 min, purity> 95%. 
 
Reaction code: liu195-89 
Preparation of 4-(pyridin-2-yloxy)aniline (74). tert-butyl (4-(pyridin-2-
yloxy)phenyl)carbamate (73) (0.182 g, 0.63 mmol) were dissolved in DCM (8 mL), 3 
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mL 4M HCl in dioxane (excessive) was added. The mixture was then allowed to stir at 
room temperature for overnight. Solvent removed under vacuum to give a white solid 
as HCl salt. The Preparation of 4-(pyridin-2-yloxy)aniline. HCl then dissolved in DCM 
and added excessive Et3N to neutralize the HCl salt. Solvent removed under vacuum 
and the crude product (brown oil) was used directly for the next step without further 
purification. The crude yield was >100%. 1H NMR (400 MHz, Chloroform-d) δ 12.07 (s, 
2H, H-10), 8.19 (dd, J = 2.0, 4.9 Hz, 1H, H-9), 7.64 (ddd, J = 2.0, 7.2, 8.3 Hz, 1H, H-
7), 7.02 – 6.90 (m, 3H, H-6, -8,- 3), 6.84 (dd, J = 1.0, 8.3 Hz, 1H, H-4), 6.76 – 6.67 (m, 
2H, H-5 and H-2). 13C NMR (101 MHz, Chloroform-d) δ 164.54, 147.74, 146.04, 143.50, 
139.19, 122.29, 117.87, 116.14, 110.78. 
 
Reaction code: liu195-91 
Preparation of 2-bromo-N-(4-(pyridin-2-yloxy)phenyl)acetamide (77). 4-(pyridin-
2-yloxy)aniline 74 (0.163 g, 0.64 mmol) was dissolved in 8 mL DCM at 0 oC, Et3N 
(0.097 g, 0.95 mmol) was added followed by addition of  2-bromoacetyl chloride (0.12 
g, 0.64 mmol). Reaction was allowed warm up to room temperature and stirred for 
overnight and monitored by TLC. Solvent was removed under vacuum and the crude 
product was purified by column chromatography (eluent PET/EtOAc 5:1) to give a 
solid (71 mg, 47%).  1H NMR (400 MHz, Chloroform-d) δ 8.19 (dd, J = 2.0, 5.1 Hz, 1H, 
H-11), 7.64 (ddd, J = 2.0, 7.1, 8.2 Hz, 1H, H-9), 6.99 – 6.90 (m, 3H, H-4, -7 and -10), 
6.83 (dd, J = 1.0, 8.3 Hz, 1H, H-8), 6.76 – 6.67 (m, 2H, H-5 and H-6), 3.65 (s, 2H, H-
2). 13C NMR (101 MHz, Chloroform-d) δ 164.54, 147.74, 146.04, 143.50, 139.19, 
122.29, 117.88, 116.14, 110.78, 45.81. LCMS m/z calc. for C13H11BrN2O2 [M]+: 307.1, 
found 307.0 with tR 2.59 min, purity> 95%. 
 
Reaction code: liu195-93 




2-yloxy)phenyl)acetamide (69). 29 (0.030 g, 0.14 mmol) was dissolved in 8 mL DCM 
at 0 oC, Et3N (0.021 g, 0.21 mmol) was added to the suspension followed by addition 
of 77 (0.051 g, 0.17 mmol). Reaction was allowed warm up to room temperature and 
stirred for overnight and monitored by TLC. Solvent was removed under vacuum and 
the crude product was purified by column chromatography (eluent PET/EtOAc 1:1) to 
give a white solid (39 mg, 64%).  1H NMR (400 MHz, DMSO-d6) δ 10.48 (s, 1H, H-7), 
8.40 – 8.20 (m, 1H, H-5), 8.19 – 8.03 (m, 1H, H-12), 7.83 (ddd, J = 2.0, 7.2, 8.2 Hz, 
1H, H-14), 7.76 (d, J = 1.0 Hz, 1H, H-2), 7.67 – 7.60 (m, 2H, H-2 and H-3), 7.49 (ddd, 
J = 2.6, 5.6, 8.0 Hz, 1H, H-4), 7.14 – 7.05 (m, 3H, H-8, -11, -15), 6.99 (dd, J = 1.0, 8.3 
Hz, 1H, H-13), 4.28 (s, 2H, H-6), 3.80 (s, 3H, H-1). 13C NMR (101 MHz, Chloroform-d) 
δ 167.21, 167.08, 150.16, 147.70, 146.55, 142.15, 139.35, 134.91, 131.51, 123.44, 
122.66, 121.76, 121.07, 118.33, 117.96, 111.22, 110.16, 35.75, 27.53. LCMS m/z 
calc. for C23H18N6O2S [M+H]+: 443.5, found 443.2 with tR 2.78 min, purity> 95%. 
 
Reaction code: liu195-77 
Preparation of 2-bromo-N-(4-chlorophenyl)acetamide (91). 4-chloroaniline (0.30 g, 
2.36 mmol) was dissolved in 10 mL DCM at 0 oC, Et3N (0.36 g, 3.54 mmol) was added 
to the suspension followed by addition of 2-bromoacetyl chloride (0.37 g, 2.36 mmol). 
Reaction was allowed warm up to room temperature and stirred for 4 hours and 
monitored by TLC. Solvent was removed under vacuum and the crude product was 
used directly for the next step. LCMS m/z calc. for C8H7BrClNO [M+H]+: 250.5, found 
250.0 with tR 2.63 min. 
 
Reaction code: liu195-113 
Preparation of N-(4-chlorophenyl)-2-(pyrimidin-2-ylthio)acetamide (103). To a 
solution of pyrimidine-2-thiol 101 (0.05 g, 0.45 mmol) in anhydrous DMF (6 mL) at 0oC 
under N2 protection, NaH 60% dispersion in mineral oil (0.20 g, 0.49 mmol) was added 
in one portion. The mixture was stirring for 45 minutes followed by addition of 2-bromo-
N-(4-chlorophenyl)acetamide (0.133 g, 0.54 mmol) dropwise. The mixture was then 
slowly warmed up to room temperature and stirred for overnight. The mixture was 
poured into Sat. NH4Cl (30 mL) and stirred vigorously for 3 minutes. The resulting 
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suspension was extracted with EtOAc (10 mL × 3). The combined organic layers were 
washed with brine, dried over Na2SO4, and concentrated. The crude compound was 
purified by column chromatography (eluent PET/EtOAc 2:1) to give a white solid (30 
mg, 24%).  1H NMR (400 MHz, Chloroform-d) δ 9.21 (s, 1H, H-5), 8.65 (app. d, J = 4.9 
Hz, 2H, H-1 and H-3), 7.51 – 7.35 (m, 2H, H-6 and H-9), 7.29 (app. d, J = 5.4 Hz, 2H, 
H-7 and H-8), 7.15 (t, J = 4.9 Hz, 1H, H-2), 3.93 (s, 2H, H-4). 13C NMR (101 MHz, 
Chloroform-d) δ 171.15, 167.10, 157.63, 136.45, 129.27, 129.01, 120.88, 117.57, 
35.54. LCMS m/z calc. for C12H10ClN3OS [M]+: 279.7, found 279.3 with tR 2.67 min, 
purity> 95%. 
 
Reaction code: liu195-119 
Preparation of N-(4-chlorophenyl)-2-((4,6-dimethylpyrimidin-2-yl)thio)acetamide 
104. 4,6-dimethylpyrimidine-2-thiol 102 (0.080 g, 0.57 mmol) was dissolved in 8 mL 
DCM at 0 oC, Et3N (0.087 g, 0.86 mmol) was added followed by addition of  2-bromo-
N-(4-chlorophenyl)acetamide (0.170 g, 0.68 mmol). Reaction was allowed warm up to 
room temperature and stirred for overnight and monitored by TLC. Solvent was 
removed under vacuum and the crude product was purified by column 
chromatography (eluent PET/EtOAc 2:1) to give a white solid (63 mg, 36%).  1H NMR 
(400 MHz, Chloroform-d) δ 9.56 (s, 1H, H-3), 7.46 – 7.38 (m, 2H, H-4 and H-7), 7.27 
(app. d, J = 6.7 Hz, 2H, H-5 and H-6), 6.86 (s, 1H, H-1), 3.90 (s, 2H, H-2), 2.51 (app. 
s, 6H, H-8 and H-9). 13C NMR (101 MHz, Chloroform-d) δ 167.65, 136.67, 129.02, 
120.86, 116.75, 35.49, 23.96. LCMS m/z calc. for C14H14ClN3OS [M+H]+: 308.8, found 
308.1 with tR 2.83 min, purity> 95%. 
 
The preparation of tert-butyl (4-(pyrimidin-2-yloxy)phenyl)carbamate (75). 2-
chloropyrimidine (0.45 g, 3.93 mmol), 72 (0.55 g, 2.62 mmol) and K2CO3 (0.36 g, 2.62 
mmol) was dissolved in NMP (10 mL) and heated at 100 oC under N2 overnight 
monitored by TLC. Once the reaction was finished, it was allowed to cool to room 
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temperature and dilute with water (100 mL). The resulting suspension was then 
extracted with EtOAc (30 mL × 3). The combined organic layers were washed with 
brine (30 mL), dried over Na2SO4, and concentrated. The crude compound was 
purified by column chromatography (eluent PET/EtOAc 2:1) to give a yellow solid (250 
mg, 33%).  1H NMR (400 MHz, DMSO-d6) δ 9.38 (s, 1H, H-8), 8.62 (app. d, J = 4.8 
Hz, 2H, H-5 and 7), 7.48 (app. d, J = 8.4 Hz, 2H, H-1 and 2), 7.24 (t, J = 4.7 Hz, 1H, 
H-6), 7.08 (app. d, J = 8.8 Hz, 2H, H-3 and 4), 1.49 (s, 9H, Boc). 13C NMR (101 MHz, 
DMSO-d6) δ 174.24, 160.43, 153.34, 147.86, 137.11, 122.26, 119.71, 117.19, 79.51, 
28.60. LCMS m/z calc. for C15H17N3O3 [M]+: 287.3, found 287.7 with tR 2.71 min, 
purity >95%. 
 
The preparation of target compound 2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)-N-(4-(pyrimidin-2-yloxy)phenyl)acetamide (70). The intermediate 76 was 
prepared using the similar manner as 74 and used directly for the next step. LCMS 
m/z calc. for C10H9N3O [M]+: 187.2, found 187.7 with tR 0.33 min. 78 (0.065 g, 0.238 
mmol), 35 (0.064 g, 0.238 mmol), HATU ( 0.135 g,, 0.357 mmol), DIPEA (0.165 mL, 
0.952 mmol) and DMAP (0.030 g, 0.0238 mmol) were dissolved in NMP (2 mL). 
Reaction mixture was allowed to stir at room temperature for overnight monitored by 
TLC. The crude product was purified by column chromatography (eluent PET/EtOAc 
1:1) to give a white solid (31 mg, 29%). 1H NMR (400 MHz, DMSO-d6) δ 10.50 (s, 1H, 
H-14), 8.63 (app. d, J = 4.8 Hz, 2H, H-11 and 13), 8.31 (d, J = 7.8 Hz, 1H, H-4), 7.75 
(app. d, J = 5.2 Hz, 2H, H-1 and 2), 7.67 (app. d, J = 8.5 Hz, 2H, H-7 and 10), 7.47 
(ddd, J = 2.6, 5.8, 8.2 Hz, 1H, H-3), 7.25 (t, J = 4.8 Hz, 1H, H-12), 7.16 (app. d, J = 8.4 
Hz, 2H, H-8 and 9), 4.30 (s, 2H, H-6), 3.79 (s, 3H, H-5). 13C NMR (101 MHz, DMSO-
d6) δ 167.13, 166.67, 165.37, 160.47, 148.77, 146.53, 142.06, 141.40, 136.67, 131.38, 
123.32, 122.46, 121.88, 120.83, 117.73, 117.30, 111.61, 35.96, 27.76. LCMS m/z calc. 
for C22H17N7O2S [M+H]+: 444.5, found 444.3 with tR 2.62 min, purity >95%. 
   
Reaction code 211-25 
The preparation of 1-(2-chloro-5-nitrobenzyl)-4-methylpiperazine (81). 47b (1.00 
g, 5.40 mmol) and 1-methylpiperazine (0.539 g, 5.40 mmol), HOAc (1 drop) were 
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dissolved in THF at rt under N2 and reaction mixture was allowed to stir for overnight, 
NaHB(OAc)3 was added then and further stirred for 7 h and monitored by TLC. Once 
finished, the mixture was poured into Sat. NH4Cl (50 mL) and stirred vigorously for 3 
minutes. The resulting suspension was extracted with EtOAc (10 mL × 3). The 
combined organic layers were washed with brine, dried over Na2SO4, and 
concentrated. The crude compound was purified by column chromatography (eluent 
MeOH/EtOAc 1:10) to give a yellow solid (0.732 g, 50.6%). 1H NMR (400 MHz, 
Chloroform-d) δ 8.38 (d, J = 2.8 Hz, 1H, H-1), 8.02 (dd, J = 2.8, 8.7 Hz, 1H, H-2), 7.49 
(d, J = 8.7 Hz, 1H, H-3), 3.65 (s, 2H, H-4), 2.49 (app. s, 8H, H-5~8), 2.33 (s, 3H, H-9). 
13C NMR (101 MHz, Chloroform-d) δ 146.75, 140.74, 138.39, 130.25, 125.05, 122.84, 
58.58, 54.95, 52.92, 45.81. LCMS m/z calc. for C12H16ClN3O2 [M]+:269.7, found 269.8 
with tR 0.95 min, purity> 95%. 
 
Reaction code Liu211-125  
The preparation of 1-methyl-4-(5-nitro-2-phenoxybenzyl)piperazine (82). 81 
(0.100 g, 0.37 mmol) and phenol (52 mg, 0.55 mmol) were dissolved in DMF heated 
to 90 oC under N2 overnight. The reaction was monitored by TLC. Once finished, the 
mixture was poured into Sat. NH4Cl (50 mL) and stirred vigorously for 3 minutes. The 
resulting suspension was extracted with EtOAc (10 mL × 3). The combined organic 
layers were washed with brine, dried over Na2SO4, and concentrated. The crude 
compound was purified by column chromatography (eluent EtOAc/MeOH 3:1) to give 
a yellow oil (23 mg, 10%). 1H NMR (400 MHz, Chloroform-d) δ 8.43 (d, J = 2.8 Hz, 1H, 
H-1), 8.05 (dd, J = 9.0, 2.8 Hz, 1H, H-2), 7.43 (app. dd, J = 8.5, 7.0 Hz, 2H, H-5 and 
7), 7.24 (td, J = 7.4, 1.1 Hz, 1H, H-3), 7.09 – 7.00 (m, 2H, H-4 and 8), 6.82 (d, J = 9.0 
Hz, 1H, H-6), 3.73 (s, 2H, H-9), 2.81- 2.37(m, 8H, H-10~13), 2.34 (s, 3H, H-14). 13C 
NMR (101 MHz, Chloroform-d) δ 161.08, 155.33, 142.97, 130.24, 129.81, 126.20, 
124.95, 123.95, 119.90, 116.41, 55.43, 55.10, 52.92, 45.93. LCMS m/z calc. for 
C18H21N3O3 [M]+: 327.4, found 327.8 with tR 2.18 min, purity> 95%. 




Reaction code Liu211-145 
The preparation of 3-((4-methylpiperazin-1-yl)methyl)-4-phenoxyaniline (83). 82 
(0.183 mg, 0.55 mmol) was dissolved in 8 mL EtOH at 55 oC under N2, NH4Cl ( 75 mg, 
1.39 mmol) dissolved in 0.11 mL water and Fe (0.16 g, 2.79 mmol) were added and 
heated to 90 oC overnight.. The reaction was monitored by TLC. Once finished, solvent 
was removed under vacuum and diluted with water (30 mL). The resulting suspension 
was extracted with EtOAc (15 mL × 3). The combined organic layers were washed 
with brine, dried over Na2SO4, and concentrated. The crude compound was purified 
by column chromatography (eluent EtOAc/MeOH 1:1) to give pink solid (158 mg, 
93 %). 1H NMR (400 MHz, Chloroform-d) δ 7.30 – 7.23 (m, 2H, H-5 and 7), 7.02 – 
6.96 (m, 1H, H-6), 6.87 (app. dd, J = 4.1, 2.1 Hz, 2H, H- 4 and 8), 6.84 (dd, J = 2.1, 
1.0 Hz, 1H, H-1), 6.82 (d, J = 8.4 Hz, 1H, H-3), 6.60 (dd, J = 8.5, 2.9 Hz, 1H, H-2), 
3.59 (app. d, J = 18.8 Hz, 2H, NH2), 3.42 (s, 2H, H-9), 2.45 (app. d, J = 31.0 Hz, 8H, 
H-10~13), 2.27 (s, 3H, H-14). 13C NMR (101 MHz, Chloroform-d) δ 159.27, 146.20, 
143.12, 131.53, 129.44, 122.19, 121.55, 117.08, 116.17, 114.96, 56.19, 55.15, 53.05, 
46.06. LCMS m/z calc. for C18H23N3O [M+H]+:298.4, found 298.1 with tR 0.70  min, 
purity> 95%. 
 
Reaction code Liu211-161 
2-((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(3-((4-methylpiperazin-1-
yl)methyl)-4-phenoxyphenyl)acetamide (79). The target compound 79 was 
prepared from 35 (13 mg, 0.045 mmol) and 83 (13 mg, 0.045 mmol) according to the 
general procedures. The crude product was purified by column chromatography 
(eluent MeOH/EtOAc 1:3) to give a yellow solid (13 mg, 54%).1H NMR (400 MHz, 
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7.78 – 7.72 (m, 1H, H-3), 7.61 (d, J = 2.7 Hz, 1H, H-10), 7.55 – 7.44 (m, 3H, H-4, 12 
and 14), 7.01 (t, J = 7.4 Hz, 1H, H-2), 6.88 (d, J = 8.7 Hz, 1H, H-9), 6.86 – 6.80 (m, 
2H, H-11 and 15), 6.78 – 6.71 (m, 1H, H-13), 3.86 (s, 2H, H-6), 3.24 (s, 3H, H-5), 2.87 
– 2.50 (m, 8H, H-16~19), 2.04 (s, 3H, H-20). 13C NMR (101 MHz, DMSO-d6) δ 167.13, 
166.57, 158.46, 149.83, 142.10, 141.44, 136.01, 131.44, 130.34, 123.37, 122.88, 
121.89, 121.21, 120.10, 117.74, 117.16, 111.68, 55.50, 54.06, 51.21, 44.20, 35.95, 
27.77. LCMS m/z calc. for C30H31N7O2S [M+H]+: 554.7, found 554.2 with tR 2.28 min, 
purity 95%.   
General procedure 8 preparation of pheny(morpholino)methanones 
Benzoic acids (1 equiv), HATU (1.5 equiv), DMAP (0.1 equiv) and amines (1 equiv) 
was dissolved in 1mL/mmol anhydrous NMP and stirred at room temperature for 5 
minutes before addition of DIPEA (6 equiv). The mixture was allowed to stir at room 
temperature for overnight. The reaction was monitored by TLC and quenched by 
addition of water. The reaction mixture was stirred for 5 minutes and the diluted with 
water and was extracted by EtOAc three times and the combined organic layers were 
combined and washed with Sat. NaHCO3 and brine and dried over Na2SO4. The crude 
product was purified by column chromatography. 
 
Reaction code: Liu211-137 
(3-Methoxyphenyl)(morpholino)methanone (119a) was prepared according to 
general procedure 8 using 3-methoxybenzoic acid 128 (0.10 g, 0.66 mmol) and 
morpholine (0.066 g, 0.79 mmol). The crude product was purified by column 
chromatography (eluent PET/EtOAc 4:1) to give a clear colorless oil (0.16 g, 55%). 1H 
NMR (400 MHz, Chloroform-d) δ 7.35 – 7.28 (m, 1H, H-1), 7.04 – 6.90 (m, 3H, H-2, 3 
and 4), 3.82 (s, 3H, H-9), 3.81 – 3.26 (m, 8H, H-5~8). 13C NMR (101 MHz, Chloroform-
d) δ 170.19, 159.73, 136.64, 129.69, 119.08, 115.66, 112.53, 66.92, 55.38, 38.62. 
LCMS m/z calc. for C12H15N3O [M]+: 222.3, found 221.8 with tR 2.29 min, purity> 95%. 
 
Reaction code: Liu211-139 
(3-Methoxyphenyl)(4-methylpiperazin-1-yl)methanone (119b) was prepared 
according to general procedure 8 using 3-methoxybenzoic acid (128) (0.10 g, 0.66 
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mmol) and 1-methylpiperazine (0.79 g, 0.79 mmol). The crude product was purified by 
column chromatography (eluent PET/EtOAc 4:1) to give a brown oil (0.079 g, 52%). 
1H NMR (400 MHz, Chloroform-d) δ 7.37 – 7.27 (m, 1H, H-1), 7.01 – 6.93 (m, 3H, H-
2, 3, 4), 3.84 (s, 3H, H-10), 3.85-3.76 (m, 2H, H-8 and 5), 3.45 (m, 2H, H-8 and 5), 
2.56-2,43 (m, 2H, H-6 and 7),2.43-2.34(m, 2H, H-6 and 7), 2.34 (s, 3H, H-9). 13C NMR 
(101 MHz, Chloroform-d) δ 170.06, 159.65, 137.13, 129.59, 119.08, 115.51, 112.41, 
55.37, 46.05. LCMS m/z calc. for C13H18N2O2 [M+H]+: 235.3, found 235.0 with tR 0.32 
min, purity> 95%. 
 
Reaction code: Liu211-147 
(3-Methoxyphenyl)(piperidin-1-yl)methanone (119c) was prepared according to 
general procedure 8 using 3-methoxybenzoic acid (128) (0.10 g, 0.66 mmol) and 
piperidine (0.79 g, 0.79 mmol). The crude product was purified by column 
chromatography (eluent PET/EtOAc 3:1) to give a colorless oil (0.10 g, 69%). 1H NMR 
(400 MHz, Chloroform-d) δ 7.41 – 7.23 (m, 1H, H-1), 7.06 – 6.86 (m, 3H, H-2, 4, 3), 
3.83 (s, 3H, H-10), 3.71 (app. s, 2H, H-5 and 9), 3.35 (app. s, 2H, H-5 and 9), 1.92 – 
1.43 (m, 6H, H- 6, 7 and 8). 13C NMR (101 MHz, Chloroform-d) δ 170.03, 159.59, 
137.84, 129.51, 118.85, 115.23, 112.14, 55.34, 24.60. LCMS m/z calc. for C13H17NO2 
[M]+: 219.3, found 219.7 with tR 2.64 min, purity> 95%. 
 
Reaction code: Liu211-159 
(3-Fluorophenyl)(morpholino)methanone (116) was prepared according to general 
procedure 8 using 132 (0.20 g, 1.43 mmol) and morpholine (0.15 g, 1.71 mmol). The 
crude product was purified by column chromatography (eluent PET/EtOAc 3:1) to give 
a yellow oily product (0.29 g, 98%). 1H NMR (400 MHz, Chloroform-d) δ 7.48 – 7.34 
(m, 1H, H-2), 7.19 (dt, J = 1.3, 7.6 Hz, 1H, H-1), 7.13 (app. ddd, J = 2.6, 4.9, 8.8 Hz, 
2H, H-3 and 4), 3.60 (m, 8H, H-5, 6, 7 and 8). 13C NMR (101 MHz, Chloroform-d) δ 
168.92 (d, J = 2.4 Hz), 162.57 (d, J = 248.4 Hz, 1JCF), 137.37 (d, J = 6.9 Hz), 130.43 
(d, J = 8.0 Hz, 3JCF), 122.73 (d, J = 3.2 Hz), 116.94 (d, J = 21.1 Hz, 2JCF), 114.42 (d, J 
= 22.8 Hz, 2JCF), 66.83. LCMS m/z calc. C11H12FNO2 [M+H]+: 210.3, found 210.0 with 
tR 2.27 min, purity> 95%. 




Reaction code: Liu211-165 
4-(3-Methoxybenzoyl)piperazin-2-one (119f) was prepared according to general 
procedure 8 using 3-methoxybenzoic acid (128) (0.10 g, 0.66 mmol) and piperazin-2-
one (0.079 g, 0.79 mmol). The crude product was purified by column chromatography 
(eluent MeOH/DCM 1:10) to give a white solid (0.077 g, 50%). 1H NMR (400 MHz, 
DMSO-d6) δ 8.13 (s, 1H, H-9), 7.38 (dd, J = 7.6, 8.7 Hz, 1H, H-4), 7.09 – 7.02 (m, 1H, 
H-2), 6.99 (app. dt, J = 1.6, 7.1 Hz, 2H, H-3 and 5), 4.07 (s, 1H, H-6), 3.90 (s, 1H, H-
6), 3.79 (s, 3H, H-10), 3.79-3.64 (broad, 1H, H-7),3.61-3.37 (s, 1H, H-7), 3.23 (s, 2H, 
H-8). 13C NMR (101 MHz, DMSO-d6) δ 169.18, 166.41, 159.62, 137.23, 130.21, 
119.37, 116.02, 112.74, 55.72, 46.20, 44.32. LCMS m/z calc. C12H14N2O3 [M]+: 234.3, 
found 234.9 with tR 1.96 min, purity> 95%. 
 
Reaction code: Liu211-169 
(2-Methoxyphenyl)(morpholino)methanone (127) was prepared according to 
general procedure 8 using 2-methoxybenzoic acid (129) (0.20 g, 1.32 mmol) and 
morpholine (0.137 g, 1.58 mmol). The crude product was purified by column 
chromatography (eluent EA/PET 1:1) to give a yellow oil (0.319 g, 92%). 1H NMR (400 
MHz, Methanol-d4) δ 7.42 (ddd, J = 1.7, 7.4, 8.4 Hz, 1H, H-2), 7.23 (dd, J = 1.8, 7.5 
Hz, 1H, H-4), 7.07 (dd, J = 0.9, 8.4 Hz, 1H, H-1), 7.02 (td, J = 0.9, 7.5 Hz, 1H, H-3), 
3.85 (s, 3H, H-11), 3.82 – 3.68 (m, 4H, H-6 and 10), 3.67 – 3.53 (m, 2H, H-7 and 8), 
3.37 – 3.14 (m, 2H, H-7 and 8). 13C NMR (101 MHz, Methanol-d4) δ 168.79, 155.39, 
130.94, 127.65, 124.62, 120.70, 111.01, 66.43, 54.81, 42.10. LCMS m/z calc. 
C12H15NO3 [M]+: 221.3, found 221.9 with tR 2.22 min, purity> 95%. 
 
Reaction code: Liu211-237 
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4-(3-Methoxybenzoyl)piperazine-2,6-dione (119g) was prepared according to 
general procedure 8 using 3-methoxybenzoic acid (128) (0.20 g, 1.32 mmol) and 
piperazine-2,6-dione (0.150 g, 1.2 mmol). The crude product was purified by column 
chromatography (eluent MeOH/DCM 1:10) to give a yellow solid (156 mg, 48%). 1H 
NMR (400 MHz, DMSO-d6) δ 11.45 (s, 1H, H-7), 7.40 (t, J = 8.1 Hz, 1H, H-2), 7.09 
(ddd, J = 1.1, 2.5, 8.3 Hz, 1H, H-3), 7.03 – 6.98 (m, 2H, H-4 and 1), 3.79 (s, 3H, H-5). 
13C NMR (101 MHz, DMSO-d6) δ 169.49, 165.06, 159.65, 135.92, 130.33, 119.69, 
116.66, 113.08, 55.76. LCMS m/z calc. C12H12N2O4 [M+H]+: 249.2, found 249.0 with 
tR 2.15min, purity> 95%. 
 
Reaction code: Liu211-239 
(R)-(3-hydroxypiperidin-1-yl)(3-methoxyphenyl)methanone  (119e) was prepared 
according to general procedure 8 using 3-methoxybenzoic acid (128) (0.20 g, 1.32 
mmol) and (R)-piperidin-3-ol (0.18 g, 1.32 mmol). The crude product was purified by 
column chromatography (eluent EA/PET 1:1) to give a white solid (0.297 g, 97%). 1H 
NMR (400 MHz, Chloroform-d) δ 7.32 (dd, J = 8.9, 7.3 Hz, 1H, H-3), 7.08 – 6.87 (m, 
3H, H-2, 3, 4), 3.83 (s, 3H, H-5), 4.41-3.05 (m, 4H, H-6 and 9), 2.61 (s, 1H, H-11), 2.22 
– 1.75 (m, 2H, H-7), 1.73 – 1.38 (m, 2H, H-8). 13C NMR (101 MHz, Methanol-d4) δ 
171.35, 159.83, 137.08, 129.51, 118.50 (d, J = 32.9 Hz), 115.12, 112.18, 65.56 (d, J 
= 21.5 Hz), 54.53, 53.94, 42.18, 32.05, 22.87. LCMS m/z calc. C13H18NO3[M]+: 235.3, 
found 235.9 with tR 2.24 min, purity> 95%. 
 
Reaction code: Liu211-247  
(3-Chlorophenyl)(morpholino)methanone (115) was prepared according to general 
procedure 8 using 3-chlorobenzoic acid (130) (0.10 g, 0.64 mmol) and morpholine 
(0.057 g, 0.64 mmol). The crude product was purified by column chromatography 
(eluent EA/PET 1:1) to give a white solid (0.082 g, 53%). 1H NMR (400 MHz, 
Chloroform-d) δ 7.45 – 7.34 (m, 3H, H-1, 3 and 4), 7.29 (dt, J = 1.3, 7.4 Hz, 1H, H-2), 
3.61 (m, 8H, H- 5, 6, 7 and 8). 13C NMR (101 MHz, Chloroform-d) δ 168.84, 137.05, 
134.72, 130.05, 129.98, 127.31, 125.17, 66.84. LCMS m/z calc. C11H11ClNO2 [M]+: 
225.7, found 225.7 with tR 2.44 min, purity> 95%. 




Reaction code: Liu211-249 
(4-Chlorophenyl)(morpholino)methanone (116) was prepared according to general 
procedure 8 using 4-chlorobenzoic acid (130) (0.10 g, 0.64 mmol) and morpholine 
(0.057 g, 0.64 mmol). The crude product was purified by column chromatography 
(eluent EA/PET 1:1) to give a white solid (0.072 g, 47%). 1H NMR (400 MHz, DMSO-
d6) δ 7.57 – 7.49 (m, 2H, H-2 and 3), 7.49 – 7.34 (m, 2H, H-1 and 4), 3.45 (m, 8H, H- 
5, 6, 7, and 8). 13C NMR (101 MHz, DMSO-d6) δ 168.48, 134.84, 134.74, 129.53, 
129.00, 66.49. LCMS m/z calc. C11H13ClNO2 [M]+: 225.7, found 225.9 with tR 2.46 min, 
purity> 95%. 
 
Reaction code: Liu211-251 
(3,5-dimethoxyphenyl)(morpholino)methanone (125) was prepared according to 
general procedure 8 using 3, ,5-dimethoxybenzoic acid (134) (0.10 g, 0.55 mmol) and 
morpholine (0.047 g, 0.55 mmol). The crude product was purified by column 
chromatography (eluent EA/PET 1:1) to give a white foaming compound (0.256 g, 
53%). 1H NMR (400 MHz, DMSO-d6) δ 6.56 (t, J = 2.3 Hz, 1H, H-2), 6.51 (app. d, J = 
2.3 Hz, 2H, H-1 and 3), 3.77 (app. s, 6H, H-4 and 5), 3.58 (s broad, 4H, H-6 and 9), 
2.51 (app. p, J = 1.8 Hz, 4H, H-7 and 8). 13C NMR (101 MHz, DMSO-d6) δ 169.02, 
160.89, 138.18, 105.16, 101.59, 55.86, 55.38, 38.72. LCMS m/z calc. C13H17NO4 [M]+: 
251.3, found 251.9 with tR 2.37 min, purity> 95%. 
 
Reaction code: Liu225-261/273/211-275 
2,6-dimethylmorpholino)(3-methoxyphenyl)methanone (119d) was prepared 
according to general procedure 8 using 3-methoxybenzoic acid (128) (0.30 g, 1.97 
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mmol) and morpholine (0.227 g, 1.97 mmol). The crude product was purified by 
column chromatography (eluent EA/PET 4:1) to give a colorless oil (0.092 g, 19 %). 
1H NMR (400 MHz, Chloroform-d) δ 7.30 (td, J = 1.0, 8.0 Hz, 1H, H-4), 7.02 – 6.87 (m, 
3H, H-1, 2 and 3), 4.65 – 4.43 (m, 1H, H-6), 3.81 (d, J = 0.9 Hz, 3H, H-5), 3.71 – 3.57 
(m, 1H, H-7), 3.70 – 3.38 (m, 2H, H-6 and 9), 2.77 (s, 1H, H-8), 2.52 (m, 2H, H-6 and 
9), 1.34 – 1.15 (m, 3H, H-10), 1.08 (s, 3H, H-11). 13C NMR (101 MHz, CDCl3) δ 169.83, 
159.69, 136.88, 129.66, 119.06, 118.75, 115.57, 115.51, 112.51, 71.95, 55.34, 53.22, 
47.50, 18.67. LCMS m/z calc. C14H19NO4 [M+H]+: 250.3, found 250.1 with tR 2.53 min, 
purity> 95%. 
 
Reaction code: Liu211-273 
morpholino(phenyl)methanone (113) was prepared according to general procedure 
8 using benzoic acid (136) (0.20 g, 1.39 mmol) and morpholine (0.121 g, 1.39 mmol). 
The crude product was purified by column chromatography (eluent EA/PET 2:1) to 
give a colorless oil (0.296 g, >100%). 1H NMR (400 MHz, DMSO-d6) δ 7.54 – 7.28 (m, 
5H, H-1, 2, 3, 4 and 5), 3.76- 3.47 (s, broad, 6H, H-6, 9, 7 and 8), 3.43 (s broad, 2H, 
H-7 and 8). 13C NMR (101 MHz, DMSO-d6) δ 169.54, 136.07, 130.05, 128.90, 127.46, 
66.55, 38.71. LCMS m/z calc. C11H13NO2 [M]+: 191.3 found 191.2 with tR 1.95 min, 
purity> 95%. 
 
Reaction code: Liu225-13 
(3,4-dimethoxyphenyl)(morpholino)methanone (124) was prepared according to 
general procedure 8 using 3,4-dimethoxybenzoic acid (133) (0.10 g, 0.55 mmol) and 
morpholine (0.048g, 0.55 mmol). The crude product was purified by column 
chromatography (eluent EA/PET 1:1) to give a white solid (0.121 g, 88%). 1H NMR 
(400 MHz, DMSO-d6) δ 7.21 – 6.78 (m, 3H, H-1, 2 and 3), 3.79 (s, 3H, H-10), 3.78 (s, 
3H, H-9), 3.60 (app. d, J = 9.7 Hz, 8H, H-4, 5, 6, and 7). 13C NMR (101 MHz, DMSO-
d6) δ 169.47, 150.33, 148.91, 128.10, 120.49, 111.60, 111.52, 66.58, 56.03. LCMS 
m/z calc. C13H17NO4 [M]+: 251.3, found 251.7 with tR 2.16 min, purity> 95%. 




Reaction code: Liu225-15 
(4-hydroxy-3-methoxyphenyl)(morpholino)methanone (123) was prepared 
according to general procedure 8 using 4-hydroxy-3-methoxybenzoic acid (0.10 g, 
0.59 mmol) and morpholine (0.052g, 0.59 mmol). The crude product was purified by 
column chromatography (eluent EA/PET 1:1) to give a white solid (0.121 g, 86%). 1H 
NMR (400 MHz, DMSO-d6) δ 9.43 (s, 1H, H-8), 6.97 (d, J = 1.9 Hz, 1H, H-1), 6.86 (dd, 
J = 1.9, 8.1 Hz, 1H, H-2), 6.80 (d, J = 8.0 Hz, 1H, H-3), 3.79 (s, 3H, H-9), 3.59 (app. t, 
J = 4.8 Hz, 4H, H-4 and 7), 3.50 (app. d, J = 4.7 Hz, 4H, H-5 and 6). 13C NMR (101 
MHz, DMSO-d6) δ 169.72, 148.55, 147.75, 126.56, 120.97, 115.34, 112.22, 66.61, 
56.12. LCMS m/z calc. C12H15NO4 [M]+: 237.3 found 237.7 with tR 1.95 min, purity> 
95%. 
 
Reaction code: Liu225-17 
4-(3,5-dimethoxybenzoyl)piperazin-2-one was prepared according to general 
procedure 8 using 3,5-dimethoxybenzoic acid (134) (0.10 g, 0.66 mmol) and piperazin-
2-one (0.066g, 0.65 mmol). The crude product was purified by column 
chromatography (eluent MeOH/DCM 1:10) to give a white solid (0.127 g, 88%). 1H 
NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H, H-7), 6.56 (t, J = 2.3 Hz, 1H, H-2), 6.53 (app. 
d, J = 2.3 Hz, 2H, H-1 and 3), 4.04 (s broad, 2H, H-5), 3.75 (app. s, 6H, H-8, 9), 3.54 
–3.37 (m, 2H, H-4), 3.28 (s broad, 2H, H-6). 13C NMR (101 MHz, DMSO-d6) δ 169.02, 
166.49, 160.92, 138.00, 105.12, 101.93, 55.89, 46.42, 44.23. LCMS m/z calc. 
C12H16N2O4 [M+H]+: 265.3 found 265.0 with tR 2.15 min, purity> 95%. 
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Reaction code: Liu225-21 
morpholino(3,4,5-trimethoxyphenyl)methanone (126) was prepared according to 
general procedure 8 using 3,4,5-trimethoxybenzoic acid (135) (0.10 g, 0.47 mmol) and 
morpholine (0.049, 0.56 mmol). The crude product was purified by column 
chromatography (eluent MeOH/DCM 1:20) to give a white solid (0.156 g, 90%). 1H 
NMR (400 MHz, Chloroform-d) δ 6.70 – 6.56 (m, 2H, H-1 and 2), 3.90 – 3.85 (m, 9H, 
H-7, 8 and 9), 3.71 (app. s, 8H, H-3, 4, 5 and 6). 13C NMR (101 MHz, Chloroform-d) δ 
170.19, 153.39, 139.36, 130.66, 104.40, 66.91, 60.90, 56.28. LCMS m/z calc. 
C14H19NO5 [M+H]+: 282.3 found 281.9 with tR  2.24 min, purity> 95%. 
 
Reaction code: Liu225-23 
(3-fluoro-5-methoxyphenyl)(morpholino)methanone (120)  was prepared 
according to general procedure 8 using 3-fluoro-5-methoxybenzoic acid (0.10 g, 0.59 
mmol) and morpholine (0.061 g, 0.71 mmol). The crude product was purified by 
column chromatography (eluent MeOH/DCM 1:20) to give a white solid (0.156 g, 90%). 
1H NMR (400 MHz, Chloroform-d) δ 6.75 (t, J = 1.8 Hz, 1H, H-3), 6.73 – 6.65 (m, 2H, 
H- 2 and 1), 3.84 (s, 3H, H-8), 3.83 – 3.29 (m, 8H, H- 4, 5, 6 and 7). 13C NMR (101 
MHz, DMSO-d6) δ 167.92, 164.38, 161.95, 161.22, 138.87, 109.40, 106.27 (d, J = 
23.2 Hz, 2JCF), 102.98 (d, J = 25.0 Hz, 2JCF), 66.42, 56.31. LCMS m/z calc. C12H14FNO3 
[M]+: 239.3 found 239.7 with tR 2.39 min, purity> 95%. 
 
Reaction code: Liu225-33 
(3-methoxy-5-methylphenyl)(morpholino)methanone (122) was prepared 
according to general procedure 8 using 3-methoxy-5-methylbenzoic acid (0.10 g, 0.59 
mmol) and morpholine (0.062 g, 0.71 mmol). The crude product was purified by 
column chromatography (eluent MeOH/DCM 1:20) to give a white solid (0.108 g, 77%). 
1H NMR (400 MHz, Chloroform-d) δ 6.79 – 6.73 (m, 2H, H-1 and 3), 6.71 (t, J = 2.0 
Hz, 1H, H-2), 3.79 (s, 3H, H-9), 3.78 – 3.30 (m, 8H, H- 4, 5, 6 and 7), 2.33 (s, 3H, H-
8). 13C NMR (101 MHz, Chloroform-d) δ 170.36, 159.64, 140.06, 136.47, 119.87, 
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116.25, 109.48, 66.93, 55.34, 21.51. LCMS m/z calc. C13H17NO3 [M]+: 235.3 found 
235.9 with tR 2.42 min, purity> 95%. 
 
Reaction code: Liu225-49 
Preparation of (3-chloro-5-methoxyphenyl)(morpholino)methanone (121). 3-
chloro-5-methoxybenzolic acid (0.200 g, 1.072 mmol) was dissolved in PhMe in the 
present of catalytic amount of DMF (0.01 equiv.) followed by addition of SOCl2 (0.255 
g, 2.14 mmol) under N2. The reaction mixture was allowed to heat up to 70oC for 2 
hours. The reaction was monitored by TLC and once the reaction finished, solvent was 
removed under vacuum and the crude product was used directly without further 
purification. The crude product was diluted with dry DCM and morpholine (0.279 g, 
3.22 mmol) was added at room temperature. The mixture was allowed to stir at room 
temperature for overnight. The reaction was monitored by TLC and quenched by 
addition of water. The reaction mixture was stirred for 5 minutes and the diluted with 
water and was extracted by EtOAc three times and the combined organic layers were 
combined and washed with brine and dried over Na2SO4. The crude product was 
purified by column chromatography (eluent MeOH/DCM 1:30) to give a white solid 
(0.073 g, 27%). 1H NMR (400 MHz, Chloroform-d) δ 6.98 – 6.91 (m, 2H, H-1 and 3), 
6.85 – 6.78 (m, 1H, H-2), 3.81 (s, 3H, H-8), 3.80 – 3.32 (m, 8H, H-4, 5, 6 and 7). 13C 
NMR (101 MHz, Chloroform-d) δ 168.67, 160.45, 137.69, 135.28, 119.16, 115.69, 
111.32, 66.80, 55.70. LCMS m/z calc. C12H14ClNO3 [M+H]+: 256.7 found 257.9 with tR  
2.52 min, purity> 95%. 
 
Reaction code: Liu211-141 
Preparation of 3-(morpholinomethyl)phenol (141). Benzaldehyde 142 (0.10 g, 0.82 
mmol), morpholine (0.071, 0.82 mmol) and HOAc (cat. 0.01 equiv) were dissolved in 
THF under N2 and stirred at rt for 8 h followed by addition of NaBH(OAc)3 (0.87 g, 4.1 
mmol). The reaction mixture was allowed to stir at room temperature for overnight. 
The reaction was monitored by TLC and quenched by addition of Sat. NaHCO3. The 
reaction mixture was stirred for 5 minutes and the diluted with water and was extracted 
by EtOAc three times and the combined organic layers were combined and washed 
with brine and dried over Na2SO4. The crude product was purified by column 
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chromatography (eluent MeOH/DCM 1:10) to give a yellow solid (0.098 g, 62%). 1H 
NMR (400 MHz, DMSO-d6) δ 9.28 (s, 1H, H-5), 7.09 (t, J = 7.8 Hz, 1H, H-2), 6.77 – 
6.67 (m, 2H, H-3 and 4), 6.67 – 6.58 (m, 1H, H-1), 3.56 (app. t, J = 4.6 Hz, 4H, H-8 
and 9), 3.36 (s, 2H, H-6), 2.32 (app. t, J = 4.6 Hz, 4H, H-7 and 10). 13C NMR (101 
MHz, DMSO-d6) δ 157.75, 129.54, 119.92, 116.05, 114.39, 66.68, 62.96, 53.67. LCMS 
m/z calc. C11H15NO2 [M]+: 221.3 found 221.8 with tR  2.29 min, purity> 95%. 
Preparation of (3-hydroxyphenyl)(4-methylpiperazin-1-yl)methanones 114, 
118a-c 
 
General procedure 9 
Methoxyphenylmethanones (1 equiv) was dissolved in DCM followed by addition of 
excessive amount of BBr3 at 0oC under inert gas. The reaction mixture was then slowly 
warm up to room temperature. The reaction was monitored by TLC and quenched by 
addition of water. The reaction mixture was stirred for 5 minutes and the diluted with 
water and was extracted by EtOAc three times and the combined organic layers were 
combined and dried over Na2SO4. The crude product was purified by column 
chromatography. 
 
Reaction code: Reaction code 211-143 
(3-hydroxyphenyl)(4-methylpiperazin-1-yl)methanone (118b) was prepared 
according to general procedure 9 using 119b (0.068 g, 0. 4 mmol) and BBr3 ( 4 mmol). 
The crude product was purified by column chromatography (eluent MeOH/DCM 1:10) 
to give white solid (10.2 mg, 16%). 1H NMR (400 MHz, Chloroform-d) δ 7.18 (t, J = 7.8 
Hz, 1H, H-3), 6.87 (dd, J = 1.5, 2.5 Hz, 1H, H-5), 6.85 – 6.78 (m, 2H, H-2 and 4), 3.81 
(m, 2H, H-7 and 10), 3.46 (m, 2H, H 7 and 10), 2.52 (m, 2H, H-8 and 9), 2.33 (m, 5H, 
H-8 and 9, H-11). 13C NMR (101 MHz, Chloroform-d) δ 170.75, 157.12, 136.15, 129.71, 
117.95, 117.55, 114.51, 45.81. LCMS m/z calc. C12H16N2O2 [M]+: 220.3, found 220.8 
with tR 0.32 min, purity> 95%. 




Reaction code: Liu211-231 and 225-267 
(2-hydroxyphenyl)(morpholino)methanone (114) was prepared according to 
general procedure 9 using 127 (0.075 g, 0.34 mmol) and BBr3 (5 mmol). The crude 
product was purified by column chromatography (eluent EA/PET 1:1) to give white 
solid (22 mg, 31%). 1H NMR (400 MHz, Methanol-d4) δ 7.45 – 7.14 (m, 2H, H-2 and 
4), 7.03 – 6.73 (m, 2H, H-1 and 3), 3.71 (app. s, 8H, H-6~9). 13C NMR (101 MHz, 
Methanol-d4) δ 169.39, 167.52, 153.50, 133.35, 130.73, 130.49, 127.90, 122.67, 
119.39, 117.32, 115.33, 66.43. LCMS m/z calc.  C11H13NO3 [M]+: 208.2, found 208.1 
with tR 0.79 min, purity> 95%. 
 
Reaction code: Liu211-235 
(3-hydroxyphenyl)(piperidin-1-yl)methanone (118c) was prepared according to 
general procedure 9 using 119c (0.05 g, 0.22 mmol) and BBr3 (0.5 mmol). The crude 
product was purified by column chromatography (eluent EA/PET 1:2) to give white 
solid (39 mg, 84%). 1H NMR (400 MHz, DMSO-d6) δ 9.64 (s, 1H, H-10), 7.22 (t, J = 
7.8 Hz, 1H, H-3), 6.87 – 6.78 (m, 1H, H-2), 6.78 – 6.69 (m, 2H, H1 and 4), 3.70 – 3.38 
(m, 2H, H-5 and 9), 3.27 (s, 2H, H-5 and 9), 1.61 (app. dp, J = 3.0, 3.9, 6.7 Hz, 2H, H-
6 and 8), 1.50 (d, J = 25.3 Hz, 4H, H- 6 and 7 and 8). 13C NMR (101 MHz, DMSO-d6) 
δ 169.22, 157.71, 138.28, 129.97, 117.41, 116.56, 113.79, 24.53.  LCMS m/z calc. 
C11H15NO2 [M+H]+: 206.2, found 207.0 with tR 2.37 min, purity> 95%. 
 
Reaction code: Liu 247-11 
(2,6-dimethylmorpholino)(3-hydroxyphenyl)methanone (118d) was prepared 
according to general procedure 9 using 119d (0.106 g, 0.43 mmol) and BBr3 (2.12 
mmol). The crude product was purified by column chromatography (eluent EA/PET 
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1:2) to give white solid (58 mg, 57%).  1H NMR (400 MHz, DMSO-d6) δ 9.68 (s, 1H. H-
1), 7.23 (t, J = 7.8 Hz, 1H, H-4), 6.93 – 6.71 (m, 3H, H-3, 2, 5), 4.34 (s, 1H, H-7), 3.53 
(app. d, J = 6.5 Hz, 3H, H-10 and 6, 11), 2.95 – 2.58 (m, 1H, H-6), 2.45 (s, 1H, H-11), 
1.45 – 0.70 (m, 6H, H-8 and 9).13C NMR (101 MHz, DMSO-d6) δ 169.16, 157.77, 
137.43, 130.04, 117.83, 116.97, 114.23, 71.67, 52.96, 47.31, 18.96. LCMS m/z calc.  
C13H17NO3 [M]+: 235.3, found 235.9 with tR 2.30 min, purity> 95%. 
Preparation of N-(benzo[d]thiazol-2-yl)acetamides (145a-c) 
 
General procedure 10 
benzo[d]thiazol-2-amines (146a-c) (1 equiv.) was dissolved in DCM followed by 
addition of acetic anhydride (1.1 equiv.)  and the mixture was allowed to heat up to 
40~60 oC under N2. The reaction was monitored by TLC and the crude product was 
purified by column chromatography. 
 
Reaction code: Liu225-135 
N-(benzo[d]thiazol-2-yl)acetamide (145a) was prepared according to general 
procedure 10 using 146a (0.10 g, 0.4 mmol) and acetic anhydride (0.5 g, 0.5 mmol). 
The crude product was purified by column chromatography (eluent EA/PET 1:2) to 
give a white solid (0.108 g, 80%). 1H NMR (400 MHz, DMSO-d6) δ 12.17 (broad, 1H, 
H-5), 7.95 (d, J = 7.9 Hz, 1H, H-4), 7.73 (d, J = 8.1 Hz, 1H, H-1), 7.42 (td, J = 1.4, 7.2, 
7.8 Hz, 1H, H-3), 7.29 (t, J = 7.5 Hz, 1H, H-2), 2.20 (s, 3H, H-6). 13C NMR (101 MHz, 
DMSO-d6) δ 172.47, 169.86, 167.47, 158.40, 148.99, 131.88, 126.51, 123.90, 122.12, 
120.94, 23.24. LCMS m/z calc. C9H8N2OS [M]+: 192.4 found 192.8 with tR 2.18 min, 
purity> 95%. 
 
Reaction code: Liu225-137 
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N-(5-bromobenzo[d]thiazol-2-yl)acetamide (145b) was prepared according to 
general procedure 10 using 146b(0.20 g, 0.87 mmol) and acetic anhydride (0.174 g, 
1.74 mmol). The crude product was purified by column chromatography (eluent 
EA/PET 1:2) to give a white solid (0.199 g, 84%). 1H NMR (400 MHz, DMSO-d6) δ 
12.47 (s, 1H, H-4), 8.18 – 7.83 (m, 2H, H-1 and 3), 7.44 (dd, J = 2.0, 8.4 Hz, 1H, H-2), 
2.20 (s, 3H, H-5). 13C NMR (101 MHz, DMSO-d6) δ 170.12, 160.12, 150.55, 131.15, 
126.52, 124.03, 123.31, 119.28, 23.24. LCMS m/z calc. C9H6BrN2OS [M]+: 270.3 
found 270.0 with tR 2.39 min, purity> 95%. 
 
Reaction code: Liu225-139 
N-(6-bromobenzo[d]thiazol-2-yl)acetamide (145c) was prepared according to 
general procedure 10 using 146c (0.10 g, 0.4 mmol) and acetic anhydride (0.5 g, 0.5 
mmol). The crude product was purified by column chromatography (eluent EA/PET 
1:2) to give a brown solid (0.21 g, 81%). 1H NMR (400 MHz, DMSO-d6) δ 12.42 (s, 1H, 
H- 4), 8.24 (d, J = 2.5 Hz, 1H, H-1), 7.67 (d, J = 8.6 Hz, 1H, H-3), 7.57 (dd, J = 2.2, 8.3 
Hz, 1H, H-2), 2.21 (s, 3H, H-5). 13C NMR (101 MHz, DMSO-d6) δ 172.48, 170.11, 
167.47, 159.23, 148.18, 134.11, 129.54, 124.69, 122.55, 115.81, 23.21. LCMS m/z 
calc. C9H6BrN2OS [M]+: 271.3 found 272.2 with tR 2.35 min, purity> 95%. 
 
Reaction code: Liu211-265 
Preparation of 1-(benzo[d]thiazol-2-yl)ethan-1-ol (143). The Grignard reagent   
methylmagnesium bromide (2M solution, 0.35 mmol) was added dropwise to a 
solution of benzo[d]thiazole-2-carbaldehyde (0.048 g,  0.294 mmol) in anhydrous THF 
under N2 at 0 oC and stirred for 30 min and warm up to rt and stirred 6 h. The mixture 
was quenched by Sat. NH4Cl and the diluted with water. The mixture was extracted 
by EtOAc three times and the combined organic layers were combined and washed 
with brine and dried over Na2SO4. The crude product was purified by column 
chromatography (eluent EA/PET 1:4) to give a yellow oil (0.039 g, 75%). 1H NMR (400 
MHz, DMSO-d6) δ 8.10 – 8.06 (m, 1H, H-3), 7.94 (dt, J = 1.1, 8.1 Hz, 1H, H-4), 7.49 
(ddd, J = 1.3, 7.2, 8.2 Hz, 1H, H-2), 7.40 (ddd, J = 1.3, 7.2, 8.3 Hz, 1H, H-1), 6.32 (d, 
J = 5.2 Hz, 1H, H-7), 5.07 (qd, J = 5.0, 6.5 Hz, 1H, H-5), 1.54 (d, J = 6.5 Hz, 3H, H-6). 
Rui Ling Liu                                                                             University of Nottingham  
184 
 
13C NMR (101 MHz, DMSO-d6) δ 180.04, 153.65, 134.87, 126.38, 125.14, 122.83, 
122.71, 67.55, 24.33. LCMS m/z calc. C9H9NOS [M]+: 179.0 found 179.7 with tR 2.34 
min, purity> 95%. 
General procedure 11 Preparation of 1-(benzo[d]thiazol-2-yl)-1-ols 148a-d 
Magnesium turnings (1.4 equiv) and a single chip of I2 were added to a Schlenk flask 
under N2. The reaction flask was gently heated with a heat gun to initiate the reaction. 
Once the flask was full of the I2 gas, anhydrous THF was added and the solution was 
gently heated for a few minutes. Alkyl bromide (1.0 equiv) was then added and the 
reaction mixture was then refluxed for an hour until the full consumption of the Mg 
turnings. 
Benzothiazole-2-carboxaldehyde (1 equiv) was dissolved in anhydrous THF and 
added dropwise the reaction mixture under ice bath. The reaction was slowly warm up 
to room temperature and stirred overnight. Once the reaction finished, Sat.NH4Cl was 
added and the aqueous layer was extracted by EtOAc three times. The combined 
organic layers were combined and washed with brine and dried over Na2SO4. The 
crude product was purified by column chromatography. 
 
Reaction code: Liu211-287 
1-(benzo[d]thiazol-2-yl)octan-1-ol (148c) was prepared according to general 
procedure 11 using 150c (0.082 g, 0.50 mmol), Mg (0.019 g, 0.78 mmol), and 
benzo[d]thiazole-2-carbaldehyde 151 (0.10 g, 0.56 mmol). The crude product was 
purified by column chromatography (eluent EA/PET 1:4) to give a white solid (0.97 g, 
66%). 1H NMR (400 MHz, DMSO-d6) δ 8.07 (dd, J = 8.1, 1.3 Hz, 1H, H-4), 7.98 – 7.88 
(m, 1H, H-1), 7.48 (ddd, J = 8.1, 7.2, 1.3 Hz, 1H, H-3), 7.40 (td, J = 7.6, 1.2 Hz, 1H, H-
2), 6.30 (d, J = 5.3 Hz, 1H, H-13), 4.90 (dt, J = 7.8, 4.9 Hz, 1H, H-5), 2.01 – 1.83 (m, 
1H,H-6), 1.83 – 1.68 (m, 1H, H-6), 1.53 – 1.38 (m, 2H, H-7), 1.27 (app. dq, J = 10.9, 
6.0, 4.3 Hz, 8H, H-8-11), 0.91 – 0.77 (m, 3H, H-12). 13C NMR (101 MHz, Chloroform-
d) δ 176.45, 152.79, 134.82, 126.07, 125.00, 122.86, 121.84, 72.39, 38.16, 31.78, 
29.37, 29.17, 25.16, 22.63, 14.09. LCMS m/z calc. C15H21NOS [M]+: 263.4, found 





















Reaction code: Liu225-203 
1-(benzo[d]thiazol-2-yl)butan-1-ol (148a) was prepared using propylmagnesium 
chloride (0.303 mmol) and benzo[d]thiazole-2-carbaldehyde (0.050 g, 0.303 mmol). 
The crude product was purified by column chromatography (eluent EA/PET 1:4) to 
give a white solid (0.40 g, 64%). 1H NMR (400 MHz, Methanol-d4) δ 7.96 (dt, J = 7.9, 
0.9 Hz, 1H, H-1), 7.93 – 7.86 (m, 1H, H-4), 7.48 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H, H-2), 
7.39 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H, H-3), 4.99 (dd, J = 8.1, 4.7 Hz, 1H, H-5), 3.34 (s, 
1H, H-9), 2.08 – 1.73 (m, 2H, H-6), 1.63 – 1.41 (m, 2H, H-7), 0.98 (t, J = 7.4 Hz, 3H, 
H-8). 13C NMR (101 MHz, Methanol-d4) δ 179.58, 152.84, 134.39, 125.82, 124.72, 
121.82, 121.66, 71.28, 48.24, 48.03, 47.81, 47.60, 47.39, 47.18, 46.96, 39.74, 18.10, 
12.75.Purity> 95%. 
 
Reaction code: Liu225-201 
1-(benzo[d]thiazol-2-yl)heptan-1-ol (148b) was prepared according to general 
procedure 11 using 150b (0.100 g, 0.61 mmol), Mg (0.021 g, 0.91 mmol), and 
benzo[d]thiazole-2-carbaldehyde 151 (0.10 g, 0.56 mmol). The crude product was 
purified by column chromatography (eluent EA/PET 1:4) to give a white solid (0.40 g, 
41%). 1H NMR (400 MHz, DMSO-d6) δ 8.07 (d, J = 7.9 Hz, 1H, H-1), 7.93 (d, J = 8.1 
Hz, 1H, H-4), 7.54 – 7.44 (m, 1H, H-2), 7.44 – 7.29 (m, 1H, H-3), 6.30 (d, J = 5.3 Hz, 
1H, H-12), 4.90 (dt, J = 7.8, 4.9 Hz, 1H, H-5), 1.90 (dtd, J = 13.0, 7.8, 4.6 Hz, 1H, H-
6), 1.77 (dq, J = 14.6, 7.5 Hz, 1H, H-6), 1.42 (app. p, J = 7.3 Hz, 2H, H-7), 1.35 – 1.13 
(m, 6H, H-7, 8 and 9), 0.92 – 0.75 (m, 3H, H-11). 13C NMR (101 MHz, DMSO-d6) δ 
179.62, 153.63, 134.77, 126.35, 125.10, 122.82, 122.68, 71.14, 37.89, 31.68, 28.96, 
25.06, 22.50, 14.40. LCMS m/z calc. C14H19NOS [M+H]+: 250.3, found 250.3 with tR 
3.05 min, purity> 95%. 




Reaction code: Liu225-197 
1-(benzo[d]thiazol-2-yl)-5-phenylpentan-1-ol (148d) was prepared according to 
general procedure 11 using 150d (0.10 g, 0.47 mmol), Mg (0.016 g, 0.66 mmol), and 
benzo[d]thiazole-2-carbaldehyde 151 (0.68 g, 0.0.42 mmol). The crude product was 
purified by column chromatography (eluent EA/PET 1:4) to give a white solid (0.50 g, 
36%). 1H NMR (400 MHz, Chloroform-d) δ 8.01 (d, J = 8.1 Hz, 1H, H-4), 7.91 (dd, J = 
8.0, 1.2 Hz, 1H, H-1), 7.50 (ddd, J = 8.3, 7.1, 1.3 Hz, 1H, H-3), 7.41 (td, J = 7.6, 7.2, 
1.2 Hz, 1H, H-2), 7.33 – 7.24 (m, 2H, H-10 and 14), 7.19 (app. td, J = 6.2, 1.7 Hz, 3H, 
H-11, 12 and 13), 5.12 (dt, J = 7.5, 3.4 Hz, 1H, H-15), 3.18 (d, J = 4.7 Hz, 1H, H-5), 
2.65 (t, J = 7.6 Hz, 2H, H-9), 2.16 – 2.04 (m, 1H, H-6), 1.98 (dddd, J = 13.6, 9.7, 8.0, 
5.5 Hz, 1H, H-6), 1.72 (dddd, J = 11.7, 10.4, 6.1, 2.7 Hz, 2H, H-7), 1.67 – 1.51 (m, 2H, 
H-8). 13C NMR (101 MHz, Chloroform-d) δ 176.01, 152.82, 142.38, 134.87, 128.40, 
128.30, 126.12, 125.72, 125.05, 122.91, 121.86, 72.34, 38.00, 35.77, 31.23, 24.82. 
LCMS m/z calc.  C18H19NOS [M+H]+: 298.4, found 298.5 with tR  3.03 min, purity> 95%. 
General procedure 12 Preparation of N-phenylacetamides 152a-c 
Substituted anilines (153a-b, 74) (1 equiv.) was dissolved in DCM followed by addition 
of acetic anhydride (3.0 equiv.) and the mixture was heated up to 40~60 oC under N2. 
The reaction was monitored by TLC and the crude product was purified by column 
chromatography. 
 
Reaction code: Liu247-23/225-235 
N-(4-chlorophenyl)acetamide (152a) was prepared according to general procedure 
12 using 153a (0.10 g, 0.79  mmol) and acetic anhydride (0.098 g, 0.94 mmol). The 
crude product was purified by column chromatography (eluent EA/PET 1:2) to give a 
white solid (0.10g, 75%). 1H NMR (400 MHz, DMSO-d6) δ 10.06 (s, 1H, H-1), 7.64 – 
7.49 (m, 2H, H-2 and 5), 7.49 – 7.23 (m, 2H, H-3 and 4), 2.05 (s, 3H, H-6). 13C NMR 
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(101 MHz, DMSO-d6) δ 168.89, 138.74, 129.00, 126.97, 120.93, 24.44. LCMS m/z 
calc. C8H8ClNO [M+H]+: 170.6, found 170.2 with tR  2.50 min, purity> 95%. 
 
Reaction code: Liu211-283 
N-(4-(cyanomethyl)phenyl)acetamide (152b) was prepared according to general 
procedure 12 using 153b (0.30 g, 0.79  mmol) and acetic anhydride (0.069 g, 0.81 
mmol). The crude product was purified by column chromatography (eluent EA/PET 
1:2) to give a yellow solid (0.32 g, 81%). 1H NMR (400 MHz, DMSO-d6) δ 9.99 (s, 1H, 
H-7), 7.59 (app. d, J = 8.2 Hz, 2H, H-1 and 4), 7.26 (app. d, J = 8.3 Hz, 2H, H-2 and 
3), 3.96 (s, 2H, H-5), 2.04 (s, 3H, H-8). 13C NMR (101 MHz, DMSO-d6) δ 168.81, 
139.22, 128.90, 125.92, 119.85, 119.80, 24.45, 22.28. LCMS m/z calc. C10H10N2O 
[M+H]+: 175.2, found 175.1 with tR  2.12 min, purity> 95%. 
 
Reaction code: Liu225-37 
N-(4-(pyridin-2-yloxy)phenyl)acetamide (152c) was prepared according to general 
procedure 12 using 74 (0.050 g, 0.224  mmol) and acetic anhydride (0.069 g, 0.67 
mmol). The crude product was purified by column chromatography (eluent EA/PET 
1:1) to give a white solid (0.32g, 63%). 1H NMR (400 MHz, DMSO-d6) δ 9.97 (s, 1H, 
H-9), 8.14 (dd, J = 2.0, 5.0 Hz, 1H, H-5), 7.83 (ddd, J = 2.0, 7.3, 8.8 Hz, 1H, H-7), 7.66 
– 7.54 (m, 2H, H-1 and 4), 7.11 (dd, J = 4.9, 7.2 Hz, 1H, H-6), 7.08 – 7.03 (m, 2H, H-
2 and 3), 6.98 (d, J = 8.3 Hz, 1H, H-8), 2.05 (s, 3H, H-10). 13C NMR (101 MHz, DMSO-
d6) δ 168.57, 163.80, 149.42, 147.85, 140.53, 136.43, 121.97, 120.72, 119.25, 111.62, 
24.38. LCMS m/z calc. C13H12N2O2 [M]+: 228.3, found 228.7 with tR 2.37 min, purity> 
95%. 
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General procedure 13 Preparation of N-(benzo[d]thiazol-2-yl)formamides 155a-
b 
The mixture of acetic anhydride (8.0 equiv.) and formic acid (6.0 equiv) were heated 
at 60oC for 2 hours and cooled to room temperature. Benzothiazolamines (1.0 equiv) 
was added portionwise and the temperature was kept under 40oC. The reaction 
mixture was stirred at room temperature for overnight. Once the reaction finished, 
solvent was removed under vacuum and the crude product was purified by column 
chromatography. 
  
Reaction code: Liu195-189 
N-(benzo[d]thiazol-2-yl)formamide (155a) was prepared according to general 
procedure 13 using 146a (0.10 g, 0.67 mmol), acetic anhydride (0.54 g, 5.33 mmol) 
and formic acid (0.18 g, 4.00 mmol). The crude product was purified by column 
chromatography (eluent EA/PET 1:2) to give a white solid (0.108 g, 93%). 1H NMR 
(400 MHz, DMSO-d6) δ 12.44 (s, 1H, H-5), 8.59 (s, 1H, H-6), 7.98 (dd, J = 1.3, 8.0 Hz, 
1H, H-4), 7.77 (d, J = 8.0 Hz, 1H, H-1), 7.44 (ddd, J = 1.3, 7.2, 8.2 Hz, 1H, H-3), 7.32 
(td, J = 1.2, 7.6 Hz, 1H, H-2). 13C NMR (101 MHz, DMSO-d6) δ 161.01, 156.72, 148.85, 
132.04, 126.72, 124.29, 122.28, 121.24. LCMS m/z calc. C8H6N2OS [M+H]+: 179.2, 
found 179.3 with tR 2.46 min, purity> 95%. 
 
Reaction code: Liu195-201 
N-(5-bromobenzo[d]thiazol-2-yl)formamide (155b) was prepared according to 
general procedure 13 using 146b (0.20 g, 0.87 mmol), acetic anhydride (0.92 g, 6.98 
mmol) and formic acid (0.24 g, 5.23 mmol). The crude product was purified by column 
chromatography (eluent EA/PET 1:2) to give a white solid (0.137 g, 61%). 1H NMR 
(400 MHz, DMSO-d6) δ 12.58 (s, 1H, H-5), 8.62 (s, 1H, H-6), 8.08 – 7.78 (m, 2H, H-1 
and 4), 7.48 (dd, J = 1.9, 8.5 Hz, 1H, H-2). 13C NMR (101 MHz, DMSO-d6) δ 161.31, 
131.30, 126.94, 124.20, 123.62, 119.49. LCMS m/z calc. C8H5BrN2OS [M]+: 257.1, 
found 257.0 with tR 2.70 min, purity> 95%. 
General procedure 14 Preparation of 2-(benzo[d]thiazol-2-ylamino)-N-(4-
chlorophenyl)acetamides 154a-b 
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N-(benzo[d]thiazol-2-yl)formamides (1.0 equiv) was dissolved in DMF and NaH (1.2 
equiv) was added under the protection of inert N2 under ice bath. The reaction mixture 
was allowed to stir 1 hour before the addition of 91 (1.0 equiv). The reaction was 
monitored by TLC and quenched by addition of Sat. NH4Cl. The reaction mixture was 
stirred for 5 minutes and the diluted with water and was extracted by EtOAc three 
times and the combined organic layers were combined and washed with brine and 
dried over Na2SO4. The crude product was purified by column chromatography. 
 
Reaction code: Liu195-193/221 
2-(benzo[d]thiazol-2-ylamino)-N-(4-chlorophenyl)acetamide (154a) was prepared 
according to general procedure 14 using N-(benzo[d]thiazol-2-yl)formamides 155a 
(0.050 g, 0.28 mmol) and 91 (0.076 g, 0.31 mmol). The crude product was purified by 
column chromatography (eluent EA/PET 1:2) to give a white solid (0.49 g, 55%). 1H 
NMR (400 MHz, DMSO-d6) δ 10.29 (s, 1H, H-7), 8.39 (t, J = 5.9 Hz, 1H, H-5), 7.72 – 
7.68 (m, 1H, H-4), 7.68 – 7.61 (m, 2H, H-8 and 11), 7.41 – 7.34 (m, 3H, H-1, 9 and 
10), 7.22 (ddd, J = 1.3, 7.3, 8.1 Hz, 1H, H-3), 7.04 (td, J = 1.2, 7.5 Hz, 1H, H-2), 4.25 
(d, J = 5.9 Hz, 2H, H-6). 13C NMR (101 MHz, DMSO-d6) δ 168.38, 166.73, 152.57, 
138.33, 131.16, 129.19, 125.99, 121.64, 121.49, 121.09, 118.65, 47.51. LCMS m/z 
calc. C15H12ClN3OS [M]+: 317.8, found 317.9 with tR 5.32 min, purity> 95%. 
 
Reaction code: Liu195-227 
2-((5-bromobenzo[d]thiazol-2-yl)amino)-N-(4-chlorophenyl)acetamide (154b) 
was prepared according to general procedure 14 using N-(5-bromobenzo[d]thiazol-
2-yl)formamide 155b (0.050g, 0.19 mmol) and 91 (0.058 g, 0.0.23 mmol). The crude 
product was purified by column chromatography (eluent EA/PET 1:2) to give a white 
solid (0.09 g, 12%). 1H NMR (400 MHz, DMSO-d6) δ 10.29 (s, 1H, H-6), 8.59 (t, J = 
5.8 Hz, 1H, H-4), 7.69 – 7.59 (m, 3H, H-1, H7 and 10), 7.52 (d, J = 1.9 Hz, 1H, H-3), 
7.40 – 7.34 (m, 2H, H-8 and 9), 7.18 (dd, J = 2.0, 8.4 Hz, 1H, H-2), 4.25 (d, J = 5.8 Hz, 
2H, H-5). 13C NMR (126 MHz, DMSO-d6) δ 174.56, 168.06, 154.17, 149.8, 138.17, 
131.83, 130.47, 129.21, 127.33, 124.05, 123.20, 121.09, 120.91, 118.78, 47.49. 
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LCMS m/z calc. C15H11BrClN3OS+[M+H]+: 397.7, found 397.9 with tR 2.92 min, purity> 
95%. 
General procedure 15 Preparation of 157a-c 
4-chloroaniline 172 (1 equiv), HATU (1.5 equiv), DMAP (0.1 equiv) and Boc-AA (1 
equiv) were dissolved in 1mL/mmol anhydrous NMP and stirred at room temperature 
for 5 minutes before addition of DIPEA (3 equiv). The mixture stirred at room 
temperature for overnight. The reaction was monitored by TLC and quenched by 
addition of water. The reaction mixture was stirred for 5 minutes and the diluted with 
water and was extracted by EtOAc three times and the combined organic layers were 
combined and washed with Sat. NaHCO3 and brine and dried over Na2SO4. The crude 
product was purified by column chromatography. 
 
Reaction code: Liu195-207 
tert-butyl (2-((4-chlorophenyl)amino)-2-oxoethyl)carbamate (157a) was prepared 
according to general procedure 15 using 4-chloroaniline 153a (0.17 g, 1.14 mmol), 
HATU (0.65 g, 1.71 mmol), DMAP (0.014 g, 0.11 mmol) and Boc-Gly-OH (0.2 g, 1.14 
mmol). The crude product was purified by column chromatography (eluent EA/PET 
1:2) to give a white solid (0.24 g, 74%). 1H NMR (400 MHz, DMSO-d6) δ 10.02 (s, 1H, 
H-5), 7.68 – 7.49 (m, 2H, H-1 and 4), 7.44 – 7.29 (m, 2H, H- 2 and 3), 7.03 (t, J = 6.1 
Hz, 1H, H-7), 3.68 (d, J = 6.1 Hz, 2H, H-6), 1.36 (s, 9H, H-Boc). 13C NMR (101 MHz, 
DMSO-d6) δ 168.88, 156.40, 138.38, 129.12, 127.14, 121.06, 78.55, 44.25, 38.72, 
28.67, 24.57. 
 
Reaction code: Liu195-155/liu225-285 
tert-butyl 3-((4-chlorophenyl)carbamoyl)pyrrolidine-1-carboxylate (157b) was 
prepared according to general procedure 15 using 4-chloroaniline 153a (0.10 g, 0.78 
mmol), HATU (0.45g, 1.7 mmol), DMAP (0.009 g, 0.08mmol) and Boc-Pro-OH (0.17g, 
0.78 mmol). The crude product was purified by column chromatography (eluent 
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EA/PET 1:2) to give a yellow oil (0.25 g, 98%). 1H NMR (400 MHz, Chloroform-d) δ 
7.54 – 7.40 (m, 2H, H-2 and 3), 7.26 (app. d, J = 8.7 Hz, 2H, H-1 and 4), 3.80 – 3.49 
(m, 3H, H-5, and 6), 3.35 (app. dt, J = 7.9, 10.8 Hz, 1H, H-7), 2.98 (app. d, J = 7.4 Hz, 
1H, H-7), 2.15 (ddd, J = 4.9, 8.8, 12.8 Hz, 2H, H-8), 1.46 (s, 9H, H-9). 13C NMR (101 
MHz, DMSO-d6) δ 138.49, 129.08, 127.26, 121.21, 78.82, 65.39, 38.72, 28.64, 24.57, 
15.64. LCMS m/z calc. C16H21ClN2O3 [M+H]+: 325.8, found 325.1 with tR 2.91 min, 
purity> 95%. 
 
Reaction code Liu195-159 
Preparation of N-(4-chlorophenyl)pyrrolidine-3-carboxamide (158b). 157b (0.25 
g, 0.76 mmol) was dissolved in 5 mL of DCM followed by addition of excessive 4N HCl 
at room temperature. The reaction mixture was stirred at room temperature for 
overnight to give a white solid (0.24 g, >100%). 1H NMR (400 MHz, DMSO-d6) δ 10.62 
(s, 1H, H-5), 7.79 – 7.53 (m, 2H, H1 and 4), 7.50 – 7.27 (m, 2H, H2 and 3), 3.39 (app.d, 
J = 4.9 Hz, 1H, H-6), 3.37 – 3.26 (m, 2H, H-8 and 9), 3.19 (app. tq, J = 5.6, 9.9 Hz, 
2H, H-8 and 9), 2.24 (app. dq, J = 7.1, 13.8 Hz, 1H, H-7), 2.03 (app. dq, J = 7.3, 14.0 
Hz, 1H, H-7). 13C NMR (101 MHz, DMSO-d6) δ 170.87, 138.38, 129.10, 127.49, 
121.30, 47.15, 45.19, 43.54, 29.34. LCMS m/z calc. C11H13ClN2O [M+H]+: 225.6, found 
225.5 with tR 1.21 min, purity> 95%. 
 
Reaction code: Liu195-167/ 225-287 
tert-Butyl 4-((4-chlorophenyl)carbamoyl)piperidine-1-carboxylate (158c) was 
prepared according to general procedure 15 using 4-chloroaniline 153a (0.24 g, 1.95 
mmol), HATU (1.11 g, 2.93 mmol), DMAP (0.023 g, 0.19 mmol) and 1-(tert-
butoxycarbonyl)piperidine-4-carboxylic acid (0.45g, 1.9 mmol). The crude product was 
purified by column chromatography (eluent EA/PET 1:2) to give a white solid (0.145 g, 
22%). 1H NMR (400 MHz, Chloroform-d) δ 7.53 – 7.45 (m, 2H, H-2 and 3), 7.32 – 7.25 
(m, 2H, H-1 and 4), 4.19 (m, 2H, H-8 and 9), 2.77 (m, 2H, H-8 and 9), 2.40 (tt, J = 3.8, 
11.5 Hz, 1H, H-6), 1.99 – 1.83 (m, 2H, H-7 and 10), 1.85 – 1.61 (m, 2H, H-7 and 10), 
1.48 (s, 9H, H-Boc). 13C NMR (101 MHz, Chloroform-d) δ 172.72, 154.70, 136.41, 
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129.34, 129.02, 121.13, 79.84, 44.27, 38.65, 28.58, 28.45. LCMS m/z calc. 
C17H23ClN2O3 [M+H]+: 339.8, found 339.0 with tR 2.95 min, purity> 95%. 
 
Reaction code: Liu195-225 
Preparation of 2-((benzo[d]thiazol-2-ylmethyl)amino)-N-(4-
chlorophenyl)acetamide 156a.  
157a (0.085 g, 0.31 mmol) was dissolved in DCM followed by addition of excessive 
amount of 4N HCl in dioxane. Reaction mixture was stirred at room temperature for 
overnight and solvent was removed under vacuum and the crude product of 184 was 
used directly for the next step without further purification. benzo[d]thiazole-2-
carbaldehyde (0.050 g, 0.31 mmol) and 158a (0.057 g, 0.31 mmol) were dissolved in 
anhydrous THF at room temperature under the protection of inert N2 atmosphere, 
catalytic amount of HOAc was added and the mixture was stirred at room temperature 
for 6 hours followed by addition of NaBH(OAc)3 (0.33 g, 1.53 mmol). The mixture 
stirred at room temperature for overnight. The reaction was monitored by TLC and 
quenched by addition of Sat. NaHCO3 The reaction mixture was stirred for 5 minutes 
and the diluted with Sat. NaHCO3 and was extracted by EtOAc three times and the 
combined organic layers were combined and washed with brine and dried over 
Na2SO4. The crude product was purified by column chromatography (eluent EA/PET 
1:1) to give a yellow oily product (0.10 g, 10%). 1H NMR (400 MHz, Chloroform-d) δ 
9.28 (s, 1H, H-12), 8.03 – 7.96 (m, 1H, H-1), 7.90 (dt, J = 0.9, 8.0 Hz, 1H, H-4), 7.60 
– 7.55 (m, 2H, H-7 and 10), 7.50 (ddd, J = 1.3, 7.2, 8.3 Hz, 1H, H-2), 7.44 – 7.36 (m, 
1H, H-3), 7.32 – 7.27 (m, 2H, H-8 and 9), 4.32 (s, 2H, H-5), 3.58 (s, 2H, H-6). 13C NMR 
(101 MHz, DMSO-d6) δ 175.04, 170.44, 153.59, 138.21, 135.10, 129.14, 127.27, 
126.38, 125.20, 122.72, 122.69, 121.13, 52.37, 50.98. LCMS m/z calc. C16H14ClN3OS 
[M+H]+: 332.8, found 332.0 with tR 2.49 min, purity> 95%. 
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Reaction code: Liu195-177 
1-(Benzo[d]thiazol-2-ylmethyl)-N-(4-chlorophenyl)pyrrolidine-3-
carboxamide(156b). Benzo[d]thiazole-2-carbaldehyde (0.023 g, 0.14 mmol) and 
158b (0.034 g, 0.14 mmol) were dissolved in anhydrous THF at room temperature 
under the protection of inert N2 atmosphere, catalytic amount of HOAc was added and 
the mixture was stirred at room temperature for 6 hours followed by addition of 
NaBH(OAc)3 (0.045 g,  0.21 mmol). The mixture stirred at room temperature for 
overnight. The reaction was monitored by TLC and quenched by addition of Sat. 
NaHCO3 The reaction mixture was stirred for 5 minutes and the diluted with Sat. 
NaHCO3 and was extracted by EtOAc three times and the combined organic layers 
were combined and washed with brine and dried over Na2SO4. The crude product was 
purified by column chromatography (eluent EA/PET 1:1) to give a white solid (0.007 g, 
13%). 1H NMR (400 MHz, Methanol-d4) δ 8.01 – 7.87 (m, 2H, H-1 and 4), 7.62 – 7.54 
(m, 2H, H-10 and 13), 7.50 (ddd, J = 1.3, 7.2, 8.3 Hz, 1H, H-3), 7.42 (ddd, J = 1.2, 7.2, 
8.3 Hz, 1H, H-2), 7.35 – 7.24 (m, 2H, H-11 and 12), 4.25 – 4.02 (m, 2H, H-4), 3.25 – 
3.05 (m, 2H, H-5), 2.94 (ddt, J = 3.6, 5.6, 10.1 Hz, 2H, H-8), 2.85 (td, J = 6.7, 8.5 Hz, 
1H, H-6), 2.34 – 1.98 (m, 2H, H-7). 13C NMR (101 MHz, Methanol-d4) δ 173.91, 172.43, 
152.47, 137.41, 135.01, 128.52, 128.36, 125.90, 125.00, 121.95, 121.67, 121.12, 
57.07, 56.57, 53.77, 48.25, 48.04, 47.82, 47.61, 47.40, 47.18, 46.97, 44.20, 28.30. 
LCMS m/z calc. C19H18ClN3OS [M+H]+: 372.8, found 372.0 with tR 2.95 min, purity> 
95%. 
 
Reaction code: Liu195-161/247-15 
1-(Benzo[d]thiazol-2-ylmethyl)-N-(4-chlorophenyl)piperidine-4-carboxamide 
(156c). 157b(0.25 g, 0.25 mmol) was dissolved in DCM followed by addition of 
excessive amount of 4N HCl in dioxane. Reaction mixture was stirred at room 
temperature for overnight and solvent was removed under vacuum and the crude 
product of 158c was used directly for the next step without further purification. 
benzo[d]thiazole-2-carbaldehyde (0.042 g, 0.26 mmol) and 158c (0.067 g, 0.26 mmol) 
were dissolved in anhydrous THF at room temperature under the protection of inert N2 
atmosphere, catalytic amount of HOAc was added and the mixture was stirred at room 
temperature for 6 hours followed by addition of NaBH(OAc)3 (0.082 g, 0.39 mmol). 
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The mixture stirred at room temperature for overnight. The reaction was monitored by 
TLC and quenched by addition of Sat. NaHCO3 The reaction mixture was stirred for 5 
minutes and the diluted with Sat. NaHCO3 and was extracted by EtOAc three times 
and the combined organic layers were combined and washed with brine and dried 
over Na2SO4. The crude product was purified by column chromatography (eluent 
EA/PET 1:1) to give a white solid (0.050 g, 52%). 1H NMR (400 MHz, Chloroform-d) δ 
7.97 (d, J = 8.1 Hz, 1H, H-4), 7.92 – 7.85 (m, 1H, H-1), 7.50 – 7.46 (m, 2H, H-12 and 
15), 7.46 – 7.34 (m, 2H, H-3 and 2), 7.31 – 7.27 (m, 2H, H-13 and 14), 3.97 (s, 2H, H-
5), 3.11 (app. dd, J = 5.7, 9.2 Hz, 2H, H-6 and 9), 2.40 – 2.19 (m, 3H, H-6 and 9 and 
10), 2.04 – 1.83 (m, 4H, H-7 and 8). 13C NMR (101 MHz, DMSO-d6) δ 174.02, 173.45, 
153.42, 138.78, 135.34, 129.02, 126.98, 126.34, 125.31, 122.80, 122.71, 121.09, 
121.00, 60.11, 53.40, 42.93, 28.98. LCMS m/z calc. C20H20ClN3OS [M+H]+: 386.9, 




















(1)  Khan, H. A.; Ahmad, A.; Mehboob, R. Nosocomial Infections and Their Control 
Strategies. Asian Pacific Journal of Tropical Biomedicine 2015, 5 (7), 509–514. 
https://doi.org/10.1016/j.apjtb.2015.05.001. 
(2)  Abdulhaq, N.; Nawaz, Z.; Zahoor, M. A.; Siddique, A. B. Association of Biofilm 
Formation with Multi Drug Resistance in Clinical Isolates of Pseudomonas 
Aeruginosa. EXCLI J 2020, 19, 201–208. https://doi.org/10.17179/excli2019-
2049. 
(3)  Sou, T.; Kukavica-Ibrulj, I.; Levesque, R. C.; Friberg, L. E.; Bergström, C. A. S. 
Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic 
Pharmacokinetic–Pharmacodynamic Modeling for Evaluation of Treatments 
against Chronic Pseudomonas Aeruginosa Lung Infections. Mol. Pharmaceutics 
2020, 17 (5), 1458–1469. https://doi.org/10.1021/acs.molpharmaceut.9b00968. 
(4)  Oliver, A.; Cantón, R.; Campo, P.; Baquero, F.; Blázquez, J. High Frequency of 
Hypermutable Pseudomonas Aeruginosa in Cystic Fibrosis Lung Infection. 
Science 2000, 288 (5469), 1251–1253. 
https://doi.org/10.1126/science.288.5469.1251. 
(5)  Mok, N.; Yuen Chan, S.; Yang Liu, S.; Lin Chua, S. Vanillin Inhibits PqsR-
Mediated Virulence in Pseudomonas Aeruginosa. Food & Function 2020, 11 (7), 
6496–6508. https://doi.org/10.1039/D0FO00046A. 
(6)  Brindhadevi, K.; LewisOscar, F.; Mylonakis, E.; Shanmugam, S.; Verma, T. N.; 
Pugazhendhi, A. Biofilm and Quorum Sensing Mediated Pathogenicity in 
Pseudomonas Aeruginosa. Process Biochemistry 2020, 96, 49–57. 
https://doi.org/10.1016/j.procbio.2020.06.001. 
(7)  Zhao, X.; Yu, Z.; Ding, T. Quorum-Sensing Regulation of Antimicrobial 
Resistance in Bacteria. Microorganisms 2020, 8 (3), 425. 
https://doi.org/10.3390/microorganisms8030425. 
(8)  Saeki, E. K.; Kobayashi, R. K. T.; Nakazato, G. Quorum Sensing System: Target 
to Control the Spread of Bacterial Infections. Microbial Pathogenesis 2020, 142, 
104068. https://doi.org/10.1016/j.micpath.2020.104068. 
(9)  Piewngam, P.; Chiou, J.; Chatterjee, P.; Otto, M. Alternative Approaches to 
Treat Bacterial Infections: Targeting Quorum-Sensing. Expert Review of Anti-
infective Therapy 2020, 18 (6), 499–510. 
https://doi.org/10.1080/14787210.2020.1750951. 
(10)  García-Reyes, S.; Soberón-Chávez, G.; Cocotl-Yanez, M. The Third Quorum-
Sensing System of Pseudomonas Aeruginosa: Pseudomonas Quinolone Signal 
and the Enigmatic PqsE Protein. Journal of Medical Microbiology, 2020, 69 (1), 
25–34. https://doi.org/10.1099/jmm.0.001116. 
Rui Ling Liu                                                                             University of Nottingham  
196 
 
(11)  Ilangovan, A.; Fletcher, M.; Rampioni, G.; Pustelny, C.; Rumbaugh, K.; Heeb, 
S.; Cámara, M.; Truman, A.; Chhabra, S. R.; Emsley, J.; Williams, P. Structural 
Basis for Native Agonist and Synthetic Inhibitor Recognition by the 
Pseudomonas Aeruginosa Quorum Sensing Regulator PqsR (MvfR). PLOS 
Pathogens 2013, 9 (7), e1003508. https://doi.org/10.1371/journal.ppat.1003508. 
(12)  Soheili, V.; Tajani, A. S.; Ghodsi, R.; Bazzaz, B. S. F. Anti-PqsR Compounds as 
next-Generation Antibacterial Agents against Pseudomonas Aeruginosa: A 
Review. European Journal of Medicinal Chemistry 2019, 172, 26–35. 
https://doi.org/10.1016/j.ejmech.2019.03.049. 
(13)  Soukarieh, F.; Liu, R.; Romero, M.; Roberston, S. N.; Richardson, W.; Lucanto, 
S.; Oton, E. V.; Qudus, N. R.; Mashabi, A.; Grossman, S.; Ali, S.; Sou, T.; 
Kukavica-Ibrulj, I.; Levesque, R. C.; Bergström, C. A. S.; Halliday, N.; Mistry, S. 
N.; Emsley, J.; Heeb, S.; Williams, P.; Cámara, M.; Stocks, M. J. Hit Identification 
of New Potent PqsR Antagonists as Inhibitors of Quorum Sensing in Planktonic 
and Biofilm Grown Pseudomonas Aeruginosa. Front. Chem. 2020, 8, 204. 
https://doi.org/10.3389/fchem.2020.00204. 
(14)  Lister, P. D.; Wolter, D. J.; Hanson, N. D. Antibacterial-Resistant Pseudomonas 
Aeruginosa: Clinical Impact and Complex Regulation of Chromosomally 
Encoded Resistance Mechanisms. Clin Microbiol Rev 2009, 22 (4), 582–610. 
https://doi.org/10.1128/CMR.00040-09. 
(15)  Wagner, S.; Sommer, R.; Hinsberger, S.; Lu, C.; Hartmann, R. W.; Empting, M.; 
Titz, A. Novel Strategies for the Treatment of Pseudomonas Aeruginosa 
Infections. J. Med. Chem. 2016, 59 (13), 5929–5969. 
https://doi.org/10.1021/acs.jmedchem.5b01698. 
(16)  Stewart, P. S. Mechanisms of Antibiotic Resistance in Bacterial Biofilms. 
International Journal of Medical Microbiology 2002, 292 (2), 107–113. 
https://doi.org/10.1078/1438-4221-00196. 
(17)  Jolly, A. L.; Takawira, D.; Oke, O. O.; Whiteside, S. A.; Chang, S. W.; Wen, E. 
R.; Quach, K.; Evans, D. J.; Fleiszig, S. M. J. Pseudomonas Aeruginosa-Induced 
Bleb-Niche Formation in Epithelial Cells Is Independent of Actinomyosin 
Contraction and Enhanced by Loss of Cystic Fibrosis Transmembrane-
Conductance Regulator Osmoregulatory Function. mBio 2015, 6 (2). 
https://doi.org/10.1128/mBio.02533-14. 
(18)  Sean, Y.T.; Song-Lin, C.; Yicai, C.; Scott, R.; Staffan, K.; Thomas, N.; Liang, Y.; 
Michael, G. Identification of Five Structurally Unrelated Quorum-Sensing 
Inhibitors of Pseudomonas aeruginosa from a Natural-Derivative Database. 
Antimicrobial Agents and Chemother. 2013, 57 (11). 
https://aac.asm.org/content/57/11/5629.short. 
(19)  Diggle, S. P.; Winzer, K.; Chhabra, S. R.; Worrall, K. E.; Cámara, M.; Williams, 
P. The Pseudomonas Aeruginosa Quinolone Signal Molecule Overcomes the 
Cell Density-Dependency of the Quorum Sensing Hierarchy, Regulates Rhl-
Dependent Genes at the Onset of Stationary Phase and Can Be Produced in 
Rui Ling Liu                                                                             University of Nottingham  
197 
 
the Absence of LasR. Molecular Microbiology 2003, 50 (1), 29–43. 
https://doi.org/10.1046/j.1365-2958.2003.03672.x. 
(20)  Lami, R. Chapter 3 - Quorum Sensing in Marine Biofilms and Environments. In 
Quorum Sensing; Tommonaro, G., Ed.; Academic Press, 2019; pp 55–96. 
https://doi.org/10.1016/B978-0-12-814905-8.00003-4. 
(21)  Abedon, S. T.; Duffy, S.; Turner, P. E. Bacteriophage Ecology. In Encyclopedia 
of Microbiology (Third Edition); Schaechter, M., Ed.; Academic Press: Oxford, 
2009; pp 42–57. https://doi.org/10.1016/B978-012373944-5.00022-5. 
(22)  Peterson, J. W. Bacterial Pathogenesis. In Medical Microbiology; Baron, S., Ed.; 
University of Texas Medical Branch at Galveston: Galveston (TX), 1996. 
(23)  Ahmed, E.; Holmström, S. J. M. Siderophores in Environmental Research: Roles 
and Applications. Microbial Biotechnology 2014, 7 (3), 196–208. 
https://doi.org/10.1111/1751-7915.12117. 
(24)  Raines, D. J.; Sanderson, T. J.; Wilde, E. J.; Duhme-Klair, A.-K. Siderophores. 
In Reference Module in Chemistry, Molecular Sciences and Chemical 
Engineering; Elsevier, 2015. https://doi.org/10.1016/B978-0-12-409547-
2.11040-6. 
(25)  Page, M. G. P. The Role of Iron and Siderophores in Infection, and the 
Development of Siderophore Antibiotics. Clin Infect Dis 2019, 69 (Suppl 7), 
S529–S537. https://doi.org/10.1093/cid/ciz825. 
(26)  Hall, S.; McDermott, C.; Anoopkumar-Dukie, S.; McFarland, A. J.; Forbes, A.; 
Perkins, A. V.; Davey, A. K.; Chess-Williams, R.; Kiefel, M. J.; Arora, D.; Grant, 
G. D. Cellular Effects of Pyocyanin, a Secreted Virulence Factor of 
Pseudomonas Aeruginosa. Toxins 2016, 8 (8), 236. 
https://doi.org/10.3390/toxins8080236. 
(27)  Ortiz-Castro, R.; Pelagio-Flores, R.; Méndez-Bravo, A.; Ruiz-Herrera, L. F.; 
Campos-García, J.; López-Bucio, J. Pyocyanin, a Virulence Factor Produced by 
Pseudomonas Aeruginosa, Alters Root Development through Reactive Oxygen 
Species and Ethylene Signaling in Arabidopsis. Mol Plant Microbe Interact 2014, 
27 (4), 364–378. https://doi.org/10.1094/MPMI-08-13-0219-R. 
(28)  Castañeda-Tamez, P.; Ramírez-Peris, J.; Pérez-Velázquez, J.; Kuttler, C.; 
Jalalimanesh, A.; Saucedo-Mora, M. Á.; Jiménez-Cortés, J. G.; Maeda, T.; 
González, Y.; Tomás, M.; Wood, T. K.; García-Contreras, R. Pyocyanin 
Restricts Social Cheating in Pseudomonas Aeruginosa. Front. Microbiol. 2018, 
9. https://doi.org/10.3389/fmicb.2018.01348. 
(29)  Zhu, Y.; Li, J. J.; Reng, J.; Wang, S.; Zhang, R.; Wang, B. Global Trends of 
Pseudomonas Aeruginosa Biofilm Research in the Past Two Decades: A 
Bibliometric Study. MicrobiologyOpen 2020, 9 (6), e1021. 
https://doi.org/10.1002/mbo3.1021. 
(30)  Rumbaugh, K. P.; Sauer, K. Biofilm Dispersion. Nature Reviews Microbiology 
2020, 1–16. https://doi.org/10.1038/s41579-020-0385-0. 
Rui Ling Liu                                                                             University of Nottingham  
198 
 
(31)  Pang, Z.; Raudonis, R.; Glick, B. R.; Lin, T.-J.; Cheng, Z. Antibiotic Resistance 
in Pseudomonas Aeruginosa: Mechanisms and Alternative Therapeutic 
Strategies. Biotechnology Advances 2019, 37 (1), 177–192. 
https://doi.org/10.1016/j.biotechadv.2018.11.013. 
(32)  Karami, P.; Khaledi, A.; Mashoof, R. Y.; Yaghoobi, M. H.; Karami, M.; Dastan, 
D.; Alikhani, M. Y. The Correlation between Biofilm Formation Capability and 
Antibiotic Resistance Pattern in Pseudomonas Aeruginosa. Gene Reports 2020, 
18, 100561. https://doi.org/10.1016/j.genrep.2019.100561. 
(33)  Whiteley, M.; Bangera, M. G.; Bumgarner, R.E.; Parsek, M. R.; Teitzel, G. M.; 
Lory, S.; Greenberg, E. P. Gene expression in Pseudomonas aeruginosa 
biofilms. Nature. 2001. 413(6858). https://www.nature.com/articles/35101627 
(accessed Aug 8, 2020). 
(34)  Stover, C.K.; Pham, X. Q.; Erwin, A. L.; Mizoguchi, S. D.; Hickey, M. J.; Brinkman, 
F. S; Hufnagle, W. O.; Kowalik, D. J.; Lagrou, M.; Garber, R. L.; Goltry, L.; 
Tolentino, E.; Westbrock-Wadman, S.; Yuan, Y.; Brody, L. L.; Coulter, S. N.; 
Folger, K. R.; Kas, A.; Larbig, K.; Lim, R.; Smith, K.; Spencer, D.; Wong, G. K.; 
Wu, Z.; Paulsen, I. T.; Reizer, J.; Saier, M. H.; Hancock, R. E.; Lory, S.; Olson, 
M. V. Complete genome sequence of Pseudomonas aeruginosa PAO1, an 
opportunistic pathogen. Nature. 2000. 406 (6799):947-8  
(35)  Yoshimura, F.; Nikaido, H. Permeability of Pseudomonas Aeruginosa Outer 
Membrane to Hydrophilic Solutes. Journal of Bacteriology 1982, 152 (2), 636–
642. 
(36)  Sugawara, E.; Nagano, K.; Nikaido, H. Alternative Folding Pathways of the Major 
Porin OprF of Pseudomonas Aeruginosa. The FEBS Journal 2012, 279 (6), 910–
918. https://doi.org/10.1111/j.1742-4658.2012.08481.x. 
(37)  Nikaido, H.; Nikaido, K.; Harayama, S. Identification and Characterization of 
Porins in Pseudomonas Aeruginosa. Journal of Biological Chemistry 1991, 266 
(2), 770–779. https://doi.org/10.1016/S0021-9258(17)35239-0. 
(38)  Clatworthy, A. E.; Romano, K. P.; Hung, D. T. Whole-Organism Phenotypic 
Screening for Anti-Infectives Promoting Host Health. Nature Chemical Biology 
2018, 14 (4), 331–341. https://doi.org/10.1038/s41589-018-0018-3. 
(39)  Megan, G.; Sebastian, L.; Matthew, B. Chemical Strategies To Target Bacterial 
Virulence. Chem Rev. 2017. 117 (5):4422-4461. 
https://pubs.acs.org/doi/abs/10.1021/acs.chemrev.6b00676. 
(40)  Rahul, S.M.; l, Atri, T.; Ritam, S.; Nagaraja, T.; Anirban, G.; Mohsina, T.; Anirban, 
B; Hemanta, K.; Santasabuj, D. Ribavirin suppresses bacterial virulence by 
targeting LysR-type transcriptional regulators. Nature. 2016. 39454 
https://www.nature.com/articles/srep39454  
(41)  González-Bello, C. Antibiotic Adjuvants – A Strategy to Unlock Bacterial 
Resistance to Antibiotics. Bioorganic & Medicinal Chemistry Letters 2017, 27 
(18), 4221–4228. https://doi.org/10.1016/j.bmcl.2017.08.027. 
Rui Ling Liu                                                                             University of Nottingham  
199 
 
(42)  Viducic, D.; Murakami, K.; Amoh, T.; Ono, T.; Miyake, Y. RpoN Modulates 
Carbapenem Tolerance in Pseudomonas Aeruginosa through Pseudomonas 
Quinolone Signal and PqsE. Antimicrobial Agents and Chemotherapy 2016, 60 
(10), 5752–5764. https://doi.org/10.1128/AAC.00260-16. 
(43)  Allen, R. C.; Popat, R.; Diggle, S. P.; Brown, S. P. Targeting Virulence: Can We 
Make Evolution-Proof Drugs? Nature Reviews Microbiology 2014, 12 (4), 300–
308. https://doi.org/10.1038/nrmicro3232. 
(44)  Colleen T.O’Loughlin; Laura, C. M; Albert, S.; Knut, D.; Martin F. S.; Bonnie L. B.  
A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and 
biofilm formation.  Pnas. 2013, 110 (44). 
https://www.pnas.org/content/110/44/17981. 
(45) Lynette, C.; Garland R. M.; Gary R. E.; Scott J. H. The biology and future 
prospects of antivirulence therapies. Nat Rev Microbiol. 2008, 6)1): 17-27. 
https://www.nature.com/articles/nrmicro1818  
(46)  Lee, J.; Zhang, L. The Hierarchy Quorum Sensing Network in Pseudomonas 
Aeruginosa. Protein Cell 2015, 6 (1), 26–41. https://doi.org/10.1007/s13238-
014-0100-x. 
(47)  Mühlen, S.; Dersch, P. Anti-Virulence Strategies to Target Bacterial Infections. 
Curr. Top. Microbiol. Immunol. 2016, 398, 147–183. 
https://doi.org/10.1007/82_2015_490. 
(48)  Bacterial Quorum Sensing: Its Role in Virulence and Possibilities for Its Control 
http://perspectivesinmedicine.cshlp.org/content/2/11/a012427.short (accessed 
Jul 16, 2020). 
(49)  Ng, W.-L.; Bassler, B. L. Bacterial Quorum-Sensing Network Architectures. 
Annual Review of Genetics. 2009, 43 (1), 197–222. 
https://doi.org/10.1146/annurev-genet-102108-134304. 
(50)  Breah, L.; Michael, J. F. Exploiting Quorum Sensing to Confuse Bacterial 
Pathogens. Microbiol Mol Biol Rev. 2013, 77, 73-111. 
https://mmbr.asm.org/content/77/1/73. 
(51)  Catherine, G.; Mélanie, T.; Solange, M.; Yves, D.; Denis, F. Quorum quenching: 
role in nature and applied developments. FEMS Microbiology Reviews. 2015, 
40 (1):86-116. https://academic.oup.com/femsre/article/40/1/86/2467695. 
(52)  Cheng, J.; Indrajeet, S.; Debarshi, P.;  Lynn, H.; Damien, M.; Tezcan, G.; 
Laurence, R.; Everett, C. P.; James, P. C.; Derek, S. T.; Designed Small-
Molecule Inhibitors of the Anthranilyl-CoA Synthetase PqsA Block Quinolone 
Biosynthesis in Pseudomonas aeruginosa. ACS Chem. Biol. 2016, 11 (11): 
3061-3067. https://pubs.acs.org/doi/abs/10.1021/acschembio.6b00575.  
(53)  Stephen, M.; Dana, S. W.; Everett, C. P. Dueling quorum sensing systems in 
Pseudomonas aeruginosa control the production of the Pseudomonas 
quinolone signal (PQS). FEMS Microbiol. Lett. 2004, 230 (1):27-34.  
https://academic.oup.com/femsle/article/230/1/27/765008. 
Rui Ling Liu                                                                             University of Nottingham  
200 
 
(54)  Dana, S. W.; Worth, C.; Edson R. Ra.; Elizabeth, A. L.; Elana, E.; James P. C.; 
Everett C. P. Regulation of Pseudomonas Quinolone Signal Synthesis in 
Pseudomonas aeruginosa. J. Bacteriol, 2005, 187(13):4372-4280. 
https://jb.asm.org/content/187/13/4372.  
(55)  Pol, N. J.; Gudrun, K.; Jessica A. T.; Karina, B. X.; Robbert, H. C.; Wim, J. Q.; 
The Multiple Signaling Systems Regulating Virulence in Pseudomonas 
aeruginosa. Microbiol. Mol. Biol. Rev, 2012, 76(1):46-65. DOI: 
10.1128/MMBR.05007-11 
(56)  Larry, A. G.; Susan, L. M.; Marina, S. K.; Everett, C. P.; Colin M. Functions 
Required for Extracellular Quinolone Signaling by Pseudomonas aeruginosa. J. 
Bacteriol, 2002, 184(23):6472-6480. https://jb.asm.org/content/184/23/6472.  
(57)  Shen, Y.; Vanessa, J.; Janine, S.; Ingo, F.; Stefan, W.; Erik, S.; Susanne, H.; 
Wulf B. Structure Elucidation and Preliminary Assessment of Hydrolase Activity 
of PqsE, the Pseudomonas Quinolone Signal (PQS) Response Protein. 
Biochemistry, 2009, 48 (43):10298-307. 
https://pubs.acs.org/doi/abs/10.1021/bi900123j. 
(58)  Pesci, E. C.; Pearson, J. P.; Seed, P. C.; Iglewski, B. H. Regulation of las and 
rhl quorum sensing in Pseudomonas aeruginosa. J. Bacteriol, 1997, 179 
(10):3127-32. https://jb.asm.org/content/179/10/3127. 
(59)  Wagner, V. E.; Gillis, R. J.; Iglewski, B. H. Transcriptome Analysis of Quorum-
Sensing Regulation and Virulence Factor Expression in Pseudomonas 
Aeruginosa. Vaccine 2004, 22, S15–S20. 
https://doi.org/10.1016/j.vaccine.2004.08.011. 
(60)  Gaoping, X.;  Eric, D.; Jianxin, H.;  François, L.;  Biliana, L.;  Marie-Hélène, C.;  
Sylvain, M.; Anastasia, P. T.; Scott, E. S.;  Laurence, G. R. MvfR, a key 
Pseudomonas aeruginosa pathogenicity LTTR-class regulatory protein, has 
dual ligands. Mol Microbiol, 2006, 62(6):1689-99. 
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2958.2006.05462.x. 
(61)  Kitao, T.; Lepine, F.; Babloudi, S.; Walte, F.; Steinbacher, S.; Maskos, K.; 
Blaesse, M.; Negri, M.; Pucci, M.; Zahler, B.; Felici, A.; Rahme, L. G. Molecular 
Insights into Function and Competitive Inhibition of Pseudomonas Aeruginosa 
Multiple Virulence Factor Regulator. mBio 2018, 9 (1). 
https://doi.org/10.1128/mBio.02158-17. 
(62)  Florian, B.; Manfred, N.; Victor, W.; Michael, M.; Rolf, M.; Susanne, H. 
Biosynthetic Pathway of Pseudomonas aeruginosa 4-Hydroxy-2-Alkylquinolines. 
J.Bacteriol. 2005, 187(11):3630–3635. https://jb.asm.org/content/187/11/3630. 
(63)  Stephan, B.; Christian, P.; Christiane, R.; Birgit, K.; Franz, N.; Susanne, H. The 
PqsR and RhlR Transcriptional Regulators Determine the Level of 
Pseudomonas Quinolone Signal Synthesis in Pseudomonas aeruginosa by 
Producing Two Different pqsABCDE mRNA Isoforms. J Bacteriol. 2014, 
196(23):4163-71. doi: 10.1128/JB.02000-14.  
Rui Ling Liu                                                                             University of Nottingham  
201 
 
(64)  Eric, D.; Suresh, G.; Anastasia, P. T.; François, L.; Katie, E. P.; Maude, S.; 
Gaoping, X.; Laurence G R.. The contribution of MvfR to Pseudomonas 
aeruginosa pathogenesis and quorum sensing circuitry regulation: multiple 
quorum sensing-regulated genes are modulated without affecting lasRI, rhlRI or 
the production of N-acyl- l-homoserine lactones. Mol Microbiol. 2005, 55(4):998-
1014. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2958.2004.04448.x 
(accessed Jul 16, 2020). 
(65)  Déziel, E.; Lépine, F.; Milot, S.; He, J.; Mindrinos, M. N.; Tompkins, R. G.; 
Rahme, L. G. Analysis of Pseudomonas Aeruginosa 4-Hydroxy-2-
Alkylquinolines (HAQs) Reveals a Role for 4-Hydroxy-2-Heptylquinoline in Cell-
to-Cell Communication. PNAS 2004, 101 (5), 1339–1344. 
https://doi.org/10.1073/pnas.0307694100. 
(66)  Schertzer, J. W.; Brown, S. A.; Whiteley, M. Oxygen Levels Rapidly Modulate 
Pseudomonas Aeruginosa Social Behaviours via Substrate Limitation of PqsH. 
Molecular Microbiology 2010, 77 (6), 1527–1538. https://doi.org/10.1111/j.1365-
2958.2010.07303.x. 
(67)  Bredenbruch, F.; Geffers, R.; Nimtz, M.; Buer, J.; Häussler, S. The 
Pseudomonas Aeruginosa Quinolone Signal (PQS) Has an Iron-Chelating 
Activity. Environmental Microbiology 2006, 8 (8), 1318–1329. 
https://doi.org/10.1111/j.1462-2920.2006.01025.x. 
(68)  Welch, M.; Hodgkinson, J. T.; Gross, J.; Spring, D. R.; Sams, T. Ligand Binding 
Kinetics of the Quorum Sensing Regulator PqsR. Biochemistry 2013, 52 (25), 
4433–4438. https://doi.org/10.1021/bi400315s. 
(69)  Masanori, T.; Toshiaki, N.; Hiroo U.; Nobuhiko, N. The Effect of a Cell-to-cell 
Communication Molecule, Pseudomonas Quinolone Signal (PQS), Produced by 
P. aeruginosa on Other Bacterial Species. Microbes Environ. 2010, 25(1):1-7. 
https://www.jstage.jst.go.jp/article/jsme2/advpub/0/advpub_ME09156/_article/-
char/ja. 
(70)  Lee, J.; Wu, J.; Deng, Y.; Wang, J.; Wang, C.; Wang, J.; Chang, C.; Dong, Y.; 
Williams, P.; Zhang, L.-H. A Cell-Cell Communication Signal Integrates Quorum 
Sensing and Stress Response. Nat Chem Biol 2013, 9 (5), 339–343. 
https://doi.org/10.1038/nchembio.1225. 
(71)  Lu, C.; Maurer, C. K.; Kirsch, B.; Steinbach, A.; Hartmann, R. W. Overcoming 
the Unexpected Functional Inversion of a PqsR Antagonist in Pseudomonas 
Aeruginosa: An in Vivo Potent Antivirulence Agent Targeting Pqs Quorum 
Sensing. Angew Chem Int Ed Engl 2014, 53 (4), 1109–1112. 
https://doi.org/10.1002/anie.201307547. 
(72)  Passador, L.; Tucker, K. D.; Guertin, K. R.; Journet, M. P.; Kende, A. S.; Iglewski, 
B. H. Functional Analysis of the Pseudomonas Aeruginosa Autoinducer PAI. J 
Bacteriol 1996, 178 (20), 5995–6000. 
(73)  Maura, D.; Rahme, L. G. Pharmacological Inhibition of the Pseudomonas 
Aeruginosa MvfR Quorum-Sensing System Interferes with Biofilm Formation 
Rui Ling Liu                                                                             University of Nottingham  
202 
 
and Potentiates Antibiotic-Mediated Biofilm Disruption. Antimicrobial Agents and 
Chemotherapy 2017, 61 (12). https://doi.org/10.1128/AAC.01362-17. 
(74)  Mayr, L. M.; Fuerst, P. The Future of High-Throughput Screening. J Biomol 
Screen 2008, 13 (6), 443–448. https://doi.org/10.1177/1087057108319644. 
(75)  Benet, L. Z.; Hosey, C. M.; Ursu, O.; Oprea, T. I. BDDCS, the Rule of 5 and 
Drugability. Adv Drug Deliv Rev 2016, 101, 89–98. 
https://doi.org/10.1016/j.addr.2016.05.007. 
(76)  Bajorath, J. Integration of Virtual and High-Throughput Screening. Nature 
Reviews Drug Discovery 2002, 1 (11), 882–894. https://doi.org/10.1038/nrd941. 
(77)  Joseph-McCarthy, D.; Campbell, A. J.; Kern, G.; Moustakas, D. Fragment-
Based Lead Discovery and Design. J. Chem. Inf. Model. 2014, 54 (3), 693–704. 
https://doi.org/10.1021/ci400731w. 
(78)  Erlanson, D. A.; Fesik, S. W.; Hubbard, R. E.; Jahnke, W.; Jhoti, H. Twenty 
Years on: The Impact of Fragments on Drug Discovery. Nature Reviews Drug 
Discovery 2016, 15 (9), 605–619. https://doi.org/10.1038/nrd.2016.109. 
(79)  Kirsch, P.; Hartman, A. M.; Hirsch, A. K. H.; Empting, M. Concepts and Core 
Principles of Fragment-Based Drug Design. Molecules 2019, 24 (23). 
https://doi.org/10.3390/molecules24234309. 
(80)  Lamoree, B.; Hubbard, R. E. Current Perspectives in Fragment-Based Lead 
Discovery (FBLD). Essays in Biochemistry 2017, 61 (5), 453–464. 
https://doi.org/10.1042/EBC20170028. 
(81)  Price, A. J.; Howard, S.; Cons, B. D. Fragment-Based Drug Discovery and Its 
Application to Challenging Drug Targets. Essays in Biochemistry 2017, 61 (5), 
475–484. https://doi.org/10.1042/EBC20170029. 
(82)  Carr, R. A. E.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-Based Lead 
Discovery: Leads by Design. Drug Discovery Today 2005, 10 (14), 987–992. 
https://doi.org/10.1016/S1359-6446(05)03511-7. 
(83)  Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-Based Lead 
Discovery. Nat Rev Drug Discov 2004, 3 (8), 660–672. 
https://doi.org/10.1038/nrd1467. 
(84)  Keserű, G. M.; Makara, G. M. Hit Discovery and Hit-to-Lead Approaches. Drug 
Discovery Today 2006, 11 (15), 741–748. 
https://doi.org/10.1016/j.drudis.2006.06.016. 
(85)  Erlanson, D. A. Introduction to Fragment-Based Drug Discovery. In Fragment-
Based Drug Discovery and X-Ray Crystallography; Davies, T. G., Hyvönen, M., 
Eds.; Topics in Current Chemistry; Springer: Berlin, Heidelberg, 2012; pp 1–32. 
https://doi.org/10.1007/128_2011_180. 
(86)  Murray, C. W.; Rees, D. C. The Rise of Fragment-Based Drug Discovery. Nature 
Chem 2009, 1 (3), 187–192. https://doi.org/10.1038/nchem.217. 
Rui Ling Liu                                                                             University of Nottingham  
203 
 
(87)  Erlanson, D. A.; de Esch, I. J. P.; Jahnke, W.; Johnson, C. N.; Mortenson, P. N. 
Fragment-to-Lead Medicinal Chemistry Publications in 2018. J. Med. Chem. 
2020, 63 (9), 4430–4444. https://doi.org/10.1021/acs.jmedchem.9b01581. 
(88)  Yang, H.; Chennamaneni, L. R.; Ho, M. W. T.; Ang, S. H.; Tan, E. S. W.; Jeyaraj, 
D. A.; Yeap, Y. S.; Liu, B.; Ong, E. H.; Joy, J. K.; Wee, J. L. K.; Kwek, P.; Retna, 
P.; Dinie, N.; Nguyen, T. T. H.; Tai, S. J.; Manoharan, V.; Pendharkar, V.; Low, 
C. B.; Chew, Y. S.; Vuddagiri, S.; Sangthongpitag, K.; Choong, M. L.; Lee, M. 
A.; Kannan, S.; Verma, C. S.; Poulsen, A.; Lim, S.; Chuah, C.; Ong, T. S.; Hill, 
J.; Matter, A.; Nacro, K. Optimization of Selective Mitogen-Activated Protein 
Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis 
Leukemia. J. Med. Chem. 2018, 61 (10), 4348–4369. 
https://doi.org/10.1021/acs.jmedchem.7b01714. 
(89)  Reich, S. H.; Sprengeler, P. A.; Chiang, G. G.; Appleman, J. R.; Chen, J.; Clarine, 
J.; Eam, B.; Ernst, J. T.; Han, Q.; Goel, V. K.; Han, E. Z. R.; Huang, V.; Hung, I. 
N. J.; Jemison, A.; Jessen, K. A.; Molter, J.; Murphy, D.; Neal, M.; Parker, G. S.; 
Shaghafi, M.; Sperry, S.; Staunton, J.; Stumpf, C. R.; Thompson, P. A.; Tran, C.; 
Webber, S. E.; Wegerski, C. J.; Zheng, H.; Webster, K. R. Structure-Based 
Design of Pyridone–Aminal EFT508 Targeting Dysregulated Translation by 
Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 
(MNK1/2) Inhibition. Journal of Medicinal Chemistry 2018. 
https://doi.org/10.1021/acs.jmedchem.7b01795. 
(90)  Schulz, M. N.; Hubbard, R. E. Recent Progress in Fragment-Based Lead 
Discovery. Current Opinion in Pharmacology 2009, 9 (5), 615–621. 
https://doi.org/10.1016/j.coph.2009.04.009. 
(91)  Hajduk, P. J.; Greer, J. A Decade of Fragment-Based Drug Design: Strategic 
Advances and Lessons Learned. Nature Reviews Drug Discovery 2007, 6 (3), 
211–219. https://doi.org/10.1038/nrd2220. 
(92)  Chilingaryan, Z.; Yin, Z.; Oakley, A. J. Fragment-Based Screening by Protein 
Crystallography: Successes and Pitfalls. Int J Mol Sci 2012, 13 (10), 12857–
12879. https://doi.org/10.3390/ijms131012857. 
(93)  Drinkwater, N.; Vu, H.; Lovell, K. M.; Criscione, K. R.; Collins, B. M.; Prisinzano, 
T. E.; Poulsen, S.-A.; McLeish, M. J.; Grunewald, G. L.; Martin, J. L. Fragment-
Based Screening by X-Ray Crystallography, MS and Isothermal Titration 
Calorimetry to Identify PNMT (Phenylethanolamine N-Methyltransferase) 
Inhibitors. Biochem J 2010, 431 (1), 51–61. https://doi.org/10.1042/BJ20100651. 
(94)  Schulz, M. N.; Landström, J.; Bright, K.; Hubbard, R. E. Design of a Fragment 
Library That Maximally Represents Available Chemical Space. J Comput Aided 
Mol Des 2011, 25 (7), 611. https://doi.org/10.1007/s10822-011-9461-x. 
(95)  Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent Developments in 
Fragment-Based Drug Discovery. J. Med. Chem. 2008, 51 (13), 3661–3680. 
https://doi.org/10.1021/jm8000373. 
Rui Ling Liu                                                                             University of Nottingham  
204 
 
(96)  Erlanson, D. A.; McDowell, R. S.; O’Brien, T. Fragment-Based Drug Discovery. 
J. Med. Chem. 2004, 47 (14), 3463–3482. https://doi.org/10.1021/jm040031v. 
(97)  Lipinski, C. A. Lead- and Drug-like Compounds: The Rule-of-Five Revolution. 
Drug Discovery Today: Technologies 2004, 1 (4), 337–341. 
https://doi.org/10.1016/j.ddtec.2004.11.007. 
(98)  Giménez, B. G.; Santos, M. S.; Ferrarini, M.; Fernandes, J. P. S.; Fernandes, J. 
P. S. Evaluation of Blockbuster Drugs under the Rule-of-Five. Die Pharmazie - 
An International Journal of Pharmaceutical Sciences 2010, 65 (2), 148–152. 
https://doi.org/10.1691/ph.2010.9733. 
(99)  Zhang, M.-Q.; Wilkinson, B. Drug Discovery beyond the ‘Rule-of-Five.’ Current 
Opinion in Biotechnology 2007, 18 (6), 478–488. 
https://doi.org/10.1016/j.copbio.2007.10.005. 
(100)  Meenakshi Singh; Benjamin Tam; Barak Akabayov. NMR-Fragment Based 
Virtual Screening: A Brief Overview. Molecules 2018, 23 (2), 233. 
https://doi.org/10.3390/molecules23020233. 
(101)  Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A ‘Rule of Three’ for Fragment-
Based Lead Discovery? Drug Discovery Today 2003, 8 (19), 876–877. 
https://doi.org/10.1016/S1359-6446(03)02831-9. 
(102)  de Souza Neto, L. R.; Moreira-Filho, J. T.; Neves, B. J.; Maidana, R. L. B. R.; 
Guimarães, A. C. R.; Furnham, N.; Andrade, C. H.; Silva, F. P. In Silico 
Strategies to Support Fragment-to-Lead Optimization in Drug Discovery. Front. 
Chem. 2020, 8, 93. https://doi.org/10.3389/fchem.2020.00093. 
(103)  Jhoti, H.; Williams, G.; Rees, D. C.; Murray, C. W. The “rule of Three” for 
Fragment-Based Drug Discovery: Where Are We Now? Nat Rev Drug Discov 
2013, 12 (8), 644–644. https://doi.org/10.1038/nrd3926-c1. 
(104)  Baker, M. Fragment-Based Lead Discovery Grows Up. Nature Reviews Drug 
Discovery 2013, 12 (1), 5–7. https://doi.org/10.1038/nrd3926. 
(105)  Keeley, A.; Petri, L.; Ábrányi-Balogh, P.; Keserű, G. M. Covalent Fragment 
Libraries in Drug Discovery. Drug Discovery Today 2020. 
https://doi.org/10.1016/j.drudis.2020.03.016. 
(106)  Hubbard, R. E.; Murray, J. B. Chapter Twenty - Experiences in Fragment-Based 
Lead Discovery. In Methods in Enzymology; Kuo, L. C., Ed.; Fragment-Based 
Drug Design; Academic Press, 2011; Vol. 493, pp 509–531. 
https://doi.org/10.1016/B978-0-12-381274-2.00020-0. 
(107)  Hanby, A. R.; Troelsen, N. S.; Osberger, T. J.; Kidd, S. L.; Mortensen, K. T.; 
Spring, D. R. Fsp3-Rich and Diverse Fragments Inspired by Natural Products 
as a Collection to Enhance Fragment-Based Drug Discovery. Chem. Commun. 
2020, 56 (15), 2280–2283. https://doi.org/10.1039/C9CC09796A. 
(108)  Lam, K. S. New Aspects of Natural Products in Drug Discovery. Trends in 
Microbiology 2007, 15 (6), 279–289. https://doi.org/10.1016/j.tim.2007.04.001. 
Rui Ling Liu                                                                             University of Nottingham  
205 
 
(109) Morrison, N. C.; Prosser, K. E.; Stokes, R. W.; Cordes, A.; Metzler-Nolte, N.; 
M. Cohen, S. Expanding Medicinal Chemistry into 3D Space: Metallofragments 
as 3D Scaffolds for Fragment-Based Drug Discovery. Chemical Science 2020, 
11 (5), 1216–1225. https://doi.org/10.1039/C9SC05586J. 
(110) Morley, A. D.; Pugliese, A.; Birchall, K.; Bower, J.; Brennan, P.; Brown, N.; 
Chapman, T.; Drysdale, M.; Gilbert, I. H.; Hoelder, S.; Jordan, A.; Ley, S. V.; 
Merritt, A.; Miller, D.; Swarbrick, M. E.; Wyatt, P. G. Fragment-Based Hit 
Identification: Thinking in 3D. Drug Discovery Today 2013, 18 (23–24), 1221–
1227. https://doi.org/10.1016/j.drudis.2013.07.011. 
(111) Davis, B. J.; Roughley, S. D. Fragment-Based Lead Discovery. In Annual 
Reports in Medicinal Chemistry; Elsevier, 2017; Vol. 50, pp 371–439. 
https://doi.org/10.1016/bs.armc.2017.07.002. 
(112) Davis, B. J.; Hubbard, R. E. Fragment-Based Ligand Discovery. In Structural 
Biology in Drug Discovery; Renaud, J., Ed.; Wiley, 2020; pp 79–98. 
https://doi.org/10.1002/9781118681121.ch4. 
(113) Scott, D. E.; Coyne, A. G.; Hudson, S. A.; Abell, C. Fragment-Based Approaches 
in Drug Discovery and Chemical Biology. Biochemistry 2012, 51 (25), 4990–
5003. https://doi.org/10.1021/bi3005126. 
(114) Murray, C. W.; Blundell, T. L. Structural Biology in Fragment-Based Drug Design. 
Current Opinion in Structural Biology 2010, 20 (4), 497–507. 
https://doi.org/10.1016/j.sbi.2010.04.003. 
(115) O’Brien, R.; Markova, N.; Holdgate, G. A. Thermodynamics in Drug Discovery. 
In Applied Biophysics for Drug Discovery; John Wiley & Sons, Ltd, 2017; pp 7–
28. https://doi.org/10.1002/9781119099512.ch2. 
(116) Tellinghuisen, J. Isothermal Titration Calorimetry at Very Low c. Analytical 
Biochemistry 2008, 373 (2), 395–397. https://doi.org/10.1016/j.ab.2007.08.039. 
(117) Ladbury, J. E.; Klebe, G.; Freire, E. Adding Calorimetric Data to Decision Making 
in Lead Discovery: A Hot Tip. Nature Reviews Drug Discovery 2010, 9 (1), 23–
27. https://doi.org/10.1038/nrd3054. 
(118) Fattori, D.; Squarcia, A.; Bartoli, S. Fragment-Based Approach to Drug??Lead 
Discovery: Overview and Advances in Various Techniques. Drugs in R & D 2008, 
9 (4), 217–227. https://doi.org/10.2165/00126839-200809040-00002. 
(119) Davis, A.; Ward, S. E. The Handbook of Medicinal Chemistry: Principles and 
Practice; Royal Society of Chemistry, 2015. 
(120) Wermuth, C. G. The Practice of Medicinal Chemistry; Academic Press, 2011. 
(121) Gao, K.; Oerlemans, R.; Groves, M. R. Theory and Applications of Differential 
Scanning Fluorimetry in Early-Stage Drug Discovery. Biophys Rev 2020, 12 (1), 
85–104. https://doi.org/10.1007/s12551-020-00619-2. 
Rui Ling Liu                                                                             University of Nottingham  
206 
 
(122) Wakayama, R.; Uchiyama, S.; Hall, D. Ionic Liquids and Protein Folding—Old 
Tricks for New Solvents. Biophys Rev 2019, 11 (2), 209–225. 
https://doi.org/10.1007/s12551-019-00509-2. 
(123) Lo, M.-C.; Aulabaugh, A.; Jin, G.; Cowling, R.; Bard, J.; Malamas, M.; Ellestad, 
G. Evaluation of Fluorescence-Based Thermal Shift Assays for Hit Identification 
in Drug Discovery. Analytical Biochemistry 2004, 332 (1), 153–159. 
https://doi.org/10.1016/j.ab.2004.04.031. 
(124) Joe, C.; Reto, W. Applied Biophysical Methods in Fragment-Based Drug 
Discovery. SLAS Discovery,   2020, 25(5) 471–490 
https://journals.sagepub.com/doi/abs/10.1177/2472555220916168. 
(125)  Ciulli, A.; Abell, C. Fragment-Based Approaches to Enzyme Inhibition. Current 
Opinion in Biotechnology 2007, 18 (6), 489–496. 
https://doi.org/10.1016/j.copbio.2007.09.003. 
(126) Ferenczy, G. G.; Keserű, G. M. Thermodynamic Profiling for Fragment-Based 
Lead Discovery and Optimization. Expert Opinion on Drug Discovery 2020, 15 
(1), 117–129. https://doi.org/10.1080/17460441.2020.1691166. 
(127) Makraki, E.; Darby, J. F.; Carneiro, M. G.; Firth, J. D.; Heyam, A.; Ab, E.; O’Brien, 
P.; Siegal, G.; Hubbard, R. E. Fragment-Derived Modulators of an Industrial β-
Glucosidase. Biochem J 2020, 477 (22), 4383–4395. 
https://doi.org/10.1042/BCJ20200507. 
(128) William, P. J. Screening Technologies for Small Molecule Discovery: The State 
of the Art. Chem. Biol. 2014, 21(9):1162-1170 
https://doi.org/10.1016/j.chembiol.2014.07.015 
(129) Renaud, J.-P.; Chung, C.; Danielson, U. H.; Egner, U.; Hennig, M.; Hubbard, R. 
E.; Nar, H. Biophysics in Drug Discovery: Impact, Challenges and Opportunities. 
Nat Rev Drug Discov 2016, 15 (10), 679–698. 
https://doi.org/10.1038/nrd.2016.123. 
(130) Ma, R.; Wang, P.; Wu, J.; Ruan, K. Process of Fragment-Based Lead 
Discovery—A Perspective from NMR. Molecules 2016, 21 (7), 854. 
https://doi.org/10.3390/molecules21070854. 
(131) Silvestre, H. L.; Blundell, T. L.; Abell, C.; Ciulli, A. Integrated Biophysical 
Approach to Fragment Screening and Validation for Fragment-Based Lead 
Discovery. PNAS 2013, 110 (32), 12984–12989. 
https://doi.org/10.1073/pnas.1304045110. 
(132) Erlanson, D. A.; Davis, B. J.; Jahnke, W. Fragment-Based Drug Discovery: 
Advancing Fragments in the Absence of Crystal Structures. Cell Chemical 
Biology 2019, 26 (1), 9–15. https://doi.org/10.1016/j.chembiol.2018.10.001. 
(133) Maveyraud, L.; Mourey, L. Protein X-Ray Crystallography and Drug Discovery. 
Molecules 2020, 25 (5), 1030. https://doi.org/10.3390/molecules25051030. 
Rui Ling Liu                                                                             University of Nottingham  
207 
 
(134) Wienen-Schmidt, B.; Oebbeke, M.; Ngo, K.; Heine, A.; Klebe, G. Two Methods, 
One Goal: Structural Differences between Cocrystallization and Crystal Soaking 
to Discover Ligand Binding Poses. ChemMedChem 2021, 16 (1), 292–300. 
https://doi.org/10.1002/cmdc.202000565. 
(135) Alexander W. Protein crystallography: alive and well. 2021, The FEBS Journal. 
https://febs.onlinelibrary.wiley.com/doi/full/10.1111/febs.15822.  
(136) Smyth, M. S.; Martin, J. H. J. X Ray Crystallography. Mol Pathol 2000, 53 (1), 
8–14. 
(137) Xuhan L.; Adriaan P. I.; Gerard J. P. v. W. Computational Approaches for De 
Novo Drug Design: Past, Present, and Future.  Artificial Neural Networks, 2020, 
pp 139-165. https://link.springer.com/protocol/10.1007/978-1-0716-0826-5_6. 
(138) Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E. W. Computational Methods in 
Drug Discovery. Pharmacol Rev 2014, 66 (1), 334–395. 
https://doi.org/10.1124/pr.112.007336. 
(139) Abbass, J.; Nebel, J.-C. Enhancing Fragment-Based Protein Structure 
Prediction by Customising Fragment Cardinality According to Local Secondary 
Structure. BMC Bioinformatics 2020, 21 (1), 170. 
https://doi.org/10.1186/s12859-020-3491-0. 
(140) Bissaro, M.; Sturlese, M.; Moro, S. The Rise of Molecular Simulations in 
Fragment-Based Drug Design (FBDD): An Overview. Drug Discovery Today 
2020. https://doi.org/10.1016/j.drudis.2020.06.023. 
(141)  Marchand, J.-R.; Caflisch, A. In Silico Fragment-Based Drug Design with SEED. 
European Journal of Medicinal Chemistry 2018, 156, 907–917. 
https://doi.org/10.1016/j.ejmech.2018.07.042. 
(142) McInnes, C. Virtual Screening Strategies in Drug Discovery. Current Opinion in 
Chemical Biology 2007, 11 (5), 494–502. 
https://doi.org/10.1016/j.cbpa.2007.08.033. 
(143) A. Srinivas Reddy; S. Priyadarshini Pati; P. Praveen Kumar; H.N. Pradeep; G. 
Narahari Sastry. Virtual Screening in Drug Discovery - A Computational 
Perspective. Current Protein and Peptide Science 2007, 8 (4), 329–351. 
https://doi.org/10.2174/138920307781369427. 
(144) Cheng, T.; Li, Q.; Zhou, Z.; Wang, Y.; Bryant, S. H. Structure-Based Virtual 
Screening for Drug Discovery: A Problem-Centric Review. AAPS J 2012, 14 (1), 
133–141. https://doi.org/10.1208/s12248-012-9322-0. 
(145) Lionta, E.; Spyrou, G.; K. Vassilatis, D.; Cournia, Z. Structure-Based Virtual 
Screening for Drug Discovery: Principles, Applications and Recent Advances. 
Current Topics in Medicinal Chemistry 2014, 14 (16), 1923–1938. 
(146) Hou, T.; Xu, X. Recent Development and Application of Virtual Screening in Drug 
Discovery: An Overview. Current Pharmaceutical Design 2004, 10 (9), 1011–
1033. https://doi.org/10.2174/1381612043452721. 
Rui Ling Liu                                                                             University of Nottingham  
208 
 
(147) Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and Scoring in 
Virtual Screening for Drug Discovery: Methods and Applications. Nature 
Reviews Drug Discovery 2004, 3 (11), 935–949. https://doi.org/10.1038/nrd1549. 
(148) Bancet, A.; Raingeval, C.; Lomberget, T.; Le Borgne, M.; Guichou, J.-F.; Krimm, 
I. Fragment Linking Strategies for Structure-Based Drug Design. J. Med. Chem. 
2020. https://doi.org/10.1021/acs.jmedchem.0c00242. 
(149) Tron, A. E.; Belmonte, M. A.; Adam, A.; Aquila, B. M.; Boise, L. H.; Chiarparin, 
E.; Cidado, J.; Embrey, K. J.; Gangl, E.; Gibbons, F. D.; Gregory, G. P.; 
Hargreaves, D.; Hendricks, J. A.; Johannes, J. W.; Johnstone, R. W.; Kazmirski, 
S. L.; Kettle, J. G.; Lamb, M. L.; Matulis, S. M.; Nooka, A. K.; Packer, M. J.; Peng, 
B.; Rawlins, P. B.; Robbins, D. W.; Schuller, A. G.; Su, N.; Yang, W.; Ye, Q.; 
Zheng, X.; Secrist, J. P.; Clark, E. A.; Wilson, D. M.; Fawell, S. E.; Hird, A. W. 
Discovery of Mcl-1-Specific Inhibitor AZD5991 and Preclinical Activity in Multiple 
Myeloma and Acute Myeloid Leukemia. Nature Communications 2018, 9 (1), 
5341. https://doi.org/10.1038/s41467-018-07551-w. 
(150)  Zhu, P.-J.; Yu, Z.-Z.; You, Q.-D.; Jiang, Z.-Y. Myeloid Cell Leukemin-1 Inhibitors: 
A Growing Arsenal for Cancer Therapy. Drug Discovery Today 2020. 
https://doi.org/10.1016/j.drudis.2020.07.021. 
(151) Bruncko, M.; Wang, L.; Sheppard, G. S.; Phillips, D. C.; Tahir, S. K.; Xue, J.; 
Erickson, S.; Fidanze, S.; Fry, E.; Hasvold, L.; Jenkins, G. J.; Jin, S.; Judge, R. 
A.; Kovar, P. J.; Madar, D.; Nimmer, P.; Park, C.; Petros, A. M.; Rosenberg, S. 
H.; Smith, M. L.; Song, X.; Sun, C.; Tao, Z.-F.; Wang, X.; Xiao, Y.; Zhang, H.; 
Tse, C.; Leverson, J. D.; Elmore, S. W.; Souers, A. J. Structure-Guided Design 
of a Series of MCL-1 Inhibitors with High Affinity and Selectivity. J. Med. Chem. 
2015, 58 (5), 2180–2194. https://doi.org/10.1021/jm501258m. 
(152) Zender, M.; Witzgall, F.; Kiefer, A.; Kirsch, B.; Maurer, C. K.; Kany, A. M.; Xu, 
N.; Schmelz, S.; Börger, C.; Blankenfeldt, W.; Empting, M. Flexible Fragment 
Growing Boosts Potency of Quorum-Sensing Inhibitors against Pseudomonas 
Aeruginosa Virulence. ChemMedChem 2020, 15 (2), 188–194. 
https://doi.org/10.1002/cmdc.201900621. 
(153) Fleitas Martínez, O.; Cardoso, M. H.; Ribeiro, S. M.; Franco, O. L. Recent 
Advances in Anti-Virulence Therapeutic Strategies With a Focus on Dismantling 
Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing 
Interference and Biofilm Inhibition. Front Cell Infect Microbiol 2019, 9. 
https://doi.org/10.3389/fcimb.2019.00074. 
(154) Klockgether, J.; Munder, A.; Neugebauer, J.; Davenport, C. F.; Stanke, F.; Larbig, 
K. D.; Heeb, S.; Schöck, U.; Pohl, T. M.; Wiehlmann, L.; Tümmler, B. Genome 
Diversity of Pseudomonas Aeruginosa PAO1 Laboratory Strains. Journal of 
Bacteriology 2010, 192 (4), 1113–1121. https://doi.org/10.1128/JB.01515-09. 
(155) Harrison, E. M.; Carter, M. E. K.; Luck, S.; Ou, H.-Y.; He, X.; Deng, Z.; 
O’Callaghan, C.; Kadioglu, A.; Rajakumar, K. Pathogenicity Islands PAPI-1 and 
PAPI-2 Contribute Individually and Synergistically to the Virulence of 
Rui Ling Liu                                                                             University of Nottingham  
209 
 
Pseudomonas Aeruginosa Strain PA14. IAI 2010, 78 (4), 1437–1446. 
https://doi.org/10.1128/IAI.00621-09. 
(156) Fletcher, M. P.; Diggle, S. P.; Cámara, M.; Williams, P. Biosensor-Based Assays 
for PQS, HHQ and Related 2-Alkyl-4-Quinolone Quorum Sensing Signal 
Molecules. Nat Protoc 2007, 2 (5), 1254–1262. 
https://doi.org/10.1038/nprot.2007.158. 
(157) Rahim, M. I.; Szafrański, S. P.; Ingendoh-Tsakmakidis, A.; Stiesch, M.; Mueller, 
P. P. Evidence for Inoculum Size and Gas Interfaces as Critical Factors in 
Bacterial Biofilm Formation on Magnesium Implants in an Animal Model. 
Colloids and Surfaces B: Biointerfaces 2020, 186, 110684. 
https://doi.org/10.1016/j.colsurfb.2019.110684. 
(158) Zaborin, A.; Gerdes, S.; Holbrook, C.; Liu, D. C.; Zaborina, O. Y.; Alverdy, J. C. 
Pseudomonas Aeruginosa Overrides the Virulence Inducing Effect of Opioids 
When It Senses an Abundance of Phosphate. PLOS ONE 2012, 7 (4), e34883. 
https://doi.org/10.1371/journal.pone.0034883. 
(159) Fletcher, M.; Cámara, M.; Barrett, D. A.; Williams, P. Biosensors for Qualitative 
and Semiquantitative Analysis of Quorum Sensing Signal Molecules. In 
Pseudomonas Methods and Protocols; Filloux, A., Ramos, J.-L., Eds.; Methods 
in Molecular Biology; Springer: New York, NY, 2014; pp 245–254. 
https://doi.org/10.1007/978-1-4939-0473-0_20. 
(160) Kumar, R.; Singh, T.; Singh, H.; Jain, S.; Roy, R. K. Design, Synthesis and 
Anticonvulsant Activity of Some New 6,8-Halo-Substituted-2h-
[1,2,4]Triazino[5,6-b]Indole-3(5h)-One/-Thione and 6,8-Halo-Substituted 5-
Methyl-2h-[1,2,4]Triazino[5,6-b]Indol-3(5h)-One/-Thione. EXCLI J 2014, 13, 
225–240. 
(161) Gladych, J. M. Z.; Hornby, R.; Hunt, J. H.; Jack, D.; Boyle, J. J.; Ferlauto, R. J.; 
Haff, R. F.; Kormendy, C. G.; Stanfield, F. J.; Stewart, R. C. Antiviral Agents. 
5H-as-Triazino[5,6-b]Indoles. J. Med. Chem. 1972, 15 (3), 277–281. 
https://doi.org/10.1021/jm00273a017. 
(162) Kgokong, J. L.; Smith, P. P.; Matsabisa, G. M. 1,2,4-Triazino-[5,6b]Indole 
Derivatives: Effects of the Trifluoromethyl Group on in Vitro Antimalarial Activity. 
Bioorganic & Medicinal Chemistry 2005, 13 (8), 2935–2942. 
https://doi.org/10.1016/j.bmc.2005.02.017. 
(163) Gupta, L.; Sunduru, N.; Verma, A.; Srivastava, S.; Gupta, S.; Goyal, N.; Chauhan, 
P. M. S. Synthesis and Biological Evaluation of New [1,2,4]Triazino[5,6-b]Indol-
3-Ylthio-1,3,5-Triazines and [1,2,4]Triazino[5,6-b]Indol-3-Ylthio-Pyrimidines 
against Leishmania Donovani. European Journal of Medicinal Chemistry 2010, 
45 (6), 2359–2365. https://doi.org/10.1016/j.ejmech.2010.02.015. 
(164) Al Osaimi, A. G.; Ali, R. S.; Saad, H. A.; El Sayed Aly, M. R. Synthesis and 
Antimicrobial Activity of Novel Fused [1,2,4]Triazino[5,6-b]Indole Derivatives. 
Russ J Gen Chem 2017, 87 (6), 1246–1255. 
https://doi.org/10.1134/S1070363217060202. 
Rui Ling Liu                                                                             University of Nottingham  
210 
 
(165) Hassan, S. Y. Synthesis, Antibacterial and Antifungal Activity of Some New 
Pyrazoline and Pyrazole Derivatives. Molecules 2013, 18 (3), 2683–2711. 
https://doi.org/10.3390/molecules18032683. 
(166) Sharma, R.; Pandey, A. K.; Shivahare, R.; Srivastava, K.; Gupta, S.; Chauhan, 
P. M. S. Triazino Indole–Quinoline Hybrid: A Novel Approach to Antileishmanial 
Agents. Bioorganic & Medicinal Chemistry Letters 2014, 24 (1), 298–301. 
https://doi.org/10.1016/j.bmcl.2013.11.018. 
(167) Hlaváč, M.; Kováčiková, L.; Prnová, M. Š.; Šramel, P.; Addová, G.; Májeková, 
M.; Hanquet, G.; Boháč, A.; Štefek, M. Development of Novel Oxotriazinoindole 
Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the 
Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity. J. 
Med. Chem. 2020, 63 (1), 369–381. 
https://doi.org/10.1021/acs.jmedchem.9b01747. 
(168) Hamid, H. M. A. Functionalised 1,2,4-Triazino[5,6-b]Indoles. Journal of 
Chemical Research 2004, 2004 (3), 183–185. 
https://doi.org/10.3184/0308234041640735. 
(169) Sareen, S.; Mathew, G.; Joseph, L. Improvement in Solubility of Poor Water-
Soluble Drugs by Solid Dispersion. Int J Pharm Investig 2012, 2 (1), 12–17. 
https://doi.org/10.4103/2230-973X.96921. 
(170) Davis, B. J.; Hubbard, R. E. Fragment-Based Ligand Discovery. In Structural 
Biology in Drug Discovery; John Wiley & Sons, Ltd, 2020; pp 79–98. 
https://doi.org/10.1002/9781118681121.ch4. 
(171) Osborne, J.; Panova, S.; Rapti, M.; Urushima, T.; Jhoti, H. Fragments: Where 
Are We Now? Biochemical Society Transactions 2020, 48 (1), 271–280. 
https://doi.org/10.1042/BST20190694. 
(172) Zender, M.; Klein, T.; Henn, C.; Kirsch, B.; Maurer, C. K.; Kail, D.; Ritter, C.; 
Dolezal, O.; Steinbach, A.; Hartmann, R. W. Discovery and Biophysical 
Characterization of 2-Amino-Oxadiazoles as Novel Antagonists of PqsR, an 
Important Regulator of Pseudomonas Aeruginosa Virulence. J. Med. Chem. 
2013, 56 (17), 6761–6774. https://doi.org/10.1021/jm400830r. 
(173) Klein, T.; Henn, C.; Jong, J. C. de; Zimmer, C.; Kirsch, B.; Maurer, C. K.; 
Pistorius, D.; Müller, R.; Steinbach, A.; Hartmann, R. W. Identification of Small-
Molecule Antagonists of the Pseudomonas aeruginosa Transcriptional 
Regulator PqsR: Biophysically Guided Hit Discovery and Optimization 
https://pubs.acs.org/doi/pdf/10.1021/cb300208g (accessed Jul 12, 2020). 
https://doi.org/10.1021/cb300208g. 
(174) S. Cremosnik, G.; Liu, J.; Waldmann, H. Guided by Evolution: From Biology 
Oriented Synthesis to Pseudo Natural Products. Natural Product Reports 2020. 
https://doi.org/10.1039/D0NP00015A. 
(175) Moningka, R.; Romero, F. A.; Hastings, N. B.; Guo, Z.; Wang, M.; Di Salvo, J.; 
Li, Y.; Trusca, D.; Deng, Q.; Tong, V.; Terebetski, J. L.; Ball, R. G.; Ujjainwalla, 
Rui Ling Liu                                                                             University of Nottingham  
211 
 
F. Fragment-Based Lead Discovery of a Novel Class of Small Molecule 
Antagonists of Neuropeptide B/W Receptor Subtype 1 (GPR7). Bioorganic & 
Medicinal Chemistry Letters 2020, 30 (23), 127510. 
https://doi.org/10.1016/j.bmcl.2020.127510. 
(176) Li, Q. Application of Fragment-Based Drug Discovery to Versatile Targets. Front 
Mol Biosci 2020, 7. https://doi.org/10.3389/fmolb.2020.00180. 
(177) Hansen, B. B.; Jepsen, T. H.; Larsen, M.; Sindet, R.; Vifian, T.; Burhardt, M. N.; 
Larsen, J.; Seitzberg, J. G.; Carnerup, M. A.; Jerre, A.; Mølck, C.; Lovato, P.; 
Rai, S.; Nasipireddy, V. R.; Ritzén, A. Fragment-Based Discovery of 
Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity. J. Med. 
Chem. 2020, 63 (13), 7008–7032. 
https://doi.org/10.1021/acs.jmedchem.0c00359. 
(178) Canning, P.; Birchall, K.; Kettleborough, C. A.; Merritt, A.; Coombs, P. J. 
Fragment-Based Target Screening as an Empirical Approach to Prioritising 
Targets: A Case Study on Antibacterials. Drug Discovery Today 2020. 
https://doi.org/10.1016/j.drudis.2020.09.003. 
(179  Wei, W.; Cherukupalli, S.; Jing, L.; Liu, X.; Zhan, P. Fsp3: A New Parameter for 
Drug-Likeness. Drug Discovery Today 2020, 25 (10), 1839–1845. 
https://doi.org/10.1016/j.drudis.2020.07.017. 
(180) Dutta, A. K.; Rösgen, J.; Rajarathnam, K. Using Isothermal Titration Calorimetry 
to Determine Thermodynamic Parameters of Protein–Glycosaminoglycan 
Interactions. Methods Mol Biol 2015, 1229, 315–324. 
https://doi.org/10.1007/978-1-4939-1714-3_25. 
(181) Su, H.; Xu, Y. Application of ITC-Based Characterization of Thermodynamic and 
Kinetic Association of Ligands With Proteins in Drug Design. Front. Pharmacol. 
2018, 9. https://doi.org/10.3389/fphar.2018.01133. 
(182) Chodera, J. D.; Mobley, D. L. Entropy-Enthalpy Compensation: Role and 
Ramifications in Biomolecular Ligand Recognition and Design. Annu Rev 
Biophys 2013, 42, 121–142. https://doi.org/10.1146/annurev-biophys-083012-
130318. 
(183) Davis, B. J.; Hubbard, R. E. Fragment-Based Ligand Discovery. In Structural 
Biology in Drug Discovery; John Wiley & Sons, Ltd, 2020; pp 79–98. 
https://doi.org/10.1002/9781118681121.ch4. 
(184) Hodgkinson, J.; Bowden, S. D.; Galloway, W. R. J. D.; Spring, D. R.; Welch, M. 
Structure-Activity Analysis of the Pseudomonas Quinolone Signal Molecule. J 
Bacteriol 2010, 192 (14), 3833–3837. https://doi.org/10.1128/JB.00081-10. 
(185) Diggle, S. P.; Matthijs, S.; Wright, V. J.; Fletcher, M. P.; Chhabra, S. R.; Lamont, 
I. L.; Kong, X.; Hider, R. C.; Cornelis, P.; Cámara, M.; Williams, P. The 
Pseudomonas Aeruginosa 4-Quinolone Signal Molecules HHQ and PQS Play 
Multifunctional Roles in Quorum Sensing and Iron Entrapment. Chemistry & 
Biology 2007, 14 (1), 87–96. https://doi.org/10.1016/j.chembiol.2006.11.014. 
Rui Ling Liu                                                                             University of Nottingham  
212 
 
(186) Fletcher, M. P.; Diggle, S. P.; Crusz, S. A.; Chhabra, S. R.; Cámara, M.; Williams, 
P. A Dual Biosensor for 2-Alkyl-4-Quinolone Quorum-Sensing Signal Molecules. 
Environ Microbiol 2007, 9 (11), 2683–2693. https://doi.org/10.1111/j.1462-
2920.2007.01380.x. 
(187) Tamaian, R.; Moţ, A.; Silaghi-Dumitrescu, R.; Ionuţ, I.; Stana, A.; Oniga, O.; 
Nastasă, C.; Benedec, D.; Tiperciuc, B. Study of the Relationships between the 
Structure, Lipophilicity and Biological Activity of Some Thiazolyl-Carbonyl-
Thiosemicarbazides and Thiazolyl-Azoles. Molecules 2015, 20 (12), 22188–
22201. https://doi.org/10.3390/molecules201219841. 
(188) Pajouhesh, H.; Lenz, G. R. Medicinal Chemical Properties of Successful Central 
Nervous System Drugs. NeuroRx 2005, 2 (4), 541–553. 
(189) Constantinescu, T.; Lungu, C. N.; Lung, I. Lipophilicity as a Central Component 
of Drug-Like Properties of Chalchones and Flavonoid Derivatives. Molecules 
2019, 24 (8). https://doi.org/10.3390/molecules24081505. 
(190) Ramos, A. F.; Woods, D. F.; Shanahan, R.; Cano, R.; McGlacken, G. P.; Serra, 
C.; O’Gara, F.; Reen, F. J. A Structure-Function Analysis of Interspecies 
Antagonism by the 2-Heptyl-4-Alkyl-Quinolone Signal Molecule from 
Pseudomonas Aeruginosa. Microbiology, 2020, 166 (2), 169–179. 
https://doi.org/10.1099/mic.0.000876. 
(191) Nam, S.; Ham, S.-Y.; Kwon, H.; Kim, H.-S.; Moon, S.; Lee, J.-H.; Lim, T.; Son, 
S.-H.; Park, H.-D.; Byun, Y. Discovery and Characterization of Pure RhlR 
Antagonists against Pseudomonas Aeruginosa Infections. J. Med. Chem. 2020, 
63 (15), 8388–8407. https://doi.org/10.1021/acs.jmedchem.0c00630. 
(192) Motbainor, H.; Bereded, F.; Mulu, W. Multi-Drug Resistance of Blood Stream, 
Urinary Tract and Surgical Site Nosocomial Infections of Acinetobacter 
Baumannii and Pseudomonas Aeruginosa among Patients Hospitalized at 
Felegehiwot Referral Hospital, Northwest Ethiopia: A Cross-Sectional Study. 
BMC Infect Dis 2020, 20 (1), 92. https://doi.org/10.1186/s12879-020-4811-8. 
(193) Starkey, M.; Lepine, F.; Maura, D.; Bandyopadhaya, A.; Lesic, B.; He, J.; Kitao, 
T.; Righi, V.; Milot, S.; Tzika, A.; Rahme, L. Identification of Anti-Virulence 
Compounds That Disrupt Quorum-Sensing Regulated Acute and Persistent 
Pathogenicity. PLOS Pathogens 2014, 10 (8), e1004321. 
https://doi.org/10.1371/journal.ppat.1004321. 
(194) Fundamentals of Medicinal Chemistry | Wiley https://www.wiley.com/en-
us/Fundamentals+of+Medicinal+Chemistry-p-9780470871690 (accessed Jan 
19, 2021). 
(195) O’Boyle, N. M.; Boström, J.; Sayle, R. A.; Gill, A. Using Matched Molecular 
Series as a Predictive Tool To Optimize Biological Activity. J. Med. Chem. 2014, 
57 (6), 2704–2713. https://doi.org/10.1021/jm500022q. 
(196)  Jorge, S. D.; Palace-Berl, F.; Masunari, A.; Cechinel, C. A.; Ishii, M.; Pasqualoto, 
K. F. M.; Tavares, L. C. Novel Benzofuroxan Derivatives against Multidrug-
Rui Ling Liu                                                                             University of Nottingham  
213 
 
Resistant Staphylococcus Aureus Strains: Design Using Topliss’ Decision Tree, 
Synthesis and Biological Assay. Bioorganic & Medicinal Chemistry 2011, 19 (16), 
5031–5038. https://doi.org/10.1016/j.bmc.2011.06.034. 
(197) Wilder, C. N.; Diggle, S. P.; Schuster, M. Cooperation and Cheating in 
Pseudomonas Aeruginosa: The Roles of the Las, Rhl and Pqs Quorum-Sensing 
Systems. ISME J 2011, 5 (8), 1332–1343. https://doi.org/10.1038/ismej.2011.13. 
(198) Rampioni, G.; Falcone, M.; Heeb, S.; Frangipani, E.; Fletcher, M. P.; Dubern, J.-
F.; Visca, P.; Leoni, L.; Cámara, M.; Williams, P. Unravelling the Genome-Wide 
Contributions of Specific 2-Alkyl-4-Quinolones and PqsE to Quorum Sensing in 
Pseudomonas Aeruginosa. PLoS Pathog 2016, 12 (11). 
https://doi.org/10.1371/journal.ppat.1006029. 
(199) Gallagher, L. A.; McKnight, S. L.; Kuznetsova, M. S.; Pesci, E. C.; Manoil, C. 
Functions Required for Extracellular Quinolone Signaling by Pseudomonas 
Aeruginosa. Journal of Bacteriology 2002, 184 (23), 6472–6480. 
https://doi.org/10.1128/JB.184.23.6472-6480.2002. 
(200) Thomann, A.; de Mello Martins, A. G. G.; Brengel, C.; Empting, M.; Hartmann, 
R. W. Application of Dual Inhibition Concept within Looped Autoregulatory 
Systems toward Antivirulence Agents against Pseudomonas Aeruginosa 
Infections. ACS Chem. Biol. 2016, 11 (5), 1279–1286. 
https://doi.org/10.1021/acschembio.6b00117. 
(201) Inhibition of the pqsABCDE and pqsH in the pqs quorum sensing system and 
related virulence factors of the Pseudomonas aeruginosa PAO1 strain by 
farnesol | Elsevier Enhanced Reader 
https://reader.elsevier.com/reader/sd/pii/S0964830520301876?token=EE7929
ED33D254832F810EA107D8B5B8379AAE20E319A818DEC905C80FA7C219
B8DB6E91F30C36F266B4A91936598A74 (accessed Jan 21, 2021). 
https://doi.org/10.1016/j.ibiod.2020.104956. 
(202) Shaker, B.; Ahmad, S.; Thai, T. D.; Eyun, S.; Na, D. Rational Drug Design for 
Pseudomonas Aeruginosa PqsA Enzyme: An in Silico Guided Study to Block 
Biofilm Formation. Front Mol Biosci 2020, 7. 
https://doi.org/10.3389/fmolb.2020.577316. 
(203) Alcalde-Rico, M.; Olivares-Pacheco, J.; Alvarez-Ortega, C.; Cámara, M.; 
Martínez, J. L. Role of the Multidrug Resistance Efflux Pump MexCD-OprJ in the 
Pseudomonas Aeruginosa Quorum Sensing Response. Front. Microbiol. 2018, 
9, 2752. https://doi.org/10.3389/fmicb.2018.02752. 
 
